Official Transcript of Proceedings

NUCLEAR REGULATORY COMMISSION

Title:	Advisory Committee on Reactor Safeguards
	Reliability and Probabilistic Risk
	Assessment Subcommittee

- Docket Number: (not applicable)
- Location: Rockville, Maryland
- Date: Thursday, March 25, 2004

Work Order No.: NRC-1384

Pages 1-173

NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers 1323 Rhode Island Avenue, N.W. Washington, D.C. 20005 (202) 234-4433

	1
1	UNITED STATES OF AMERICA
2	NUCLEAR REGULATORY COMMISSION
3	+ + + +
4	ADVISORY COMMITTEE ON REACTOR SAFEGUARDS
5	(ACRS)
6	MEETING OF THE SUBCOMMITTEE ON
7	RELIABILITY AND PROBABILISTIC RISK ASSESSMENT
8	+ + + +
9	THURSDAY,
10	MARCH 25 , 2004
11	+ + + +
12	ROCKVILLE, MARYLAND
13	+ + + +
14	
15	The Subcommittee met at the Nuclear
16	Regulatory Commission, Two White Flint North, Room
17	T2B3, 11545 Rockville Pike, at 1:00 p.m., Dr. George
18	E. Apostolakis, Chairman, presiding.
19	
20	COMMITTEE MEMBERS PRESENT:
21	GEORGE E. APOSTOLAKIS, Chairman
22	MARIO V. BONACA, Member
23	F. PETER FORD, Member
24	THOMAS S. KRESS, Member
25	STEPHEN L. ROSEN, ACRS Member

		2
1	<u>COMMITTEE MEMBERS PRESENT (Continued)</u> :	
2	WILLIAM J. SHACK, Member	
3	JOHN D. SIEBER, Member	
4	MICHAEL SNODDERLY, ACRS Staff	
5	<u>NRC STAFF PRESENT</u> :	
6	STEPHEN DINSMORE	
7	MARY DROUIN	
8	DONALD HARRISON	
9	BILL KEMPER	
10	STU MAGRUDER	
11	GARETH PARRY	
12	MARK REINHART	
13	MARK RUBIN	
14	BOB TJADER	
15	MIKE TSCHILTZ	
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

1 CONTENTS 2 Praft Action Plan for Implementation of 3 Draft Action Plan for Implementation of 4 Phased Approach to PRA Quality: 5 Gareth Parry, NRR 6 Mary Drouin 7 Commission Discussion 8		3
3 Draft Action Plan for Implementation of 4 Phased Approach to PRA Quality: 5 Gareth Parry, NRR 6 Mary Drouin 7 Commission Discussion 8 9 9 10 11 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11 10 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11 10 11 11 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11	1	<u>CONTENTS</u>
4 Phased Approach to PRA Quality: 5 Gareth Parry, NRR 114 6 Mary Drouin 114 7 Commission Discussion 149 8	2	PAGE
5 Gareth Parry, NRR	3	Draft Action Plan for Implementation of
6 Mary Drouin 114 7 Commission Discussion 149 8 9 10 10 1 11 12 13 14 13 14 15 16 17 18 19 20 1 21 23 24	4	Phased Approach to PRA Quality:
7 Commission Discussion 149 8 9 10 10 14 15 12 13 14 15 16 17 16 19 19 17 19 19 18 19 19 19 19 19 19 19 19 10 19 19 12 19 19 13 19 19 14 19 19 15 19 19 16 19 19 17 19 19 18 19 19 19 19 19 10 19 19 11 19 19 12 19 19 13 19 19 14 19 19 15 19 19 16 19 19 17 19 19 18 19	5	Gareth Parry, NRR 6
8 9 9 10 10 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11 10 11 11 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11 10 11 11 11 12 11 13 11 14 11 15 11 16 11 17 11 18 11 19 11 11 11 12 11 13 11 14 11 15 11 16 11	6	Mary Drouin
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	7	Commission Discussion
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	8	
11 12 13 14 15 16 17 18 19 20 21 22 23 24	9	
12 13 14 15 16 17 18 19 20 21 22 23 24	10	
13 14 15 16 17 18 19 20 21 22 23 24	11	
14 15 16 17 18 19 20 21 22 23 24	12	
15 16 17 18 19 20 21 22 23 24	13	
16 17 18 19 20 21 22 23 24	14	
17 18 19 20 21 22 23 24	15	
18 19 20 21 22 23 24	16	
19 20 21 22 23 24	17	
20 21 22 23 24	18	
21 22 23 24	19	
22 23 24	20	
23 24	21	
24	22	
	23	
25	24	
	25	

	4
1	<u>PROCEEDINGS</u>
2	(1:15 p.m.)
3	CHAIRMAN APOSTOLAKIS: The meeting will
4	now come to order.
5	This is a meeting of the Advisory
6	Committee on Reactor Safeguards, Subcommittee on
7	Reliability and Probabilistic Risk Assessment.
8	I'm George Apostolakis, Chairman of the
9	Subcommittee. Members in attendance are Mario Bonaca,
10	Peter Ford, Thomas Kress and Steve Rosen and Jack
11	Sieber.
12	The purpose of this meeting is to discuss
13	the NRC staff's implementation plan in response to the
14	Commission's policy statement endorsing a phased
15	approach to PRA quality. The Subcommittee will gather
16	information, analyze relevant issues and facts, and
17	formulate proposed positions and actions as
18	appropriate for deliberation by the full committee.
19	Mike Snodderly is the Designated Federal
20	Official of this meeting.
21	The rules for participation in today's
22	meeting have been announced as part of the notice of
23	this meeting published in the <u>Federal Register</u> on
24	February 27, 2004.
25	A transcript of the meeting is being kept

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	5
1	and will be made available as stated in the Federal
2	<u>Register</u> notice.
3	It is requested that speakers first
4	identify themselves and speak with sufficient clarity
5	and volume so that they can be readily heard.
6	We have received no written comments or
7	requests for time to make oral statements from members
8	of the public regarding today's meeting.
9	As you know, in a staff requirements
10	memorandum, dated December 18, 2003, the Commission
11	approved implementation of a phased approach to
12	achieving an appropriate quality for PRAs for NRC's
13	risk informed regulatory decision making.
14	The SRM requested an action plan that
15	defines a practical strategy for the implementation of
16	the phased approach to PRA quality. I understand the
17	NRC staff held a public meeting on February 24, 2004,
18	to present their views and their understanding of the
19	phased approach and solicit feedback from
20	stakeholders.
21	The action plan in response to the
22	Commission's December 18 SRM is due to the Commission
23	in July 2004. The full committee, the full ACRS will
24	review and comment upon the draft action plan at its
25	April meeting, and of course the subcommittee is

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	6
1	expected to make a recommendation to the full
2	committee concerning this matter.
3	We will now proceed with the meeting, and
4	I call upon Gareth Parry of the Office of Nuclear
5	Reactor Regulation to begin the proceedings.
6	MR. PARRY: Good afternoon. Here at the
7	table with me is Mary Drouin from the Office of
8	Research, Donald Harrison and Stuart Magruder from
9	NRR, and at the side table is Mike Tschiltz, the PRA
10	Branch Chief in DSSA and NRR.
11	We form collectively the small group that
12	has been working on the drafting of this plan.
13	As George said, the purpose of this
14	meeting is to prevent present I said "prevent"
15	yesterday, too.
16	(Laughter.)
17	DR. KRESS: Freudian slip?
18	MR. PARRY: It's got to be.
19	is to present the draft action plan for
20	response to the SRM on stabilizing the PRA quality
21	expectations and requirements and to solicit your
22	input, as if we needed to solicit it.
23	(Laughter.)
24	MR. PARRY: The outline of the
25	presentation is as follows. I'll go briefly through

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	7
1	the background and objectives, both what we think the
2	Commission's objectives are and what the objectives of
3	the plan are.
4	I'll spend a little bit of time on the
5	definition of the phases, and we'll probably spend
б	quite a lot of time on the two viewgraphs that we have
7	in which we interpret how this phased approach is
8	going to be implemented when it comes to decision
9	making.
10	Incidentally, we had a public meeting
11	yesterday afternoon at which essentially these same
12	viewgraphs were presented, and we had a lot of
13	discussion on those charts at that point, too.
14	Then I will outline the staff and the
15	industry activities that are needed to achieve the
16	phased approaches. So a little briefly about the
17	resolution of technical issues, which is also
18	something that was called out in the SRM.
19	We have identified two potential policy
20	issues. They may not end up being policy issues, but
21	they're issues that we have identified amongst
22	ourselves as ones that we're not sure which way we
23	should go yet.
24	And then I'll talk a little bit about the
25	schedule.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	8
1	I'll start, first of all, by just making
2	a general comment on PRA quality. There's definitely
3	ambiguity about the meaning of the term "PRA quality,"
4	and what I heard this morning didn't disabuse me of
5	that.
6	We have been trying very hard to get away
7	from the phrase "a quality PRA" or "a high quality
8	PRA" by relating quality to the requirements for a
9	specific application. So we want to say things like
10	the PRA is of sufficient quality to support an
11	application.
12	DR. ROSEN: Why don't you call it
13	"suitable"?
14	MR. PARRY: Excuse me?
15	DR. ROSEN: Why don't you call it
16	"suitable"? "Suitable PRA."
17	MR. PARRY: Suitable PRA.
18	DR. ROSEN: It suits the purposes for
19	which it's intended. What I'm really suggesting is
20	you get away from it. Find another term; engineer
21	another term.
22	CHAIRMAN APOSTOLAKIS: PRA suitability.
23	DR. ROSEN: Yeah.
24	MR. PARRY: Okay. Well, we can think
25	about that.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	9
1 DR. ROSEN: Think about it	:. I mean,
2 that's just the top of my head,b ut	I think I
3 understand your problem with those words,	and I think
4 I know what you were trying to do. So if	you thought
5 about it a while, I think you would com	ne up with a
6 better set of words.	
7 DR. KRESS: It's too late. E	verybody has
8 quality on their mine.	
9 MR. PARRY: They do, I know,	and the SRM
10 is written in that was, too.	
DR. ROSEN: Well, you make	e the point
12 though well. I think you're convincing t	hat it's the
13 wrong term. It makes it very hard.	
14 CHAIRMAN APOSTOLAKIS: Let's	give Gareth
15 five minutes.	
DR. ROSEN: Oh, Chair.	
17 CHAIRMAN APOSTOLAKIS: I	mean that,
18 please.	
19 (Laughter.)	
20 DR. ROSEN: As soon as you d	o, I will.
21 PARTICIPANT: Why don't you	go with his
22 conclusions first?	
23 CHAIRMAN APOSTOLAKIS:	Give your
24 conclusions first.	
25 MR. PARRY: Well, we don't rea	ally have any

	10
1	conclusions.
2	CHAIRMAN APOSTOLAKIS: You don't have any.
3	MR. PARRY: Because what we're going to do
4	is present what we think the
5	CHAIRMAN APOSTOLAKIS: So you don't really
6	need five minutes. Okay.
7	MR. PARRY: No, no, I do. I'll take that,
8	too.
9	In any case, as far as quality as it
10	relates to PRAs goes, the way we've defined it is the
11	same definition that you find in Reg. Guide 1.174 and
12	in 1.200, and we've specifically identified scope as
13	being one of the elements of quality, if you like, and
14	level of detail and technical acceptability.
15	And you remember in Reg. Guide 1.174 we
16	used to have a section that used to be called PRA
17	quality. I think it has been changed now to address
18	these things like scope, level of detail, and
19	technical acceptability.
20	And the concept here is that certainly the
21	greater the emphasis on risk insights in any
22	application, the more stringent the requirements on
23	the PRA will be.
24	DR. FORD: Uncertainty doesn't come into
25	this at all?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	11
1	MR. PARRY: Not at that level, no.
2	CHAIRMAN APOSTOLAKIS: It's the technical
3	acceptability, I suppose.
4	MR. PARRY: Yeah, it's buried in there, and
5	it's buried also in the decision making, but that's
6	where it belongs.
7	CHAIRMAN APOSTOLAKIS: I think it's under
8	technical acceptability.
9	MR. PARRY: It really is because otherwise
10	you could also ask the question are initiating events
11	in there. It's just another part of the PRA that we
12	need to address.
13	The purpose of the SRM. We think the
14	Commission's objectives in writing this SRM, there are
15	many of them, and they are scattered throughout both
16	through the SRM and the white paper that was attached
17	to it.
18	But basically I think what they're trying
19	to do, what they are trying to do is to increase the
20	use of risk insights through the use of and using
21	their words now high quality, more complete PRAs as
22	a means of enhancing safety.
23	And an additional thing is to provide a
24	pathway for predictability in the use of PRAs by
25	establishing clear expectations on PRA quality.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	12
1	The big strength of this SRM, I think, is
2	it facilitates near term progress and enhancement of
3	safety through the use of available methods while also
4	building the pathway to getting better and better
5	methods and more broad reaching applications.
6	One of the things that the Commission is
7	concerned about is trying to create an atmosphere
8	where we can be more efficient in our review of risk
9	informed applications, and we're going to strive for
10	increased effectiveness in the use of PRAs in the
11	longer term.
12	So in a general high level sense, those
13	are the Commission's objectives.
14	What the SRM has done is to propose a
15	phased approach to achieving the appropriate quality,
16	which is really the vehicle by which we can make
17	short-term progress but develop towards the more
18	complete PRAs.
19	I talked about my second bullet while
20	explaining the first. That's what the approach in the
21	SRM is, is to have this phased approach, and what it
22	directs us to do is to develop an action plan for a
23	practical strategy for implementation of this phased
24	approach.
25	An additional topic in the SRM is that we

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

should address the resolution of certain technical issues, and I think you guys are, in large part responsible for having these in there, the issues such as model uncertainty, dealing with seismic and other external events, and of course, particularly human performance issues, and we had at least a couple of those this morning. And we'll address a little bit on that, although I think our focus today is really on the action plan for the implementation of the phased approach, and --CHAIRMAN APOSTOLAKIS: Are you working with the industry at all on this or are you coordinating anything with the industry, or is it strictly NRC staff? MR. PARRY: We've had two public meetings with the industry where we've shared our thoughts on this and got feedback from them, which is --CHAIRMAN APOSTOLAKIS: Mr. Gaertner this morning said that EPRI's creating or already has created a project to address the issue of model uncertainty. George, I think there's a MS. DROUIN: misunderstanding. The two public meetings have been

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

on the action plan.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

(202) 234-4433

13

	14
1	CHAIRMAN APOSTOLAKIS: Yes.
2	MS. DROUIN: We have not had any public
3	meetings on these technical issues, and plan to.
4	CHAIRMAN APOSTOLAKIS: But you also told
5	us, Mary, some time ago that you are preparing
6	regulatory guide on this issue.
7	MS. DROUIN: We told you that we were
8	going to prepare something. It would not be in
9	Regulatory Guide 1.200. It would be in some other
10	form.
11	CHAIRMAN APOSTOLAKIS: Okay, but you are
12	still working on that?
13	MS. DROUIN: Yes.
14	MR. PARRY: We'll talk about that a little
15	later.
16	CHAIRMAN APOSTOLAKIS: And this effort is
17	not coordinated with that of EPRI at this time.
18	MS. DROUIN: Yes and no.
19	CHAIRMAN APOSTOLAKIS: Okay. That's a
20	definitive answer. If you come back to it later
21	MS. DROUIN: When we come back to it, I'll
22	explain a little bit more then.
23	MR. BRADLEY: This is Biff Bradley of NEI.
24	We did broach this here yesterday in the
25	public meeting because the industry has a number of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	15
1	activities underway, and we did want to coordinate
2	with NRC, and we did raise this yesterday, and I think
3	the answer we got is that was a reasonable thing to
4	try to do.
5	CHAIRMAN APOSTOLAKIS: Very good, but we
6	will come back to it.
7	MR. PARRY: Yes, although we'll come back
8	to it really briefly because the focus today is really
9	on the phased approach and the implementation.
10	CHAIRMAN APOSTOLAKIS: I can see technical
11	issues associated with model uncertainty and human
12	performance issues. I though the technical issues on
13	the seismic area had been resolved.
14	Are you referring to standards?
15	MR. PARRY: Yes and no. I mean, standards
16	for PRAs, but also bounding methods if you don't use
17	PRAS.
18	CHAIRMAN APOSTOLAKIS: Yeah, but I mean,
19	SMA and seismic margins.
20	MR. PARRY: Well, more like quantitative
21	bounding methods, I think, because you'll see as we
22	talk later on in what context this might become
23	important.
24	MS. DROUIN: And any technical issues that
25	would come out of the external events, our intent is

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

16 1 to handle it through the standard now that the 2 standard is out and we review it. You know, any 3 issues would come out through, you know, the 4 endorsement. 5 CHAIRMAN APOSTOLAKIS: When you say the standard is out, has it been approved? 6 7 MS. DROUIN: We are currently reviewing 8 it. 9 CHAIRMAN APOSTOLAKIS: Reviewing it. 10 MR. PARRY: Okay. The status of the 11 activities --12 CHAIRMAN APOSTOLAKIS: Hold it. You didn't --13 14 MR. PARRY: Okay. 15 CHAIRMAN APOSTOLAKIS: Back, back. All modes of operation, is that somewhere in there? 16 17 MR. PARRY: Yeah. You'll see that it is. CHAIRMAN APOSTOLAKIS: Everything is in 18 19 the future here, isn't it? Very good. 20 DR. SIEBER: You didn't say yes and no. 21 (Laughter.) 22 MR. PARRY: Be patient. 23 DR. ROSEN: It's not our long suit, 24 Gareth. 25 MR. PARRY: I know that.

(202) 234-4433

NEAL R. GROSS

	17
1	(Laughter.)
2	CHAIRMAN APOSTOLAKIS: You don't need to
3	comment on everything we say.
4	MR. PARRY: Okay. The status of this plan
5	at the moment is, as I told you, the working group is
6	here. We made the draft plan available on $3/15$, and
7	you got copies of it, and also it was made publicly
8	available, and that's what we discussed yesterday at
9	the public meeting.
10	So we're in the process of soliciting
11	CHAIRMAN APOSTOLAKIS: So this is the
12	group.
13	MR. PARRY: With Mike, yeah.
14	CHAIRMAN APOSTOLAKIS: Okay.
15	MR. PARRY: So we're in the process of
16	soliciting input from stakeholders, both internal and
17	external. We're going to have several internal
18	meetings as well, and we're trying to finalize the
19	well, we will finalize the plan for transmission to
20	the Commission in July this year.
21	So what I'd like to do now is to go
22	through the definition of the phased approach, and
23	tell you what the different phases are, and the things
24	that I want to focus on really are things like what

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

18 1 to have for the various phases, but also what level of 2 staff review is associated with being in the different 3 phases. 4 CHAIRMAN APOSTOLAKIS: So what 5 distinguishes the phases is strictly the availability of standards and guidance documents; is that correct? 6 7 MR. PARRY: Of guidance documents 8 generally, yes. It's not just standards. Guidance 9 documents for performing the application, such as Reg. Guide 1.177, for example, and also guidance documents 10 11 that enable the quality us to assess that's 12 appropriate for those applications. I think the guidance document for the 13 14 application also has to specify the appropriate 15 quality for the PRA. DR. ROSEN: Now, is it the staff's intent 16 17 or desire to move through the phases in some sort of orderly manner? In other words, to get ultimately to 18 19 the higher numbered phases? MR. PARRY: What the Commission directs us 20 21 to is to progress towards Phase 3, and I will discuss 22 what that means, and ultimately perhaps to a Phase 4, 23 but the Commission recognizes that going to Phase 4 is 24 extremely resource intensive both on the part of the 25 industry and on the part of the staff.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

DR. ROSEN: So what that says is that this desire to move forward through the phases depends on the availability of these guidance documents, either standard or industry guidance documents or regulatory guides.

So let me posit for you a potential and 6 7 ask you how you would deal with it. What if, for example, just random, the industry which is known to 8 9 be working on low power shutdown standards under A&S, what if, for example, the industry were to decide, 10 11 well, it's too much work and we really don't want to 12 do that? Does that mean that one would not be able to move forward in that area because there was no 13 14 standard available?

15 MR. PARRY: Well, can I answer that question by talking you through the phases? Because 16 17 I think it's not a -- you can move through the phases for some applications and not for others, is what it 18 19 really means. For those applications that would 20 require a low power shutdown element of risk to be 21 calculated, if we did not have the standard, we 22 couldn't move forward to Phase 2, except under certain 23 circumstances, which I will explain to you.

DR. ROSEN: Okay, and staying with that example for a moment more, if you didn't have such a

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

	20
1	standard and there was some need expressed in the
2	industry to do something in a risk informed way with
3	either low power or shutdown affected systems, then
4	would the staff just say, "Well, that's too bad," or
5	would you work independently on a regulatory guide?
6	Is there a way around this?
7	MR. PARRY: Again, you're getting ahead of
8	the presentation, and we will discuss all of these
9	issues. Okay? It's the easiest way to do it. When
10	I get to that part, it is probably the easiest way to
11	explain.
12	DR. ROSEN: Well, I'm just wondering who's
13	in charge here. I mean, if you say it's standards,
14	then it's the industry and the community at large, and
15	a little bit that worries me because the regulatory
16	responsibilities is focused here, not in the industry.
17	MR. PARRY: Right.
18	DR. ROSEN: If the staff believes it needs
19	to move PRA ahead if it needs some sort of consensus
20	standard it's transferred responsibility to the
21	industry, unless you have a work-around, and I hope
22	you do.
23	MS. DROUIN: The staff could always come
24	at any point and elect, you know, say there is some
25	place where there is a need for a standard and if

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	21
1	industry I hate to use the word "industry" because
2	it's not industry that develops it.
3	DR. ROSEN: It's stakeholders.
4	MS. DROUIN: Standards, the FDOs, but
5	anyway, if they elect not to do it, you know, the
6	staff, I mean, the Commission can always come in and
7	direct the staff to do it.
8	This to me in my mind becomes a policy
9	issue. If there is going to be a hole there and that
10	hole is needed in order to move forward, then that's
11	going to have to go up to the Commission and say what
12	do we do. Do we develop it ourselves in the form of
13	a regulatory guide or a NUREG?
14	DR. BONACA: Why necessarily the staff?
15	I mean, you could always say we cannot approve this
16	application because there is no basis for us to judge.
17	Therefore, go ahead and do
18	MS. DROUIN: You can do that way also.
19	There's different options.
20	DR. BONACA: I think that, you know, this
21	is a mode in which there hasn't been necessarily the
22	burden on the staff to produce everything.
23	MS. DROUIN: That's right.
24	MR. TSCHILTZ: If I could comment on this,
25	this is Mike Tschiltz.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

I'd just like to say that I think the premise of the plan right now as we envision it is that it's dependent upon the industry being involved in these activities, and that if they aren't, we seriously need to rethink how the plan is going to work because it's based upon the premise that the industry is going to be involved in development of these standards.

9 DR. BONACA: I think that's exactly right. 10 MR. SNODDERLY: Steve, the other thing, 11 the short answer to your question is you would be in 12 Phase 1 if the standard is not developed for low power 13 shutdown, and Gareth is going to then take you through 14 what Phase 1 is and what that means.

MR. PARRY: Yeah, in addition to the technical guidance documents, as we call them, we also will have to revisit our internal documents like office instructions to enable us to deal with licensee submittals in an appropriate manner, like, you know, deciding what the right priority for review is, things like that.

Okay. Phase 1, that's where we're at right now, and PRA quality generally. I mean, any of the current regulatory guides for a specific application, it's like Reg. Guide 1.174 or 175. They

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

1 all have in them statements that the PRA quality has 2 to be commensurate with the needs of the application. 3 And the way that is judged is really --4 the way the quality of the PRA is judged is almost entirely -- well, entirely in the context of what's 5 needed for the application, and there really is no 6 7 requirement for a review of the base PRA. It's really left up to the reviewers to decide on the things that 8 9 they need to look at to determine whether the 10 application is acceptable. 11 You could look at the SRP Chapter 19, for 12 example. There's a lot of discussion of what you look at to look at the change in CDF or LERF. It really 13 14 doesn't deal very much with the base PRA. It focuses 15 more on the change, and that's largely because of the structure of the acceptance quidelines that we used in 16 Reg. Guide 1.174. 17 But one specific thing that, again, these 18 19 guidance documents say is that all of it contributes 20 to risk, and when I talk about a contributor to risk 21 here in the context today, I'm talking about the mode 22 of operation, and I'm talking about whether it's an 23 internal or external initiating event. 24 I might talk about contributors as So 25 being the sum of all internal initiating events

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

23

24 1 perhaps. Another one might be seismic contribution. 2 Another one might be fire. Another one might be high winds. 3 4 So when I talk about a contributor to risk 5 in the context that I'm talking today, I'm talking about the big contributors, the pieces for which you 6 7 would perhaps do a separate PRA, for example, or a 8 separate analysis. And all of these have to be addressed, but 9 10 typically since most licensees do not have a PRA that 11 covers all of the contributors, these early guidance 12 documents do allow the use of alternate methods to deal with the out-of-scope items, and they could be 13 14 the methods that have been used, the qualitative 15 arguments with perhaps compensatory measures, you know, that can be argued to say the risk from this 16 17 contributor is not going to change because we have these compensatory measures in place. 18 19 We might use bounding analyses to show that something is not particularly important or even 20 21 just to feed into the calculation as a conservative 22 estimate of the change that we allow. 23 And another way is to just restrict the 24 scope of the application. So that's Phase 1.

Phase 2 is described as -- the words the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

	25
1	SRM uses, an issue specific approach to PRA quality,
2	but we used the term "application type" approach, and
3	an application type might be something like ISI, IST.
4	CHAIRMAN APOSTOLAKIS: That's exactly what
5	confuses me. I thought in Phase 1, you said that we
6	were in Phase 1 right now.
7	MR. PARRY: We currently are in Phase 1,
8	right.
9	CHAIRMAN APOSTOLAKIS: And yet we are
10	approving risk informed ISI and all of that. So
11	what's the difference within Phase 1 and Phase 2 in
12	this respect?
13	MR. PARRY: Let me go through it. It's
14	what will happen in the future.
15	Okay. The difference is well, there's
16	two differences. The first one is that the PRA
17	quality now is demonstrated by comparison with an
18	applicable consensus standard for those elements that
19	are required for the application. So this is a
20	confidence building step in the process because now we
21	can assess the quality of the PRA by looking at
22	consensus standards.
23	Therefore, we have more confidence that
24	the PRA is adequate.
25	CHAIRMAN APOSTOLAKIS: Well, that's not a

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	26
1	difference because we already do that.
2	MR. PARRY: No, we don't already do that,
3	and staff
4	CHAIRMAN APOSTOLAKIS: ASME?
5	MR. PARRY: We've only just approved Reg.
6	Guide 1.200 for trial use last month. When we've
7	completed that
8	CHAIRMAN APOSTOLAKIS: But the ASME
9	standard?
10	MR. PARRY: But it had to be approved
11	through the reg. guide. That's when when we're
12	applying that, we have these pilot applications which
13	will test that regulatory guide, and when we've
14	completed that, then we will have a tool that we can
15	have confidence in the quality of the PRA.
16	CHAIRMAN APOSTOLAKIS: Again, still, how
17	many units in the country have implemented risk
18	informed ISI? Just about all of them.
19	MR. PARRY: Seventy-something, right.
20	CHAIRMAN APOSTOLAKIS: So you're saying
21	that we have approved something that has been
22	implemented by 77 out of 102, three units.
23	MR. PARRY: Right.
24	CHAIRMAN APOSTOLAKIS: Without high
25	confidence?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	27
1	MR. PARRY: Well, I don't say without high
2	confidence. Without the demonstrable documentation of
3	that quality. This is a
4	CHAIRMAN APOSTOLAKIS: Well, these PRAs,
5	I think all of them
6	MR. PARRY: They've been reviewed.
7	CHAIRMAN APOSTOLAKIS: have gone
8	through the NEI process, right? The review process.
9	MR. PARRY: That's the situation, George.
10	CHAIRMAN APOSTOLAKIS: Yeah.
11	DR. SIEBER: I don't think that's
12	unreasonable, you know. Applying risk information to
13	in-service inspection is better than applying no
14	information to it, and so you've got to improve the
15	process by risk informing ISI.
16	CHAIRMAN APOSTOLAKIS: Even though you
17	don't have high confidence.
18	MR. PARRY: You might have confidence.
19	It's just that it's okay. Let's not
20	CHAIRMAN APOSTOLAKIS: Streamlines. This
21	streamlines it.
22	MR. PARRY: Yes, it does streamline it.
23	Let's not focus on that specific item. Look at the
24	next one. Okay? This is another difference, is that
25	now in Phase 2 what we're saying is that all

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	28
1	contributors to risk sorry. This is still the same
2	all contributors to risk have to be addressed.
3	That hasn't changed, but it's the next bullet.
4	All significant risk contributors
5	applicable to the issue are actually included in the
6	PRA scope.
7	Currently with the Phase 1, we're allowing
8	other methods to be used than PRA, even for
9	significant contributors.
10	CHAIRMAN APOSTOLAKIS: Oh, the
11	"significant" refers to the total PRA.
12	MR. PARRY: Right, and the significance of
13	the contributor means that if you take it into
14	consideration
15	DR. SIEBER: What force and risk is this?
16	MR. PARRY: Yeah, if you take it into
17	consideration, it could change the decision
18	substantially. Those are the words that are in the
19	white paper. Okay?
20	We have to define those words in a
21	practical sense, but those are the words in the white
22	paper.
23	CHAIRMAN APOSTOLAKIS: For a risk
24	contributor to be significant, it must have been
25	quantified. So are you saying now that you have to

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1quantify everything?2That's what you say on the third bullet,3I guess.4MR. PARRY: That's what the third bullet5says.6MR. HARRISON: Or you have to have some7type of screening approach that gives you an estimate.8MR. PARRY: Right.9CHAIRMAN APOSTOLAKIS: So this is a major10change now, is it not?11MR. PARRY: This is a change. This is a12considerable change, yes.13CHAIRMAN APOSTOLAKIS: This is a14considerable change when it comes to scope. There is15no more, oh, we don't quantify this because it's, you16know, I'm waiting. This is a very important change.17MR. PARRY: And this, I think, is what the18Commission is after, is to try and push people in that19direction.20MR. TSCHILTZ: The concept is that once21the guidance and the standards exist to move people to22the next level by the phased approach to PRA quality23and to do what is acceptable or what you've proven to24be acceptable in Phase 1, which is the risk informed25ISI, we don't think we've made any inappropriate		29
3 I guess. 4 MR. PARRY: That's what the third bullet 5 says. 6 MR. HARRISON: Or you have to have some 7 type of screening approach that gives you an estimate. 8 MR. PARRY: Right. 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 MR. TSCHILTZ: The concept is that once 11 MR. TSCHILTZ: The concept of the the quility 12 and to do what is acceptable or what you've proven to 12 be acceptable in Phase 1, which is the risk informed	1	quantify everything?
4 MR. PARRY: That's what the third bullet 5 says. 6 MR. HARRISON: Or you have to have some 7 type of screening approach that gives you an estimate. 8 MR. PARRY: Right. 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	2	That's what you say on the third bullet,
5 says. 6 MR. HARRISON: Or you have to have some 7 type of screening approach that gives you an estimate. 8 MR. PARRY: Right. 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 Know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 MR. TSCHILTZ: The concept is that once 20 MR. TSCHILTZ: The concept is that once 21 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	3	I guess.
6 MR. HARRISON: Or you have to have some 7 type of screening approach that gives you an estimate. 8 MR. PARRY: Right. 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	4	MR. PARRY: That's what the third bullet
 type of screening approach that gives you an estimate. MR. PARRY: Right. CHAIRMAN APOSTOLAKIS: So this is a major change now, is it not? MR. PARRY: This is a change. This is a considerable change, yes. CHAIRMAN APOSTOLAKIS: This is a considerable change when it comes to scope. There is no more, oh, we don't quantify this because it's, you know, I'm waiting. This is a very important change. MR. PARRY: And this, I think, is what the Commission is after, is to try and push people in that direction. MR. TSCHILTZ: The concept is that once the guidance and the standards exist to move people to the next level by the phased approach to PRA quality and to do what is acceptable or what you've proven to be acceptable in Phase 1, which is the risk informed 	5	says.
8 MR. PARRY: Right. 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	6	MR. HARRISON: Or you have to have some
 9 CHAIRMAN APOSTOLAKIS: So this is a major 10 change now, is it not? 11 MR. PARRY: This is a change. This is a 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed 	7	type of screening approach that gives you an estimate.
10change now, is it not?11MR. PARRY: This is a change. This is a12considerable change, yes.13CHAIRMAN APOSTOLAKIS: This is a14considerable change when it comes to scope. There is15no more, oh, we don't quantify this because it's, you16know, I'm waiting. This is a very important change.17MR. PARRY: And this, I think, is what the18Commission is after, is to try and push people in that19direction.20MR. TSCHILTZ: The concept is that once21the guidance and the standards exist to move people to22the next level by the phased approach to PRA quality23and to do what is acceptable or what you've proven to24be acceptable in Phase 1, which is the risk informed	8	MR. PARRY: Right.
11MR. PARRY: This is a change. This is a12considerable change, yes.13CHAIRMAN APOSTOLAKIS: This is a14considerable change when it comes to scope. There is15no more, oh, we don't quantify this because it's, you16know, I'm waiting. This is a very important change.17MR. PARRY: And this, I think, is what the18Commission is after, is to try and push people in that19direction.20MR. TSCHILTZ: The concept is that once21the guidance and the standards exist to move people to22the next level by the phased approach to PRA quality23and to do what is acceptable or what you've proven to24be acceptable in Phase 1, which is the risk informed	9	CHAIRMAN APOSTOLAKIS: So this is a major
 12 considerable change, yes. 13 CHAIRMAN APOSTOLAKIS: This is a 14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed 	10	change now, is it not?
13CHAIRMAN APOSTOLAKIS:This is a14considerable change when it comes to scope. There is15no more, oh, we don't quantify this because it's, you16know, I'm waiting. This is a very important change.17MR. PARRY: And this, I think, is what the18Commission is after, is to try and push people in that19direction.20MR. TSCHILTZ: The concept is that once21the guidance and the standards exist to move people to22the next level by the phased approach to PRA quality23and to do what is acceptable or what you've proven to24be acceptable in Phase 1, which is the risk informed	11	MR. PARRY: This is a change. This is a
14 considerable change when it comes to scope. There is 15 no more, oh, we don't quantify this because it's, you 16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	12	considerable change, yes.
no more, oh, we don't quantify this because it's, you know, I'm waiting. This is a very important change. MR. PARRY: And this, I think, is what the Commission is after, is to try and push people in that direction. MR. TSCHILTZ: The concept is that once the guidance and the standards exist to move people to the next level by the phased approach to PRA quality and to do what is acceptable or what you've proven to be acceptable in Phase 1, which is the risk informed	13	CHAIRMAN APOSTOLAKIS: This is a
16 know, I'm waiting. This is a very important change. 17 MR. PARRY: And this, I think, is what the 18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	14	considerable change when it comes to scope. There is
MR. PARRY: And this, I think, is what the Commission is after, is to try and push people in that direction. MR. TSCHILTZ: The concept is that once the guidance and the standards exist to move people to the next level by the phased approach to PRA quality and to do what is acceptable or what you've proven to be acceptable in Phase 1, which is the risk informed	15	no more, oh, we don't quantify this because it's, you
18 Commission is after, is to try and push people in that 19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	16	know, I'm waiting. This is a very important change.
19 direction. 20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	17	MR. PARRY: And this, I think, is what the
20 MR. TSCHILTZ: The concept is that once 21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	18	Commission is after, is to try and push people in that
21 the guidance and the standards exist to move people to 22 the next level by the phased approach to PRA quality 23 and to do what is acceptable or what you've proven to 24 be acceptable in Phase 1, which is the risk informed	19	direction.
the next level by the phased approach to PRA quality and to do what is acceptable or what you've proven to be acceptable in Phase 1, which is the risk informed	20	MR. TSCHILTZ: The concept is that once
and to do what is acceptable or what you've proven to be acceptable in Phase 1, which is the risk informed	21	the guidance and the standards exist to move people to
24 be acceptable in Phase 1, which is the risk informed	22	the next level by the phased approach to PRA quality
	23	and to do what is acceptable or what you've proven to
25 ISI, we don't think we've made any inappropriate	24	be acceptable in Phase 1, which is the risk informed
11	25	ISI, we don't think we've made any inappropriate

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	30
1	decisions based upon the information we have, and we
2	don't think Phase 2 is going to change that.
3	But it is progressing. It's a
4	bootstrapping approach to progressing the technology.
5	MR. MAGRUDER: And improving efficiencies,
6	staff efficiencies.
7	MR. PARRY: Yes. So to achieve this Phase
8	2 then
9	CHAIRMAN APOSTOLAKIS: Well, wait. Let's
10	go back. I thought significant contributors were what
11	you and I understand, you know, have been
12	understanding for 20 years now. Whatever significant
13	is, ah, fire, risk, fire, seismic.
14	MR. PARRY: Right, exactly.
15	CHAIRMAN APOSTOLAKIS: Look at the last
16	bullet though. It says the significance of a
17	container is done by whether taking into account will
18	change the decision. That's a very different
19	definition of significance.
20	MR. PARRY: Well, yes, but remember Phase
21	2 is application type specific. Okay? So for a
22	particular application, something might contribute
23	considerably to the core damage frequency, like fires
24	may contribute significantly to the core damage
25	frequency, but if they're not relevant for a specific

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	31
1	application, then you don't need a fire
2	PARTICIPANT: Like ISI.
3	MR. PARRY: Like ISI, right.
4	You wouldn't need a fire PI.
5	MR. MAGRUDER: Maybe we should change it.
б	In that last bullet instead of saying "significance,"
7	maybe we should say "the relevance of the
8	contributor."
9	MR. PARRY: Well, except we're parroting
10	the words from the SRM though.
11	MR. MAGRUDER: Right, but when it's a
12	different meaning than significant in the strict PRA
13	sense.
14	MR. PARRY: Well, maybe not. I mean, for
15	a particular application it still has the same
16	connotation.
17	MR. MAGRUDER: Yes.
18	MR. SNODDERLY: I think it's important
19	because it's where the Commission was trying to define
20	what "significant" meant.
21	MR. PARRY: Right, and I think what they
22	were trying to address here, I believe, was the scope
23	issue.
24	CHAIRMAN APOSTOLAKIS: But somehow
25	somebody has to make a judgment before the PRA that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	32
1	something will change the decision.
2	MR. PARRY: Yes.
3	CHAIRMAN APOSTOLAKIS: And how do we do
4	that?
5	MR. PARRY: Well, I'll talk about that in
6	a minute.
7	MR. SNODDERLY: A judgment that becomes
8	apparent when you have a standard, but without the
9	standard, then it becomes much tougher on these guys.
10	MR. PARRY: Make a note to yourself that
11	you want that question answered because I will come
12	back to it. Okay?
13	In Phase 2 then what we've got to have is
14	the guidance for using the PRA in making the decision,
15	and what that guidance has to do, I think, is include
16	the definition of the scope of the PRA that you need.
17	So that will tell you in that guidance well,
18	actually I can answer your question now.
19	We think probably what will happen is that
20	in terms of if we are at regulatory guides, for
21	example, that we would write a regulatory guide in a
22	generic sense that would say typically you would
23	expect that for this type of application that you need
24	to consider internal events and fires, but maybe not
25	seismic. Okay? Maybe not low power shutdown.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	33
1	When we talk about the implementation
2	later on, that doesn't mean that every licensee would
3	have to do a fire PRA, but the only ones that would
4	not have to do it would be those that could
5	demonstrate that for their plant and for their
6	application that the fire contribution was
7	insignificant to the decision.
8	CHAIRMAN APOSTOLAKIS: So the burden is on
9	the licensee
10	MR. PARRY: To demonstrate the
11	significance.
12	CHAIRMAN APOSTOLAKIS: to show that
13	something is not relevant to the decision.
14	MR. PARRY: Yeah, given that the generic
15	guidance suggests that it is.
16	CHAIRMAN APOSTOLAKIS: That's reasonable.
17	MR. PARRY: And then the other portion of
18	the guidance is that the assessment of the quality of
19	the PRA for each scope item that's going to be used in
20	the application has to exist, and where it will exist
21	from our point of view is in Reg. Guide 1.200 as an
22	endorsement of the relevant standards for those scope
23	items.
24	CHAIRMAN APOSTOLAKIS: What is the trial
25	period then being on this?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	34
1	MR. PARRY: I think it's about a year,
2	right, Donny?
3	MR. HARRISON: Yeah. Right now it would
4	project to be about December of this year would be
5	when we'd finish the trial period for Reg. Guide
6	1.200, for the internal events. So it's this year.
7	CHAIRMAN APOSTOLAKIS: The end of this
8	year?
9	MR. HARRISON: End of this year, yeah.
10	MR. SNODDERLY: George, right now Donny is
11	scheduled to come not Donny but someone a group
12	will be coming before us at the May full committee to
13	brief us, an information briefing, on the status of
14	the pilot reviews.
15	CHAIRMAN APOSTOLAKIS: Very good.
16	MR. PARRY: Actually it will be Donny.
17	Okay. Let's move on to Phase 3 then.
18	Phase 3 is one in which we believe that the regulatory
19	framework is in place that would enable a licensee to
20	construct a PRA that would have sufficient quality to
21	address all the current applications. It would be
22	like a rolling up of all the quality requirements for
23	all of those applications into one umbrella type
24	document.
25	So that's what we see Phase 3 as being,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	35
1	and this is the phase that the SRM directed us to
2	achieve by December 31st, 2008.
3	CHAIRMAN APOSTOLAKIS: Yeah, Phase 2
4	actually the SRM says "in the short term."
5	MR. PARRY: "In the short term," right.
6	CHAIRMAN APOSTOLAKIS: Now, what is the
7	definition of a "short term"? Something that's not
8	long?
9	MR. PARRY: Yes, you could say that, but
10	I think it's determined really by practicality because
11	it's dependent on when the standards will be issued
12	and when they will be endorsed by the NRC, and as you
13	know, the standards for low power shutdown and fires
14	are somewhere out in the future. they're not this
15	year. they're next year at the earliest.
16	So that has to define the short term.
17	CHAIRMAN APOSTOLAKIS: So Phase
18	MR. PARRY: Plus some applications.
19	CHAIRMAN APOSTOLAKIS: Phase 2 then
20	optimistically will not be in place before the year
21	2007?
22	MR. PARRY: No, we may have a Phase 2. We
23	think Phase 2 is an application specific state. So
24	for some applications we may be in a Phase 2 earlier
25	than that, and we have a good example of that which

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	36
1	we'll talk about in a minute.
2	It's actually an interesting example
3	because it's an example of an application which could
4	be in different phases at different times.
5	CHAIRMAN APOSTOLAKIS: But by December
6	31st, 2008?
7	MR. PARRY: We will roll up all that we
8	have.
9	CHAIRMAN APOSTOLAKIS: Will that be Phase
10	3 or any application now is a good PRA?
11	MR. PARRY: That's the goal, given that
12	the standards that are out there to be constructed
13	should be enough to support the applications that we
14	currently think of.
15	CHAIRMAN APOSTOLAKIS: But isn't the
16	Commission saying by this deadline that the standards
17	have been ready? I don't recall the Commission
18	putting a condition.
19	MR. PARRY: No, they haven't, but they
20	knew when the standards were due to be published. So
21	I think the reason they chose 2008 was probably in
22	recognition of the fact that those standards were not
23	going to be ready immediately.
24	I'm sure they built that into their
25	considerations.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

ere hat , I
, I
, I
use
13
use
lly
ere
her
of
we
ing
to
ing
hat
eed
.rd,
int
ep?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	38
1	What is the thing that could stop you?
2	MR. PARRY: Well, that could stop us?
3	There's two parts to that question, I think. We
4	could, as an agency define the regulatory framework,
5	and that thing that would stop us there would be
6	actually, I think, would be the standards.
7	But in terms of full implementation of
8	Phase 3, I think what could stop us is the ability of
9	the industry to have enough resources to develop the
10	PRAs to the standards and to have them peer reviewed
11	because the peer review is also an essential part of
12	any of these standards.
13	DR. FORD: Now, why would it be the
14	we're starting to get into an area which, I guess, is
15	more of a business aspect, but surely the licensees
16	based on what we saw from SDP this morning, there's a
17	huge business advantage to them to develop this. So
18	why should it be the licensees pushing you rather than
19	you pushing them?
20	MR. PARRY: I cannot really answer that.
21	MR. TSCHILTZ: I can say I don't think
22	that South Texas' viewpoint is commonly shared across
23	the industry about the use of PRA.
24	MR. PARRY: Or the economic benefit
25	really.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	39
1	MR. SNODDERLY: Gareth, could you share
2	with the Subcommittee, because I thought you had some
3	good thoughts, on what do you think would be the
4	drivers for getting to Phase 3?
5	MR. PARRY: Well, I think one of the
6	drivers could be 5069 if there were to be seen a good
7	economic benefit for reducing the special treatment of
8	primers (phonetic), for example. And I'll explain why
9	we might think that might be the case when we talk a
10	little later because I have 5069 as an example a
11	little later, and I think it's probably better to talk
12	about it then.
13	But another area that you might think that
14	could be of benefit, although I'm not really sure; I'm
15	not sure whether this is real or not, but when you're
16	talking about the SDP, for example, a lot of the
17	problems we get into when a preliminary Phase 2 of the
18	SDP comes out to be white or higher, then we get into
19	the argument using a Phase 3 of the SDP.
20	Currently the only approach we have is to
21	use really the SPAR models. The licensee has his own
22	model that he can use. I could see that if that
23	became a bid issue that having a Phase 3 PRA had been
24	developed to standards would be a much stronger
25	argument for producing a Phase 3 SDP argument that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	40
1	would bear some weight.
2	But that's just a couple of examples. You
3	know, we don't know all of the pros and cons of who
4	would want to develop things this way.
5	Okay. Phase 4. Phase 4 is Mike wanted
6	to just add a chart of pie in the sky here but it's
7	really going to be reached when the PRAs have been
8	developed to state of the art, and really state of the
9	art, I think what we're thinking of here is beyond
10	what industry currently does.
11	So you can think of it as something like
12	capability Category 3. It really is, you know, a
13	Rolls Royce of a PRA. I guess I can say that.
14	But in the white paper the Commission did
15	recognize that this would be extremely resource
16	intensive for both licensees and the NRC, particularly
17	because one of the things they would expect in the
18	phase 4 is that the staff has reviewed and approved
19	the licensee PRAs. Now, because the
20	DR. ROSEN: Do you know how many cases
21	there are of the staff's review and approval of PRAs?
22	I assume approval means some sort of formal approval,
23	like an SER.
24	MR. PARRY: SER. I don't think there are
25	any of any current PRAs.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

41 1 DR. SIEBER: Now you're talking about a 2 general approval? I'm talking about an 3 MR. PARRY: No. 4 individual approval. 5 DR. SIEBER: No, but general approval as opposed to specific issues. 6 7 MR. PARRY: Oh, as opposed to specific 8 issues, yes, right, yes. 9 DR. SIEBER: For any use. 10 MR. PARRY: Yes, for any use. 11 MR. HARRISON: Yeah, I think this would be 12 a case where if you're asking for an NRC stamp on the licensee's PRA that says this PRA is good for anything 13 14 you want to use it for and --15 DR. ROSEN: A state of the art PRA. 16 MR. HARRISON: As a state of the art PRA. 17 DR. ROSEN: Do you know how many of those there are? 18 19 MR. HARRISON: None. 20 No, none probably. MR. PARRY: 21 Currently now. Do you know DR. ROSEN: 22 how many there have been in the history of the 23 technology? 24 MR. MAGRUDER: I think the only ones we've 25 done that I'm aware of are not actually licensees'

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	42
1	PRAs, but we've approved PRAs for the advanced
2	reactors. We've approved a PRA for the ABWR, the AP-
3	600, AP-1000, but not
4	DR. ROSEN: But I'm only talking about the
5	current fleet.
6	MR. MAGRUDER: Yeah.
7	DR. ROSEN: The current operating fleet.
8	MR. MAGRUDER: I don't believe we've
9	approved any.
10	DR. ROSEN: Well, it's a trick question,
11	I think, but I was willing to have a number given me,
12	but I think the answer is one. The gentlemen who were
13	here this morning are the holders of that PRA.
14	MR. HARRISON: I would even say in that
15	situation that was an approval for the exemption. If
16	they were to come in for another applications, they
17	would get reviewed again. Now, maybe
18	DR. ROSEN: An SER for exemption.
19	MR. HARRISON: The exemption. So it's not
20	really an SER for the PRA. So the PRA is a strong
21	supporting element.
22	DR. ROSEN: I'm talking about a document
23	that arrived in 1989.
24	DR. ROSEN: Oh, is this the graded QA?
25	MR. HARRISON: Yeah, it was for graded QA.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	43
1	MR. PARRY: 1989?
2	MR. HARRISON: Oh, '99 probably.
3	DR. ROSEN: No, '89.
4	MR. PARRY: No, then you couldn't say that
5	that was state of the art because the current PRA is
6	probably an order of magnitude lower in core damage
7	frequency and totally different from what was existing
8	then.
9	DR. ROSEN: The question was very
10	specific. How many times has the staff written an SER
11	that said this PRA is a state of the art PRA, as of
12	today, as of the date they signed the letter?
13	DR. SIEBER: Never.
14	DR. ROSEN: I think the good answer I
15	restricted it later to domestic operating plants
16	because it's true that some of the advanced plants had
17	those, but for domestic operating plants, there has
18	only been one, and the reason I go through this
19	unless you're willing to contest that subject, we'll
20	leave it at one is because it's an enormous
21	undertaking.
22	At least having experienced it once in my
23	career, it took all four national laboratories got a
24	hand in it, and it went on for years.
25	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	44
1	during the PRA in the first place.
2	DR. ROSEN: Un-huh. Now, that was the
3	first time they were ever involved and a lot of people
4	had to be trained and so on, but it took an enormous
5	amount of time and resources, and I think it is
6	totally unrealistic to say that the staff is going to
7	do that order of magnitude review on I don't know how
8	many PRAs that would be reflected in 103 operating
9	plants. Probably 60 or 70 maybe.
10	DR. FORD: But surely, Steve, what you're
11	saying is unless that roadblock is overcome in some
12	way or another, you might as well forget this whole
13	portrait.
14	DR. ROSEN: That's what I'm saying. I'm
15	saying that what this pays for is totally unrealistic.
16	The staff is going to do direct review and approval.
17	Unrealistic, can't work.
18	Now, it can work if the staff uses some
19	sort of other process, some sort of surrogate process
20	in which a standard is set in place and the licensees
21	or applicants have their work reviewed in accordance
22	with the standard prior period.
23	MR. PARRY: That's Phase 3.
24	DR. ROSEN: Well, then Phase 4 if you're
25	going to talk about direct staff review and approval.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	45
1	MR. PARRY: Which it does.
2	DR. ROSEN: My experience is you just will
3	never have the resources.
4	MR. PARRY: You might want to comment on
5	that in your letter if you feel that way. Fortunately
6	our plan doesn't really address Phase 4. The SRM
7	didn't ask us to do anything beyond that because I
8	think they realize that there are these resource
9	problems associated with it, too. Maybe not as much
10	as you're pointing out.
11	DR. ROSEN: Well, everyone is learning
12	something, and maybe all of our efficiencies in the
13	process, but I still think it would be an enormous
14	undertaking.
15	MR. PARRY: We agree.
16	MR. HARRISON: And just to make it clear,
17	the SRM specifically said not to even start to pursue
18	Phase 4 until you finish Phase 3.
19	MR. PARRY: Yeah.
20	MR. HARRISON: So basically the direction
21	was don't even go there until some time after 2008.
22	DR. ROSEN: Yeah. So we'll reserve our
23	comments on that.
24	MR. PARRY: Okay.
25	MR. MAGRUDER: The Commission put it in

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	46
1	the SRM, I think, because they considered this a
2	policy statement on where they want PRAs to go in the
3	future, and they wanted to have a vision for us to
4	look at in the future, and this is obviously, like
5	Mike characterized, this is pie in the sky, but that's
6	ultimately the vision.
7	MR. TSCHILTZ: Well, I think I'd like to
8	characterize my statement as I think it's a good thing
9	to reevaluate once we've reached Phase 3 based upon
10	what we know at that point in time.
11	CHAIRMAN APOSTOLAKIS: But there is
12	something that is not right if the first time one sees
13	the word "state of the art" is in Phase 4, you mean
14	Phase 3 is not state of the art?
15	MR. PARRY: I think it's good industry
16	practice.
17	CHAIRMAN APOSTOLAKIS: State of the
18	practice?
19	MR. PARRY: Yeah, I think.
20	CHAIRMAN APOSTOLAKIS: How different is
21	state of the practice from state of the art? What do
22	you mean by state of the art?
23	MR. PARRY: Well, if you look at
24	capability in Category 3, it does an awful lot of
25	I mean, where there are capability Category 3

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	47
1	requirements they do involve a lot of work that is
2	really an embellishment. It probably doesn't prevent
3	you from getting a pretty good understanding of risk.
4	Personally I think capability Category 2
5	ought to be appropriate.
6	Now, Stanley has got a comment to make.
7	MR. LEVINSON: Stanley Levinson from
8	Areva.
9	Capability Category
10	PARTICIPANT: Areva?
11	MR. LEVINSON: Areva, formerly Framatome
12	AMP.
13	The point Gareth is trying to make is for
14	most of the applications, if not all of the envisioned
15	applications, capability Category 3 is sufficient
16	depth and breadth of the PRA to support those
17	applications.
18	MR. PARRY: You meant two, right?
19	MR. LEVINSON: Capability Category 2.
20	What did I say?
21	MR. PARRY: Three.
22	MR. LEVINSON: Capability Category 2. To
23	go on to capability Category 3 involves a lot more
24	additional work, presumably for very little benefit in
25	the game that you get in being able to support an

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	48
1	application.
2	MS. DROUIN: You refer to, for example, on
3	your initiating events in Category 2 you might for
4	your low frequency ones discard them. For capability
5	Category 3, you would subsume them and carry them
6	forward. You would model all of your contributors.
7	You would do a lot less screenings.
8	MR. LEVINSON: You would keep everything
9	in there. Everything would be as plant specific as
10	possible. You wouldn't be getting the commensurate
11	gain from doing all of this extra work in terms of
12	being able to support a risk informed application.
13	It's leading you to be in a position where
14	you can make a risk based decision instead of a risk
15	informed decision.
16	CHAIRMAN APOSTOLAKIS: But we know we'll
17	never be there.
18	MR. LEVINSON: And we shouldn't be there.
19	Risk based is, you know, an ideal.
20	CHAIRMAN APOSTOLAKIS: I think it is
21	unfortunate to use the word "state of the art." Use
22	some other one. State of the art to me means you have
23	the latest model or technique that some professor
24	published in the Journal of Such-and-such last July,
25	that somebody at the National Laboratory came up with

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	49			
1	a new improved way of doing Monte Carlo simulation,			
2	and you have that in your PRA.			
3	That's state of the art.			
4	DR. ROSEN: Can I summarize that, George?			
5	CHAIRMAN APOSTOLAKIS: Yeah.			
6	DR. ROSEN: I think I agree with you, but			
7	I think state of the art means to me innovation.			
8	CHAIRMAN APOSTOLAKIS: Well, that's the			
9	latest method for doing something.			
10	DR. ROSEN: It's innovative, not been done			
11	before, obviously clearly superior.			
12	MR. PARRY: Right, as opposed to good			
13	enough for the application.			
14	CHAIRMAN APOSTOLAKIS: Stated practice is			
15	what Stanley just described. You know, this is good			
16	enough for the decision.			
17	MR. PARRY: It's been done before.			
18	CHAIRMAN APOSTOLAKIS: It has been tried			
19	by a lot of licensees.			
20	MR. PARRY: And generally accepted.			
21	CHAIRMAN APOSTOLAKIS: And it has been			
22	accepted as a way of doing business. So it seems to			
23	me that we should strive to be the state of the			
24	practice which should be improving slowly with time as			
25	people appreciate new, but			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	50			
1	MR. PARRY: Without discouraging state of			
2	the art.			
3	CHAIRMAN APOSTOLAKIS: Yeah, I would take			
4	the word "state of the art" out.			
5	MR. PARRY: These are the words that were			
6	in the SRM.			
7	DR. ROSEN: See, I want to take it			
8	further, George. I want to agree with you. State of			
9	the practice is what we should encourage, but we			
10	should also encourage in some way incentivize			
11	innovation.			
12	CHAIRMAN APOSTOLAKIS: Yes, absolutely,			
13	and that's one of the major roles of this committee:			
14	push a little bit. So the words "state of the art"			
15	are from the Commission?			
16	MR. PARRY: Yes.			
17	MR. MAGRUDER: But I think we understand			
18	your point that we're really			
19	CHAIRMAN APOSTOLAKIS: That's what comes			
20	to my mind when they say "state of the art."			
21	MR. PARRY: Yeah, and I think that's what			
22	we agree.			
23	MS. DROUIN: But don't interpret if you			
24	use "state of the practice" which we connotate to the			
25	capability Category 2, that that doesn't mean you			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 don't have innovation and you don't have improvement 2 because of course you do. 3 CHAIRMAN APOSTOLAKIS: Let me give you an 4 example, Mary. As you know, there is a lot of 5 activity in Europe, and I think some of the American codes are beginning to comply, especially ABS, using 6 7 BDDs, binary decision diagrams to do their Now, I would call that state of the 8 calculations. This is now the most advanced. It does things 9 art. You don't need to cut off values 10 very rapidly. 11 according to their claims and so on. 12 You don't need to do that in order to make a regulatory decision because existing tools are good 13 14 enough, but that would be state of the sense that it's 15 the latest innovation. Okay? That doesn't mean that it's needed, but it's the latest innovation. 16 17 Is that what this means? By the way, there is talk among people now 18 19 that maybe our codes, like Sapphire, should be 20 upgraded to us BDD. So the state of the practice follows slowly behind, but it is aware of what the 21 22 state of the art is. 23 Obviously that's not what the Commission 24 means, I don't think. 25 MR. PARRY: It's not clear what they mean.

(202) 234-4433

(202) 234-4433

1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 51

	52	
1	CHAIRMAN APOSTOLAKIS: It's not clear what	
2	they mean.	
3	MR. PARRY: But I think in a sense, I	
4	think they do mean the limits of innovation because I	
5	think there are some the words in the SRM. I can't	
6	remember them.	
7	CHAIRMAN APOSTOLAKIS: Anyway, enough said	
8	on this. We all understand what	
9	MR. PARRY: Okay, but as I say, if you	
10	want to comment on that in a letter, I think it would	
11	be useful information, but we will take that away from	
12	this meeting.	
13	CHAIRMAN APOSTOLAKIS: To go with ten	
14	other guys. It's exhausting.	
15	MR. PARRY: Okay. One thing that I also	
16	told you is we'd look at the different levels of	
17	review between these phases. It was pointed out	
18	yesterday that perhaps the word "ad hoc" is not really	
19	giving the right connotation to review for Phase 1.	
20	Really it's based on the experience of the reviewer,	
21	what he will look at, but there's no formal process	
22	that says you must look at this; you must look at	
23	that. It's more, you know, looking at the analysis	
24	and saying, "Okay. I think I need to follow this	
25	thread to make sure that I think that the answer is	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	53	
1	right."	
2	So that's what Phase 1 is. That's what we	
3	do now.	
4	Phase 2 helps us with our efficiency, but	
5	also, I think, in terms of being able to state things	
6	with more confidence because what we would expect in	
7	Phase 2 then is that there is a reliance on peer	
8	review in accordance with Reg. Guide 1.200, and our	
9	review then would be focused on those things, on those	
10	parts of the PRA which didn't meet the standard after	
11	having Reg. Guide 1.200 these are the ASME	
12	standards having Reg. Guide 1.200 apply to it.	
13	And we would also do some sort of audits	
14	just to make sure that we agreed with the peer review	
15	comments.	
16	Phase 3 is essentially the same as Phase	
17	2 because they haven't really changed very much	
18	there, but there is the potential that we could do a	
19	one time review of the PRA if the PRA had been done to	
20	the Phase 3 framework.	
21	And Phase 4, as we already discussed,	
22	would involved staff review and approval of the base	
23	PRA.	
24	CHAIRMAN APOSTOLAKIS: Have you presented	
25	this to the Commission?	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	54			
1	MR. PARRY: No.			
2	CHAIRMAN APOSTOLAKIS: You have not			
3	briefed?			
4	MR. PARRY: Not yet, but I'm sure they've			
5	seen it.			
б	CHAIRMAN APOSTOLAKIS: Because this is			
7	really a very concise and understandable description			
8	of the phases.			
9	MR. PARRY: Thank you.			
10	CHAIRMAN APOSTOLAKIS: I must say when I			
11	read the SRM i had a lot of questions in my mind, but			
12	if this is the interpret, then I think it's very nice			
13	and concise.			
14	MR. PARRY: Thank you.			
15	We think that we have the right			
16	interpretation.			
17	CHAIRMAN APOSTOLAKIS: Are you going to			
18	brief them at all before July?			
19	MR. PARRY: It's not on our agenda right			
20	now.			
21	CHAIRMAN APOSTOLAKIS: It's not a			
22	participatory review process with them.			
23	MR. PARRY: Probably not. We'll send it			
24	out like that.			
25	MR. SNODDERLY: But it is on our agenda in			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	55			
1	May, our May meeting with the Commissioners.			
2	CHAIRMAN APOSTOLAKIS: Oh, with the			
3	Commissioners.			
4	MR. SNODDERLY: Yes.			
5	CHAIRMAN APOSTOLAKIS: Can I have a copy			
6	of your slides?			
7	(Laughter.)			
8	MR. PARRY: He's got them.			
9	CHAIRMAN APOSTOLAKIS: Good. Thank you.			
10	MR. PARRY: Okay. Now we get to the			
11	controversial part.			
12	DR. ROSEN: Well, I thought there was			
13	quite a bit of controversy already.			
14	MR. PARRY: Okay. I'm going to talk now			
15	about the implementation, and I'm going to talk about			
16	it using this flow chart, which is slightly different			
17	from the one that you have in the draft plan. It was			
18	modified slightly to fix a problem that we had with			
19	the words in there.			
20	But let me talk you through it, and again,			
21	we had some, I think, very useful discussion on this			
22	flow diagram yesterday, and it involved even the			
23	logic, but also some of the wording in here, and that			
24	we will, in fact, work on this to make it a little			
25	clearer.			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	56			
1	The way this works is that supposing we			
2	have a specific application in mind or a licensee has.			
3	What Box 2 asks is are we in Phase 3 yet. Do we have			
4	all of the Phase 3 guidance in place?			
5	If we have, then we would kick off to the			
б	next flow chart, while I'll talk about I think in a			
7	few minutes.			
8	(Laughter.)			
9	MR. PARRY: If we're not in Phase 3 yet,			
10	then we'll go to Box 3 and ask what are the risk			
11	contributors that are needed to support the identified			
12	application.			
13	And, again, I'll remind you what I mean by			
14	contributor is do I include low power shutdown; do I			
15	include external events.			
16	In Box 4 we'd ask is the guidance in place			
17	to address the identified contributors for this			
18	specific application. So if the specific application			
19	requires an internal events PRA and a fire PRA, what			
20	that box is asking me is do I have the standards in			
21	place for the fire and the internal events.			
22	If I say yes, I'm in Phase 2. So I come			
23	out on the right-hand side of the box, the Box 4, and			
24	I go to Box 10, and			
25	MR. TSCHILTZ: Just a clarification on			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	57
1	that. It's more than just the standards. It's also
2	the regulatory guidance and industry documents that go
3	along with the specific application.
4	MR. PARRY: Yes. Thanks, Mike. It's all
5	of the guidance in place.
6	Now, Phase 2 then in Box 10 asks has the
7	licensee's base PRA conformed to the existing standard
8	for the risk significant contributors. If it has,
9	then, yes, we're doing a Phase 2 application, and it
10	will get a normal well, sorry a high priority
11	NRC review of that application.
12	Now, you'll notice that the words that we
13	use in these boxes are high and low priority. Don't
14	necessarily get hung up on those words right now. We
15	haven't really figured out precisely what that means,
16	but it certainly denotes a relative priority at least.
17	CHAIRMAN APOSTOLAKIS: But also I assume
18	it means that the decision will be weak.
19	MR. PARRY: It will be timely, whatever
20	that
21	CHAIRMAN APOSTOLAKIS: I mean there is
22	guidance. There are documents.
23	MR. PARRY: Right.
24	CHAIRMAN APOSTOLAKIS: They comply.
25	MR. PARRY: It should be relatively quick.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	58		
1	You're right.		
2	CHAIRMAN APOSTOLAKIS: Yeah. Now, when		
3	you say "high priority," you don't drop everything as		
4	you're doing. Right?		
5	MR. PARRY: No, no, no.		
6	CHAIRMAN APOSTOLAKIS: In terms of future		
7	activities, you put it high under		
8	MR. PARRY: The real distinction is		
9	between the high and the low. The low go to the		
10	bottom of the pile, and the high come into the pile at		
11	the appropriate level.		
12	DR. KRESS: They get factored in.		
13	MR. PARRY: No, they get normal.		
14	DR. BONACA: more is the extent of		
15	review you're going to perform there?		
16	CHAIRMAN APOSTOLAKIS: What?		
17	DR. BONACA: Is it possible?		
18	MR. PARRY: No, I think the		
19	DR. BONACA: As a measure of the amount of		
20	review you're		
21	MR. PARRY: Actually I think that's what		
22	makes it high or low. If you need to do a lot of		
23	review, then that means it's going to get a lower		
24	priority.		
25	PARTICIPANT: It's inversely proportional.		

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	59			
1	MR. PARRY: It's a resource thing.			
2	DR. BONACA: That's how I read it.			
3	MR. PARRY: That's really effectively the			
4	impact, yeah.			
5	PARTICIPANTS: In some way.			
6	MR. PARRY: Okay. Now, if the licensee's			
7	base PRA does not conform to all of those standards,			
8	for example, if he doesn't have a fire PRA and yet he			
9	should have one, then he's really coming in with a			
10	Phase 1 type application when we have the Phase 2			
11	guidance in place.			
12	CHAIRMAN APOSTOLAKIS: When is this			
13	applied now? In the future?			
14	MR. PARRY: When we have the			
15	CHAIRMAN APOSTOLAKIS: In 2008?			
16	MR. PARRY: When we have the guidance in			
17	place of Phase 2, right. It doesn't apply right now.			
18	CHAIRMAN APOSTOLAKIS: No, you can even go			
19	to Phase 3 you said from Box 2.			
20	MR. PARRY: That's also in the future.			
21	CHAIRMAN APOSTOLAKIS: So this whole thing			
22	is for 2008?			
23	MR. PARRY: This is explaining well,			
24	maybe before 2008.			
25	CHAIRMAN APOSTOLAKIS: Because you will			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	60			
1	never go to Phase 3 before 2008.			
2	MR. PARRY: We won't go to Phase 3 before			
3	2008, but we can certainly come down			
4	CHAIRMAN APOSTOLAKIS: This time			
5	invariate.			
6	MR. PARRY: Yeah. This is trying to			
7	explain how the process will work when we get into the			
8	various phases. So when we get into Phase 2, that's			
9	where I'm at now. I have the Phase 2 guidance for a			
10	specific application and			
11	CHAIRMAN APOSTOLAKIS: Wait a minute. Let			
12	me understand again Box 2. In the year of 2009, if			
13	everything goes as planned, there will be guidance in			
14	place for Phase 3.			
15	MR. PARRY: Right. So we wouldn't need to			
16	come down this.			
17	CHAIRMAN APOSTOLAKIS: That doesn't mean			
18	you automatically go to the right because the licensee			
19	may have not			
20	MR. PARRY: That's true. That's true,			
21	which is another question.			
22	CHAIRMAN APOSTOLAKIS: So it's not a			
23	matter of the guidance existing. Also the licensee			
24	must have complied.			
25	MS. DROUIN: You will see that when we get			

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

 8 is. 9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next 		61		
 flow chart I think you need to send that message. MR. PARRY: No, no, no. MS. DROUIN: That message is on the next flow chart. MR. PARRY: Is also on the next one. It is. DR. ROSEN: It's continued. MR. PARRY: Right. MR. SNODDERLY: It goes to the next viewgraph. MR. PARRY: Right, it goes to the next one. MR. SNODDERLY: And it would receive a higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	ow chart.			
4 MR. PARRY: No, no, no. 5 MS. DROUIN: That message is on the next 6 flow chart. 7 MR. PARRY: Is also on the next one. It 8 is. 9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next	AIRMAN APOSTOLAKIS:	No, but in this		
5 MS. DROUIN: That message is on the next 6 flow chart. 7 MR. PARRY: Is also on the next one. It 8 is. 9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next	hink you need to sen	l that message.		
 flow chart. MR. PARRY: Is also on the next one. It is. DR. ROSEN: It's continued. MR. PARRY: Right. MR. SNODDERLY: It goes to the next viewgraph. MR. PARRY: Right, it goes to the next one. MR. SNODDERLY: And it would receive a higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	. PARRY: No, no, no			
7 MR. PARRY: Is also on the next one. It 8 is. 9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive at 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next	. DROUIN: That mess	ge is on the next		
 8 is. 9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next 	flow chart.			
9 DR. ROSEN: It's continued. 10 MR. PARRY: Right. 11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next	. PARRY: Is also on	the next one. It		
 MR. PARRY: Right. MR. SNODDERLY: It goes to the next viewgraph. MR. PARRY: Right, it goes to the next one. MR. SNODDERLY: And it would receive a higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	is.			
11 MR. SNODDERLY: It goes to the next 12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next	. ROSEN: It's conti	ued.		
<pre>12 viewgraph. 13 MR. PARRY: Right, it goes to the next 14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next</pre>	. PARRY: Right.			
 MR. PARRY: Right, it goes to the next one. MR. SNODDERLY: And it would receive a higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	MR. SNODDERLY: It goes to the next			
<pre>14 one. 15 MR. SNODDERLY: And it would receive a 16 higher priority than Box 11. 17 MR. PARRY: Well, wait until we get there. 18 Forget that for now. Wait until we get to the next</pre>	viewgraph.			
 MR. SNODDERLY: And it would receive a higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	. PARRY: Right, it	goes to the next		
 higher priority than Box 11. MR. PARRY: Well, wait until we get there. Forget that for now. Wait until we get to the next 	one.			
17MR. PARRY: Well, wait until we get there.18Forget that for now. Wait until we get to the next	. SNODDERLY: And it	would receive a		
18 Forget that for now. Wait until we get to the next	higher priority than Box 11.			
	. PARRY: Well, wait u	ntil we get there.		
	Forget that for now. Wait until we get to the next			
19 viewgraph.				
20 Box 10, for the risk significant	x 10, for the	isk significant		
21 contributors, right, he hasn't done a PRA for one of	contributors, right, he hasn't done a PRA for one of			
22 the risk significant contributors. Then he comes	the risk significant contributors. Then he comes			
down, no, out of Box 10 to Box 12, and remember that	of Box 10 to Box 12,	and remember that		
24 one of our requisites for all of these risk informed	uisites for all of th	ese risk informed		
25 applications is that all contributors need to be	s that all contrib	utors need to be		

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	62
1	addressed one way or another.
2	If the risk contributors are not addressed
3	by any other means, then that's an inadequate
4	submittal and it will be rejected.
5	If, on the other hand, they are addressed,
6	we'll kick out and go to Box 13, and there's a typo in
7	there and that should read "low priority." Okay? For
8	which we apologize.
9	That may be correct in the
10	MS. DROUIN: It's correct in the plan.
11	MR. PARRY: It's correct in the plan, but
12	it's not on this figure.
13	PARTICIPANT: That makes a hell of a
14	difference.
15	MR. PARRY: Yeah, it does make a hell of
16	a difference, yeah. Okay?
17	So that was the easy part of this. Okay?
18	DR. BONACA: So that's the stimulus to
19	MR. PARRY: Yes.
20	DR. BONACA: perform whatever guidance
21	is available.
22	MR. PARRY: Right.
23	MR. MAGRUDER: Yeah, that becomes the
24	stimulus for the licensee to do the PRA for the scope
25	of what they need.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	63
1	DR. BONACA: And that really interprets
2	what is really written in the SRM, in fact, at the
3	bottom of the page.
4	MR. PARRY: Right. That's the clear one.
5	Now, supposing now that we're in Box 4 and
6	three is an application that has identified a number
7	of significant, potentially significant contributors
8	to the decision, but the guidance isn't all in place
9	yet. So we come out of there with no
10	And we enter Box 5, which is where we got
11	hung up yesterday tremendously, and even though we had
12	fixed the words from what you have in the plan to more
13	accurately represent the message that we were trying
14	to generate by this particular box.
15	Okay. What we're saying in this box is,
16	and this is a proposal, okay; this is going to be a
17	source of quite a lot of discussion, I believe. What
18	we're saying in this box is has the licensee got an
19	application where he's using a PRA scope that's
20	greater than that for which the guidance exists, okay,
21	and you can think of this as if there's guidance out
22	there for internal event fire PRA, but he wants to use
23	a fire PRA in his application, but he's using i for a
24	specific purpose, which is to expand the scope of the
25	application, and a good example of this would be 5069,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	64
1	what 5069 does is it allows relaxation from special
2	treatment requirements. If it current let me flip
3	forward. I think there's a yeah, let me flip
4	forward to Slide 19.
5	In the current vision of 5069, what the
6	NEI 00.04 categorization process does is it allows the
7	use of non-PRA methods for certain contributors. But
8	what it does is that it restricts the scope of SSEs to
9	which 5069 could be applied by saying if you're in one
10	of these non-PRA methods and you're using those SSE's
11	to demonstrate that the risk is small from those
12	contributors, you're not allowed to put those in the
13	scope of 5069. So they all remain in their current
14	classifications.
15	All of the risk one SSEs that you rely on
16	will remain risk one. You can't adjust them.
17	Now, we have Reg. Guide 1.200. Once we
18	have regulatory guide endorsing NEI 00.04, which would
19	come from DG-1121, and if it endorses the current
20	version of NEI 00.04, then what we could have is we
21	could have a Phase 2 application because we have all
22	of the guidance in place, but only for those licensees
23	that are just going to recategorize the components
24	that are in the Level 1 and the limited Level 2 PRA.
25	If they follow the guidance in NEI 00.04
1	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	65
1	and don't recategorize the things that these fires,
2	seismic, others, then there will be a Phase 2.
3	Now, if they want to use a fire PRA in
4	addition to the internal events PRA, it means they
5	have a chance of putting a lot more components into
6	the risk three category, therefore more relaxation.
7	But this would then be a Phase 1
8	application effectively until the standard for the
9	fire PRA is completed. Okay?
10	So now let me back up to the flow chart.
11	What we've suggested here in this box is if they were
12	to do that before we have the standards available,
13	this would have to be a more resource intensive review
14	on our part and, therefore, we propose tentatively
15	that this would be low priority. Okay?
16	Now, we're getting arguments that, well,
17	okay, but this doesn't really give incentive to
18	licensees to develop PRAs, and there's truth in that.
19	MR. TSCHILTZ: It does incentivize the
20	development of the standard.
21	PARTICIPANTS: Yeah.
22	MR. PARRY: So we had identified this as
23	a potential policy issue. Now, maybe after
24	discussions among the staff, we may decide that that's
25	not where we go, but currently we can see that it

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

66 might be because it has some pros and some cons 1 2 associated with it. 3 Now, one of the things that occurred to me 4 this morning while listening to the tech spec 4(b) 5 initiative this morning is that that's -- and that's an example we've been discussing -- is that that is an 6 7 area where we think the fire PRA would be extremely useful, if not essential, to do this, and yet the 8 standards don't exist. 9 Well, this hasn't been 10 I'm wondering. 11 thought through, but it's possible that if we were to 12 argue that that was clearly a safety improvement by using that, then even before the standards were 13 14 available, we might not choose to make that a low 15 priority review, which I think addresses to some extent the question that you had obviously. 16 17 CHAIRMAN APOSTOLAKIS: But there's an element here that at least to me is very new. 18 Ιt 19 the consequences various appears that of 20 possibilities, the consequences are really whether you 21 place the application you're assigning a high priority 22 or low priority. 23 PARTICIPANTS: Yes. 24 CHAIRMAN APOSTOLAKIS: Which is not 25 mentioned in the SRM at all, as far as I remember.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1MR. PARRY: Well, it is.2CHAIRMAN APOSTOLAKIS: It is?3MR. PARRY: Yes, it is.4CHAIRMAN APOSTOLAKIS: Tell me where.5MR. TSCHILTZ: It's in the Phase 26section, at the end of Phase 2.7MR. PARRY: See, how this example is a8little beyond that. Okay?9CHAIRMAN APOSTOLAKIS: This isn't a10real the real thing is that if you don't have the11 if you have it and you don't comply, it takes much12longer to approve it, does it not?13MR. MAGRUDER: Right.14CHAIRMAN APOSTOLAKIS: That's really what15happens.16MR. MAGRUDER: Right.17CHAIRMAN APOSTOLAKIS: Because you can't18say forever, "Look. It's low priority. We have other19things to do."20DR. ROSEN: Oh, no?21Laughter.)22DR. ROSEN: I would just revise you23remarks and extend it by saying you can and the staff24has many, many times said, "Look. This is such low25priority we'll probably never get to it because by the		67
3 MR. PARRY: Yes, it is. 4 CHAIRMAN APOSTOLAKIS: Tell me where. 5 MR. TSCHILTZ: It's in the Phase 2 6 section, at the end of Phase 2. 7 MR. PARRY: See, how this example is a 8 little beyond that. Okay? 9 CHAIRMAN APOSTOLAKIS: This isn't a 10 real the real thing is that if you don't have the 11 if you have it and you don't comply, it takes much 12 longer to approve it, does it not? 13 MR. MAGRUDER: Right. 14 CHAIRMAN APOSTOLAKIS: That's really what 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	1	MR. PARRY: Well, it is.
4 CHAIRMAN APOSTOLAKIS: Tell me where. 5 MR. TSCHILTZ: It's in the Phase 2 6 section, at the end of Phase 2. 7 MR. PARRY: See, how this example is a 8 little beyond that. Okay? 9 CHAIRMAN APOSTOLAKIS: This isn't a 10 real the real thing is that if you don't have the 11 if you have it and you don't comply, it takes much 12 longer to approve it, does it not? 13 MR. MAGRUDER: Right. 14 CHAIRMAN APOSTOLAKIS: That's really what 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	2	CHAIRMAN APOSTOLAKIS: It is?
5MR. TSCHILTZ:It's in the Phase 26section, at the end of Phase 2.7MR. PARRY:8little beyond that.8little beyond that.9CHAIRMAN APOSTOLAKIS:10real the real thing is that if you don't have the11 if you have it and you don't comply, it takes much12longer to approve it, does it not?13MR. MAGRUDER:14CHAIRMAN APOSTOLAKIS:15happens.16MR. MAGRUDER:17CHAIRMAN APOSTOLAKIS:18say forever, "Look. It's low priority. We have other19things to do."20DR. ROSEN:21(Laughter.)22DR. ROSEN:23remarks and extend it by saying you can and the staff24has many, many times said, "Look. This is such low	3	MR. PARRY: Yes, it is.
 section, at the end of Phase 2. MR. PARRY: See, how this example is a little beyond that. Okay? CHAIRMAN APOSTOLAKIS: This isn't a real the real thing is that if you don't have the if you have it and you don't comply, it takes much longer to approve it, does it not? MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: That's really what happens. MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: Because you can't say forever, "Look. It's low priority. We have other things to do." DR. ROSEN: Oh, no? (Laughter.) DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low 	4	CHAIRMAN APOSTOLAKIS: Tell me where.
7MR. PARRY: See, how this example is a8little beyond that. Okay?9CHAIRMAN APOSTOLAKIS: This isn't a10real the real thing is that if you don't have the11 if you have it and you don't comply, it takes much12longer to approve it, does it not?13MR. MAGRUDER: Right.14CHAIRMAN APOSTOLAKIS: That's really what15happens.16MR. MAGRUDER: Right.17CHAIRMAN APOSTOLAKIS: Because you can't18say forever, "Look. It's low priority. We have other19things to do."20DR. ROSEN: Oh, no?21ILaughter.)22DR. ROSEN: I would just revise you23remarks and extend it by saying you can and the staff24has many, many times said, "Look. This is such low	5	MR. TSCHILTZ: It's in the Phase 2
 8 little beyond that. Okay? 9 CHAIRMAN APOSTOLAKIS: This isn't a 10 real the real thing is that if you don't have the 11 if you have it and you don't comply, it takes much 12 longer to approve it, does it not? 13 MR. MAGRUDER: Right. 14 CHAIRMAN APOSTOLAKIS: That's really what 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low 	6	section, at the end of Phase 2.
 9 CHAIRMAN APOSTOLAKIS: This isn't a 10 real the real thing is that if you don't have the 11 if you have it and you don't comply, it takes much 12 longer to approve it, does it not? 13 MR. MAGRUDER: Right. 14 CHAIRMAN APOSTOLAKIS: That's really what 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low 	7	MR. PARRY: See, how this example is a
10 real the real thing is that if you don't have the 11 if you have it and you don't comply, it takes much 12 longer to approve it, does it not? 13 MR. MAGRUDER: Right. 14 CHAIRMAN APOSTOLAKIS: That's really what 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	8	little beyond that. Okay?
 if you have it and you don't comply, it takes much longer to approve it, does it not? MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: That's really what happens. MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: Because you can't say forever, "Look. It's low priority. We have other things to do." DR. ROSEN: Oh, no? (Laughter.) DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low 	9	CHAIRMAN APOSTOLAKIS: This isn't a
12 longer to approve it, does it not? MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: That's really what happens. MR. MAGRUDER: Right. MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: Because you can't say forever, "Look. It's low priority. We have other things to do." DR. ROSEN: Oh, no? (Laughter.) DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low	10	real the real thing is that if you don't have the
 MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: That's really what happens. MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: Because you can't say forever, "Look. It's low priority. We have other things to do." DR. ROSEN: Oh, no? (Laughter.) DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low 	11	if you have it and you don't comply, it takes much
14CHAIRMAN APOSTOLAKIS: That's really what15happens.16MR. MAGRUDER: Right.17CHAIRMAN APOSTOLAKIS: Because you can't18say forever, "Look. It's low priority. We have other19things to do."20DR. ROSEN: Oh, no?21(Laughter.)22DR. ROSEN: I would just revise you23remarks and extend it by saying you can and the staff24has many, many times said, "Look. This is such low	12	longer to approve it, does it not?
 15 happens. 16 MR. MAGRUDER: Right. 17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low 	13	MR. MAGRUDER: Right.
MR. MAGRUDER: Right. CHAIRMAN APOSTOLAKIS: Because you can't say forever, "Look. It's low priority. We have other things to do." DR. ROSEN: Oh, no? (Laughter.) DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low	14	CHAIRMAN APOSTOLAKIS: That's really what
17 CHAIRMAN APOSTOLAKIS: Because you can't 18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	15	happens.
<pre>18 say forever, "Look. It's low priority. We have other 19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low</pre>	16	MR. MAGRUDER: Right.
<pre>19 things to do." 20 DR. ROSEN: Oh, no? 21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low</pre>	17	CHAIRMAN APOSTOLAKIS: Because you can't
20DR. ROSEN: Oh, no?21(Laughter.)22DR. ROSEN: I would just revise you23remarks and extend it by saying you can and the staff24has many, many times said, "Look. This is such low	18	say forever, "Look. It's low priority. We have other
21 (Laughter.) 22 DR. ROSEN: I would just revise you 23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	19	things to do."
DR. ROSEN: I would just revise you remarks and extend it by saying you can and the staff has many, many times said, "Look. This is such low	20	DR. ROSEN: Oh, no?
23 remarks and extend it by saying you can and the staff 24 has many, many times said, "Look. This is such low	21	(Laughter.)
24 has many, many times said, "Look. This is such low	22	DR. ROSEN: I would just revise you
	23	remarks and extend it by saying you can and the staff
25 priority we'll probably never get to it because by the	24	has many, many times said, "Look. This is such low
	25	priority we'll probably never get to it because by the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	68
1	time we get to it, there will be something else here
2	that's higher priority.
3	MR. PARRY: Effectively that's what it
4	means.
5	DR. ROSEN: The only one that leaves us
6	constrained to the dust bin of history.
7	DR. BONACA: Box 6, it's an issue.
8	CHAIRMAN APOSTOLAKIS: What?
9	DR. BONACA: Box 6 is an issue because, I
10	mean
11	MR. PARRY: It is.
12	DR. BONACA: I mean, just because they
13	were a pilot, you know, Texas Project went through,
14	but that would be a case where somebody comes with a
15	PRA like Texas project and submit the application to
16	cover a wide scope of components for which there is no
17	guidance now and you put them on a slow burn. They
18	may have the best PRA that there is.
19	MR. PARRY: But the reason that we did
20	that though is because of the resources. That's the
21	reason we put that in here.
22	MR. TSCHILTZ: If I can also look at the
23	approach from the staff's point of view, if you have
24	103 different facilities taking different approaches
25	to all of this and then having to do individual

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	69
1	specific reviews for each one of these, the burden
2	becomes huge, especially for something like 5069.
3	DR. BONACA: No, I'm not arguing the fact
4	that there isn't a logic behind that. It's just
5	simply that I'm reflecting on this as I also think on
6	the letter that the SME sent essentially filling that
7	already the timetable is addressed and they may not be
8	able to support it.
9	So if standards take so long to develop,
10	what's the timetable? I'm afraid that I won't in my
11	lifetime be able to see much progress.
12	DR. ROSEN: I want to comment, Mario, on
13	your point about the South Texas initiative. It was
14	not done in this framework.
15	PARTICIPANTS: Right.
16	DR. ROSEN: It was done in this 50.12
17	exemption framework, which I would suspect anybody
18	else who came in and said they want an exemption from
19	regulations and showed cause as South Texas did in
20	their case, that you would take them out of this
21	process and handle it some other way.
22	DR. BONACA: Plus there was an enormous,
23	intense review that took place because it was an
24	interesting pilot. I'm only saying that, however, in
25	this case you could have somebody with the reputation

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

70 1 developing state of the art PRA, covering all of the 2 ground, et cetera, and you won't be able to do much 3 with it. MR. TSCHILTZ: If I can comment, I think 4 5 one of the thought that we were having was if a licensee came in with a new approach to something on 6 7 a proof of principle or proof of concept on something, that that wouldn't really be in this process because 8 9 you're trying to do something that will then eventually become guidance or become a standard or it 10 11 may feed back in. 12 Similar to like pilot applications, you wouldn't want to say, "Well, we're piloting the 13 14 guidance. Therefore it's not in place. Therefore, 15 you get a low priority review during the pilot. We don't want to be in that type of Catch-22. 16 Catch-22. You would never 17 DR. ROSEN: have got to 5069 if that's the way you were doing it. 18 19 MR. TSCHILTZ: Right, and so one thought 20 is that things like that are really not part of this 21 They're a developmental process. process. 22 CHAIRMAN APOSTOLAKIS: Can you find 23 different word? High/low priority is not the right in 24 my mind. Can't you find other words that indicate 25 happiness and unhappiness?

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	71
1	(Laughter.)
2	CHAIRMAN APOSTOLAKIS: I'm serious. Low
3	priority is like, you know, I'll punish you. You go
4	outside for an hour. I mean, come on, and then you
5	have these problems.
6	But the Commission mentions low priority,
7	but it doesn't mean or nonconformance?
8	MR. PARRY: It is one of the issues, I
9	think, that we have to address in our implementation
10	plan of what the different levels of priority are.
11	Maybe there need to be more than two.
12	CHAIRMAN APOSTOLAKIS: Yeah, or you can
13	say, you know, NRC staff detailed review required,
14	which means, you know, you send them 1,000 RAIs. I
15	mean something a little more professional than saying
16	that we'll punish you. You're going down.
17	MR. PARRY: Well, okay.
18	CHAIRMAN APOSTOLAKIS: I don't like it.
19	I mean, do other members feel that a high priority
20	DR. ROSEN: It's perfectly clear to me,
21	George, what low priority for NRC staff review of a
22	license request means. From an industry's perspective
23	that means nothing. It means you can forget it.
24	That's what it means.
25	CHAIRMAN APOSTOLAKIS: So it's really a
-	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

rejection of the submittal. Well, you should actually say that.

Well, but we haven't set 3 MR. TSCHILTZ: 4 that structure yet. I mean, what I envision you could 5 have is for the normal review process right now is we have goals that say we'll complete 95 percent of those 6 7 reviews in one year. In two years we will complete all license application reviews. I could envision one 8 9 answer being that if it's a low priority or a resource 10 intensive, that for those they would not be on that one year-two year clock. They would be on a different 11 12 time clock.

13 DR. ROSEN: As your resources become 14 available, which is what --

MR. MAGRUDER: Well, but you would still want to have a date. You would still want to say two years or three or something like that.

I mean, if I could just 18 MR. TSCHILTZ: 19 interject, the one thing that I think I see that I 20 don't think anyone has commented on is that there's 21 some licensees who are progressive in regard to the 22 developing PRAs for which standards don't exist, and 23 I would open it to Biff to comment if he disagrees on 24 this, is that I think the vast majority of licensees 25 now that they see that standards are being developed

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

73 1 for these different portions of the PRA are going to wait till the standard is in place before they invest 2 in developing those PRAs because they don't want to 3 4 develop something that's not in accordance with the 5 standard that's going to come out a year or two later. DR. ROSEN: I heard the other argument the 6 7 other day that some licensees are suggesting that 8 since the standards are not in place, that in fact, 9 be standards that still they cannot enough 10 practitioners actually get out and do these things. 11 So it's kind of a reverse Catch-22 thing. You can't 12 get a standard until, you know, a majority of people do it, the state of the practice, let's say. 13 14 So standards don't come along until kind 15 of everybody does it this way. Then you get a standard. So that's just the obverse of what you were 16 17 just saying. Sine Mike invited me to 18 MR. BRADLEY: 19 comment, I will. I would tend to agree with him that 20 there are a lot of licensees that aren't going to 21 further develop their PRAs now, given that standards 22 are imminent or semi-imminent. 23 However, there are a lot of licensees that 24 have put significant investments into, say, fire PRAs. 25 About half of the licensees do have fire PRAs versus

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

74
five or some other method, and the same is true with
seismic. About 50 percent of the licensees do have
seismic PRAs and our concern with this BOTS-5, BOTS-6,
as it was. It would tend to say, well, you have that
model, and in some cases it may be a pretty good model
even though the standard is not developed yet, and it
would essentially say, "Well, I can't use it."
For applications I'm doing between now and
the time that standards out, which in the case of fire
we're talking a long time to get the standard
developed, you know, peer reviewed, endorsed by the
staff. We're talking five to eight to ten years, you
know, a fair length of time. In that long interim
plants may have a pretty good fire PRA that they're
pretty much going to have to put it on the shelf.
That was our concern with that box.

And even in the example of 5069, the way that is tailored, if a plant is planning to use a fire PRA, it's probably because they chose to develop a fire PRA instead of a five. So they don't have the fall-back position of being able to take everything on their five, say, shutdown path keep that high and keep it risk one. They'd either have to go out -- they'd nearly be forced to go out and do five even though they have a fire PRA.

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

	75
1	So there are a number of we saw troubling
2	issues with that BOTS. I understand the staffs need
3	to conserve their resources on this, but a Gareth
4	said, there was just a tremendous amount of discussion
5	yesterday on that BOTS-5 and BOTS-6.
6	MR. PARRY: And we were aware that there
7	would be when we chose to go this path. So really
8	it's a that's why we proposed it as a potential
9	policy issue in which we would develop all of the pros
10	and cons, including what we just heard from Biff.
11	So I think this is not cut and dry, but
12	this is an issue, I think, that is significant and,
13	you know, some of these things you can't really
14	predict how it would work out if you chose one path or
15	another.
16	CHAIRMAN APOSTOLAKIS: But, again, what
17	bothers me about this is that the whole thing is
18	driven by the existence of standards.
19	MR. PARRY: But that's the way the phases
20	are defined, George.
21	CHAIRMAN APOSTOLAKIS: It is very
22	troubling. I mean, I can see the standards playing a
23	role, but you reach the point where you say, you know,
24	you have done a state of the art
25	MR. PARRY: Who says?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	76
1	CHAIRMAN APOSTOLAKIS: analysis of
2	fires, but because there is no standard, whew, we are
3	punishing you. That doesn't make sense to me. This
4	is too standard driven. Somehow we have to relax that
5	a little bit.
б	DR. ROSEN: Well, the part about standards
7	driven that bothers me is that if the standards
8	development organization decides not to proceed on the
9	schedule that's on or not at all, then I think that
10	leaves the whole thing in the staff's hands.
11	MR. PARRY: If they don't do that though,
12	then we're probably in Phase 1 forever, and that does
13	leave us in
14	DR. ROSEN: Then that's obviously not
15	where the staff wants to be.
16	MR. TSCHILTZ: But I think the other thing
17	that we learned at yesterday's meeting was that maybe
18	the prioritization of development of standards needs
19	to be rethought because fire is fairly far out in the
20	future, but when you look at its contribution to risk
21	and the insights you get from it, they're substantial
22	as compared to others.
23	So maybe there ought to be a
24	reprioritization of the scheduling of the development
25	of some of these standards so that the high priority

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	77
1	are the ones that are at the greatest risk
2	contributor.
3	CHAIRMAN APOSTOLAKIS: Is there any
4	evidence anywhere that some organization or some
5	groups are resisting the issuance of standards and
6	guidance?
7	MR. TSCHILTZ: No, I don't think so.
8	CHAIRMAN APOSTOLAKIS: Dragging their
9	feet?
10	MS. DROUIN: I don't think you have
11	absolute agreement that there's standards. I think
12	you have a consensus, which is different than
13	everybody agreeing.
14	CHAIRMAN APOSTOLAKIS: But you're going
15	now to the technical level.
16	MS. DROUIN: No. I'm just saying whether
17	or not you should have standards.
18	CHAIRMAN APOSTOLAKIS: One way of
19	interpreting the four phases, and this diagram
20	certainly supports that, is that it puts pressure on
21	everybody to develop the guidance of the standard.
22	Okay?
23	Even if you have an excellent PRA, Box 6
24	says you had better develop the standards as soon as
25	you can. Question: do I need that? Is anybody

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	78
1	resisting having standards so that I need to publish
2	this and say, "You do it or else"?
3	I don't know.
4	MR. PARRY: I have certainly heard people
5	argue that you don't need standards, that all you need
6	is peer review, but again, if you don't know how the
7	peer review from our point as a regulatory agency,
8	we don't know the rules that the peer review has used.
9	It's sort of buying a pig in a poke.
10	CHAIRMAN APOSTOLAKIS: So far the peer
11	reviews really have tremendous latitude, don't they?
12	The so-called standards really tell them what elements
13	to look at, but how these elements are satisfied or
14	performed, I don't think there is much guidance.
15	MR. PARRY: That's true.
16	CHAIRMAN APOSTOLAKIS: But that's where
17	the action is, right?
18	MR. PARRY: Yeah, but you know, a lot of
19	the things but that's where the peer reviews
20	probably do come into their own because they will
21	use
22	CHAIRMAN APOSTOLAKIS: Right.
23	MR. PARRY: But they are required to
24	document whether the assumptions that have been made
25	or the methods that are used are appropriate.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	79
1	CHAIRMAN APOSTOLAKIS: Which we have
2	already, right?
3	MR. PARRY: Which then you can read.
4	CHAIRMAN APOSTOLAKIS: We do have that
5	now, don't we?
6	MR. PARRY: Well, that's what the peer
7	review process asked people to do, right?
8	CHAIRMAN APOSTOLAKIS: Yes. Let me make
9	it clear what confuses me a little bit. If this whole
10	effort, the intent of the SRM and the implementation
11	plan, is to make sure that we have guidance
12	collectively how that means standards and regulatory
13	guides as soon as we can, I'm a little puzzled by
14	that because I haven't sensed that people have
15	objected to having standards.
16	I mean, it takes time, sure. You have to
17	agree. You have disagreements, this and that and so
18	on, the other thing. So why go through all of this?
19	You have a whole SRM just to develop standards. Is
20	that the point or am I missing something?
21	MR. MAGRUDER: I think that one of the
22	main points of the SRM is to make sure that the staff
23	and the public have more confidence in the results of
24	the PRAs and how we use the PRAs, and I think the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	80
1	have consensus standards in place so that everybody
2	can point to them and say, "We know this is a good PRA
3	because it meets this standard.
4	CHAIRMAN APOSTOLAKIS: Even at the expense
5	of perhaps punishing somebody who is doing a good job
6	now, but because there's no standard, we put them on
7	the low priority.
8	MR. MAGRUDER: Well, I'm not sure if
9	punishing is the right word.
10	CHAIRMAN APOSTOLAKIS: Penalizing.
11	MR. MAGRUDER: I don't think. I think
12	MR. PARRY: Not even penalize. It's just
13	not allowing as much
14	MR. MAGRUDER: Prioritizing our reviews,
15	I think is
16	DR. ROSEN: I have a little bit different
17	take on this same subject. It's very clear, and I
18	agree that the Commission wants to have criteria for
19	judging the adequacy of PRAs, and that's absolutely
20	correct and we should have them.
21	And they have chosen to select the
22	consensus standards process for doing that, forgetting
23	those criteria in place for judging adequacy, and
24	that's exactly the right thing to do.
25	In fact, there's a circular from the OMB

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	81
1	that suggests that you had better do that, and
2	certainly the Commission rightfully reads those
3	circulars from the OMB.
4	And that's the course they're on now. All
5	of this makes sense. The question is: what if the
6	standards organization either decides not to do the
7	standard at all, in other words, there is no consensus
8	standard being developed, or they choose to stretch it
9	out for much, much longer than the Commission has
10	tolerance for.
11	So what I think the out for this and I
12	frame the problem and I think the solution for the
13	problem is for the staff to make it explicit that if
14	this thing gets protracted for too long or if the
15	standards aren't going to be done at all, that the
16	staff is going to independently develop its own what
17	do you call them? Regulatory guides? Whatever other
18	document that the staff wants to have for judging the
19	adequacy of the work.
20	I mean, that gets you out of the bind of
21	putting this over into the standards development.
22	DR. SIEBER: But the staff always has that
23	option.
24	DR. ROSEN: The staff always has that
25	option, but they ought to make it

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	82
1	DR. SIEBER: You can use it at any time.
2	DR. ROSEN: They kind of make it explicit
3	in the overarching material that leads us into these
4	diagrams, I think.
5	CHAIRMAN APOSTOLAKIS: But what if the
6	standard says do a human reliability analysis? As far
7	as I'm concerned, it's useless unless you tell me how
8	you're going to do it.
9	DR. ROSEN: Well, then you're a
10	stakeholder who ought to say so when you
11	CHAIRMAN APOSTOLAKIS: But to make such a
12	big deal out of having a standard that is vacuous
13	bothers me. Don't you need the regulatory guide to
14	tell you how to actually do the things that the ASME
15	standard requires?
16	MR. PARRY: No, not necessarily.
17	CHAIRMAN APOSTOLAKIS: Yeah, you do.
18	MR. PARRY: What the standard I'll pick
19	on HRA as one area what it does, it tells you the
20	thing that the HRA has to do. What it falls short on
21	is telling you which quantitative method to use, and
22	I don't but it does have certain requirements for
23	that quantitative method, which I think if they're
24	applied correctly will give the right relative values
25	to the human error probabilities for the various

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	83
1	scenarios.
2	DR. SIEBER: Agreed.
3	MR. PARRY: And we can live with that
4	because we know those HEPs are always going to be
5	uncertain, and we will factor that into our decision
6	making.
7	MS. DROUIN: Let me go a step further,
8	George, picking up with what Gareth said. If I go
9	back to when we were reviewing the IPEs, you know, we
10	ha da lot of problems with the HRAs. I would submit
11	that the standard as it exists today, if it had
12	existed prior to the generic letter, a lot of the
13	problems that we had with HRA would not have occurred.
14	CHAIRMAN APOSTOLAKIS: Fine.
15	MS. DROUIN: Because it has enough
16	guidance in it for some of the major problems we
17	found.
18	CHAIRMAN APOSTOLAKIS: Why are you trying
19	Regulatory Guide 1.200? What's in it?
20	DR. SIEBER: It endorses the standard.
21	CHAIRMAN APOSTOLAKIS: That's all it does?
22	PARTICIPANT: Well, it does much more.
23	DR. SIEBER: Yeah, there's a lot more in
24	it.
25	MS. DROUIN: It does more than that.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	84
1	CHAIRMAN APOSTOLAKIS: And why was there
2	a need for 1.200? Because the ASME standard by itself
3	is not sufficient.
4	MR. PARRY: But Reg. Guide 1.200 doesn't
5	fill in the gaps that you are worried about in the
6	ASME standard. It's a vehicle for endorsing the ASME
7	standard according to some high level requirements on
8	these analyses.
9	CHAIRMAN APOSTOLAKIS: It imposes some
10	addition stuff. I mean, there is explanations, as I
11	recall.
12	DR. ROSEN: We're not giving standards
13	enough credit in this discussion. The other value of
14	standards is that it establishes the framework for
15	advancing in the future.
16	MS. DROUIN: Absolutely.
17	DR. ROSEN: People can come in and say,
18	"Here. With respect to this paragraph of the standard
19	we need to expand it. Here's a suggested alternative
20	that's better." And that's the way to move forward.
21	CHAIRMAN APOSTOLAKIS: Isn't it true that
22	I can have two licensees both complying with the ASME
23	standard, submit an application, and one is rejected
24	and the other is accepted at PRA expense?
25	MR. PARRY: I think it's possible, but I

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

think it would be on the basis that the assumptions 2 that one had made were not appropriate. That would be the basis for rejection because if they met the 3 4 standard, they would at least have the fundamental 5 logic framework of the PRA set out correctly; is that right, Mary? 6

1

7 MS. DROUIN: No. I would disagree with you that I think the likelihood if somebody met the 8 standards, two different people meeting it different 9 ways, and one of them being rejected, I think the 10 11 likelihood of that is very small, and the reason why 12 is because the standard does impose a peer review, and I think if you just relied on Chapter 4 of the 13 14 standard, then I would agree with what Gareth said.

15 But the standard does impose that peer review, and I think that's a critical part of the 16 17 standard that people keep forgetting, and I think because that peer review is in there, I think the 18 likelihood of your example occurring is very small. 19 CHAIRMAN APOSTOLAKIS: 20 Haven't we said 21 many times that the standards don't tell you how to do 22 sometime? 23 Particular MR. PARRY: if they're

24 responding to the peer review comment.

> MS. DROUIN: Yes.

> > NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

25

	86
1	CHAIRMAN APOSTOLAKIS: I thought we said
2	a lot of
3	DR. ROSEN: The standards don't tell you
4	how to do something, but the peer reviewers are
5	typically high level practitioners, the people who are
6	on the peer review, plus regulators. And these high
7	level practitioners are actually more critical of what
8	they see than you might ordinarily expect.
9	Having been through one
10	CHAIRMAN APOSTOLAKIS: So I have to rely
11	on the kindness of strangers.
12	DR. ROSEN: Actually you're relying on the
13	unkindness of strangers.
14	MR. LEVINSON: Actually, to agree with
15	Steve, you're relying on the unkindness of strangers.
16	I've been involved in the peer reviews, and there is
17	no kindness among the peer review team. I mean, they
18	go in there, and they really want to tear that PRA
19	down.
20	CHAIRMAN APOSTOLAKIS: I think this
21	discussion is completely off
22	MR. LEVINSON: But that's not the point I
23	wanted to make. When you're talking about standards
24	and the ability to get them done and whether that
25	would curtail the process and what the NRC staff would
1	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	87
1	have to make up, right, the NRC is participating with
2	the ASME and ANSI or ASME and ANS that the two main
3	standard development organizations in a joint risk
4	management standards coordinating committee to insure
5	that there is some proper direction and coordination
6	with the subsequent development of the standards so
7	that, one, you don't get gaps and, two, you don't get,
8	you know, multiple people working on the same thing.
9	DR. ROSEN: And they came in to brief us
10	just the last month or so.
11	MR. LEVINSON: Yes, they did, Kent Bulkey
12	and
13	DR. ROSEN: Yes, and his colleagues.
14	MR. LEVINSON: Ray Widener and Wes
15	Raleigh came in. I just wanted to remind you that
16	CHAIRMAN APOSTOLAKIS: Yeah. We have an
17	SRM that wants to increase public confidence in what
18	we're doing by requiring standards, but then our own
19	confidence depends on a bunch of guys who are peer
20	reviewers, and we rely on their conscience that they
21	will do a good job.
22	MR. TSCHILTZ: In part, but I think we
23	learned a lot from what we got out of the asme
24	standard, Reg. Guide 1.200.
25	CHAIRMAN APOSTOLAKIS: Sure. I don't want

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	88
1	to put it down.
2	MR. TSCHILTZ: But what we learned from
3	the NEI peer reviewers, the ASME standards and Reg.
4	Guide 1.200 is that if things don't progress in a
5	logical sequence of events, you end up with documents
6	and requirements that are misaligned and are difficult
7	for anybody to wade through. I call it a Ph.D. in PRA
8	technology to align all of the differences in between
9	these documents.
10	And it's not a result of a bad effort by
11	anyone. It's just the sequence of which things
12	occurred, and so I think we have an overly complex set
13	of requirements right now that I think we're hoping to
14	avoid by involving things in a more
15	CHAIRMAN APOSTOLAKIS: Right. Now, you
16	will address the technical issues later?
17	MR. PARRY: Yes.
18	CHAIRMAN APOSTOLAKIS: Right?
19	MR. PARRY: Yes.
20	CHAIRMAN APOSTOLAKIS: Okay. So let's
21	take a break now.
22	MR. PARRY: Well, can I finish this? You
23	know, we did the same thing yesterday. Can I just
24	finish this viewgraph and then we'll come back?
25	CHAIRMAN APOSTOLAKIS: Okay.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	89
1	MR. PARRY: Assuming that we've got
2	through Box 5 with a no, okay, which means that the
3	licensee is using the scope of PRA for which the
4	standard is, all that box says, all that Box 7 says is
5	is he treating all of the risk contributors one way or
6	another.
7	If he is, this is our normal process.
8	This is what we do now. It will be a high priority
9	review. If he doesn't address the risk contributors
10	that are not in the scope, it's an inadequate
11	submittal. And so that's the process as currently
12	existing.
13	Okay. So now we can have a break if you'd
14	like, and we'll come back to the second one, which
15	hopefully we'll breeze through.
16	CHAIRMAN APOSTOLAKIS: Okay. Until 3:15.
17	(Whereupon, the foregoing matter went off
18	the record at 2:54 p.m. and went back on
19	the record at 3:13 p.m.)
20	Okay. Let's continue then.
21	MR. PARRY: I think we should try and get
22	through this one pretty quickly.
23	(Laughter.)
24	MR. PARRY: Because I think there is
25	somewhat less controversy over this, hopefully.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	90
1	You remember on the first two boxes on the
2	previous slide, there's Box 2. If we had enough Phase
3	3 guidance, we'd skip out to Phase 3, and basically
4	what this diagram says is that really there's a choice
5	that the licensee has here. Either he can conform to
б	the full Phase 3 framework and then he can have a PRA
7	for which he could request a one time review that, you
8	know, would be good for everything or he could stay in
9	effectively Phase 2 space where he would submit a
10	specific application and he would demonstrate that he
11	was in Phase 2 for that specific application.
12	And if he did not conform to Phase 2 for
13	that application, his submittal would be rejected
14	automatically. What this really means is that there
15	is no Phase 1 when we're in Phase 3. Okay?
16	DR. SIEBER: Would you say that because of
17	this process if everybody had lead feet you would stop
18	at Phase 2?
19	MR. PARRY: Well, that's a question, and
20	in fact, it's the other potential policy issue that
21	we've put down right now, is whether when we get to
22	this stage the expectation is that everybody migrates
23	towards a Phase 3 PRA, and they're not allowed to do
24	individual Phase 2 applications.
25	DR. SIEBER: But it doesn't say that right
-	

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	91
1	now, right?
2	MR. PARRY: It doesn't say that right now,
3	no. It doesn't say that because right now we have at
4	Box 19, for example, which is Phase 2 as high
5	priority.
6	DR. SIEBER: Right.
7	MR. PARRY: Now, if we had put low
8	priority in that box, I think we would have got some
9	significant
10	DR. SIEBER: That would be a
11	MR. PARRY: We'd be discussing this till
12	five o'clock.
13	DR. SIEBER: That would be de facto a
14	Phase 3.
15	MR. PARRY: Yeah.
16	MR. HARRISON: But I think one thing
17	that's worth noting is that once you've got the Phase
18	3 guidance in place and licensees could go in that
19	direction, we won't be entertaining Phase 1
20	applications.
21	MR. PARRY: Yeah, that's clear.
22	DR. ROSEN: This is very troublesome
23	language. Box 2 I'm referring to.
24	MR. PARRY: Yeah, you're right, and that
25	was raised yesterday, too, and it really is a bad

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	92
1	word. Again, it's a word we borrowed from the SRM,
2	and I think what we are going to interpret by that is
3	all current applications, all that sort of stuff we do
4	now or are planning to do in the next few years, and
5	so that would include like 5046 and 5069, which are
6	not in existence yet, but it wouldn't involve a
7	radical new application that would require, say, a
8	Level 3 PRA.
9	DR. ROSEN: Where I'm going, Gareth, is
10	5046 is radical and new. To me I think it's going to
11	be a long time until you get 5046 under your belt.
12	MR. PARRY: But the way it's going though,
13	does it look to you like the metrics would be used to
14	make the decision are likely to be different from the
15	ones we use now?
16	Because I think the one thing, I think,
17	that would really throw a spanner in the works is if
18	we started one thing, full Level 2 and full Level 3
19	PRAs because those standards are not even being
20	well, I think they're being talked about, but not in
21	any serious way being developed, I don't believe; is
22	that right, Mary?
23	MS. DROUIN: There's a lot of talk within
24	ASME of writing a Level 3 standard and there is talk
25	about putting together a team to write a Level 3.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	93
1	In terms of expanding the LERF part of the
2	Level 2. That has been kind of tabled for right now.
3	MR. PARRY: The LERF part of Level
4	MS. DROUIN: Of full Level 2.
5	DR. ROSEN: See, "all" is a very little
6	word, but it's a very big word.
7	MR. PARRY: Yeah.
8	DR. ROSEN: And "envisioned" is another
9	one.
10	MR. PARRY: Yeah, that's even bigger.
11	DR. ROSEN: It's even bigger, yeah. It's
12	whose vision are you talking about.
13	MR. PARRY: Yeah, that was raised
14	yesterday.
15	DR. ROSEN: Would it really be harmful to
16	this if you said for currently implemented
17	applications?
18	MR. HARRISON: And I would even say
19	currently risk informed applications so that it's
20	nothing beyond what you're doing in the risk informed.
21	CHAIRMAN APOSTOLAKIS: Currently
22	anticipated?
23	MR. HARRISON: Yeah, I think it could be.
24	MS. DROUIN: I like anticipated because I
25	do think it can include 69, and I disagree. I think

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

94 1 it can include 5046. I don't disagree that 5046 is 2 several years, but I don't think it's several years in 3 determining what your scope needs are from a PRA 4 perspective. 5 MR. PARRY: Right. I agree. I think "anticipated" is probably the right word to use. 6 7 DR. ROSEN: All right. Well, we can differ on that one, but "all" and "envisioned" are two 8 words --9 Yeah, we agree. We agree. 10 MR. PARRY: 11 CHAIRMAN APOSTOLAKIS: Why are people 12 talking about the Level 3 standard? What interest do they have? 13 14 MS. DROUIN: Now you're really opening up 15 a can of worms. You know, I don't ant to speak on behalf of ASME. 16 CHAIRMAN APOSTOLAKIS: No, but I mean your 17 impression. Does anybody here speak for the ASME? 18 MS. DROUIN: 19 Stanley? MR. BRADLEY: Biff Bradley from NEI. 20 21 I was trying to recollect the discussions. 22 I think as part of a license renewal there is some 23 level three work that has to be done, and it seems 24 like there was some discussion in the committee along those lines that led to the Level 3 decision. 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	95
1	MR. HARRISON: Stanley Levinson.
2	Even Level 3 wasn't, you know, 100 percent
3	endorsed. I mean, it passed, but it wasn't unanimous,
4	and the Level 2 stuff
5	MS. DROUIN: But it did pass.
6	MR. HARRISON: It did pass, and then
7	CHAIRMAN APOSTOLAKIS: It did pass means?
8	MR. HARRISON: It meant that the ASME
9	CNRM, Committee for Nuclear Risk Management, would
10	take the steps to put together a writing team to try
11	to put together a standard for the Level 3.
12	The Level 2 did not pass. It was tabled,
13	as Mary said, but I understand, you know, particularly
14	with all of this stuff going on, right or wrong,
15	there's renewed interest in that, and that may be
16	brought up again.
17	CHAIRMAN APOSTOLAKIS: Level 3 would be
18	required in licensing.
19	MR. HARRISON: Level 3 is used to support
20	the SAMA (phonetic) analysis for the environmental
21	reports for license renewal application.
22	MS. DROUIN: But here's, you know, an
23	interesting one because then you'd have a hole.
24	MR. HARRISON: Right.
25	MS. DROUIN: You have a LERF, and then you

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	96
1	go to a Level 2 standard, but you've got not the
2	remaining part of your Level 2 standards are not
3	there.
4	MR. HARRISON: But what has been pointed
5	out in yesterday's meeting and in today's meeting,
6	that for the most part the components that, you know.
7	Gareth has been talking about don't include the Level
8	2 and the Level 3 in order to be able to proceed with
9	this.
10	So there may not be the urgency, you know,
11	to progress with those as, say, with the fire
12	standard.
13	MS. DROUIN: Correct.
14	MR. HARRISON: And that kind of
15	information needs to be brought back to the STOs to
16	push them in the right direction.
17	MR. PARRY: Okay. I'm going to skip over
18	the next slide because we've already discussed it, and
19	I'll skip over this one, too, because we'll address
20	those later on.
21	What I want to do is to go through the
22	staff and industry activities that we think need to be
23	performed to implement this phased approach, and I'll
24	talk about the staff activities in terms of a number
25	of tasks which, as the moment, they're pretty much

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	97
1	conceptual. They need fleshing out considerably
2	because we really have been concerned more about the
3	philosophy of the approach and defining the phases and
4	what we think it means.
5	And also I think a couple of the tasks
6	have been reversed in order from the draft test plan
7	that you sent out, just to convince you that we're a
8	dynamic team here.
9	Okay. The first action plan task is
10	basically to identify the types of applications. So
11	these are the applications that we're going to be
12	talking about, and we've categorized them. If you
13	remember in the SRM, it talked about binding
14	applications, and I think the way we've interpreted
15	that really is to say for categories of applications
16	that are things like operational uses by licensees,
17	and these are things like to support the maintenance
18	rule.
19	There's the use in the oversight program,
20	and I think where this might have, as I said earlier,
21	a big value is the use of the licensee PRA in Phase 3
22	of the significance determination process.
23	Then there's the license amendments, which
24	is what we tend to, I think, gravitate towards
25	focusing on in a lot of our discussions. We talk

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

98
about things like risk informed ISI and 5069.
And then finally there's the
implementation of new rules.
DR. ROSEN: Where would you put risk
management tech specs?
MR. PARRY: It would be a license
amendment.
MR. HARRISON: It would be a license
amendment, yeah.
MR. PARRY: The second task is for each of
these application types is to identify the guidance
document. We should say that for many of them some
guidance documents already exist when we have
regulatory guides for many applications.
But what they don't do in the area of
they're not very explicit in the area of PRA quality,
and I think in terms of we could be more explicit
about the required scope of the PRA as a function of
the existence of guidance documents, such as
standards, for example. So we would probably be
modifying some of these guidance documents.
But in this task what we're going to do is
to breach type of application. We identify how the
PRA results are used in making the decision and on the
basis of that, we talk about defining the scope and

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1level of detail of PRA required.2These are all preliminary tasks to3actually doing the real work.4The third task is to identify the types of5staff activities and define what we need to do to6develop the necessary guidance documents, and the7types of things we'll have to do, the things like8supporting development and endorsement of PRA9standards. We already have tasks to do that, but we10will have the explicit standards in there.11Updates to regulatory guides. Then I12talked about that in the last task.13One of these guides that we will be14updating obviously is Reg. Guide 1.200. We'll15probably update that as a result of the pilot studies16or the trial use studies, and we'll certainly be17updating it when we endorse the other standards as18they come in.19We will develop methods and develop20supporting documents for some of the technical issues21that were discussed earlier, and Larry will talk a22little later about some of the work that their Office23of Research is doing in some of these technical areas24and the NUREGs that we think will emerge after that.25And we'll also develop I think I said		99
3actually doing the real work.4The third task is to identify the types of5staff activities and define what we need to do to6develop the necessary guidance documents, and the7types of things we'll have to do, the things like8supporting development and endorsement of PRA9standards. We already have tasks to do that, but we10will have the explicit standards in there.11Updates to regulatory guides. Then I12talked about that in the last task.13One of these guides that we will be14updating obviously is Reg. Guide 1.200. We'll15probably update that as a result of the pilot studies16or the trial use studies, and we'll certainly be17updating it when we endorse the other standards as18they come in.19We will develop methods and develop20supporting documents for some of the technical issues21that were discussed earlier, and Larry will talk a22little later about some of the work that their Office23and the NUREGs that we think will emerge after that.	1	level of detail of PRA required.
 The third task is to identify the types of staff activities and define what we need to do to develop the necessary guidance documents, and the types of things we'll have to do, the things like supporting development and endorsement of PRA standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that. 	2	These are all preliminary tasks to
5 staff activities and define what we need to do to develop the necessary guidance documents, and the types of things we'll have to do, the things like supporting development and endorsement of PRA standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. 9 We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that.	3	actually doing the real work.
 develop the necessary guidance documents, and the types of things we'll have to do, the things like supporting development and endorsement of PRA standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that. 	4	The third task is to identify the types of
types of things we'll have to do, the things like supporting development and endorsement of PRA standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that.	5	staff activities and define what we need to do to
 supporting development and endorsement of PRA standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that. 	6	develop the necessary guidance documents, and the
 standards. We already have tasks to do that, but we will have the explicit standards in there. Updates to regulatory guides. Then I talked about that in the last task. One of these guides that we will be updating obviously is Reg. Guide 1.200. We'll probably update that as a result of the pilot studies or the trial use studies, and we'll certainly be updating it when we endorse the other standards as they come in. We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of these technical areas and the NUREGs that we think will emerge after that. 	7	types of things we'll have to do, the things like
10 will have the explicit standards in there. 11 Updates to regulatory guides. Then I 12 talked about that in the last task. 13 One of these guides that we will be 14 updating obviously is Reg. Guide 1.200. We'll 15 probably update that as a result of the pilot studies 16 or the trial use studies, and we'll certainly be 17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of these technical areas 23 and the NUREGs that we think will emerge after that.	8	supporting development and endorsement of PRA
11Updates to regulatory guides. Then I12talked about that in the last task.13One of these guides that we will be14updating obviously is Reg. Guide 1.200. We'll15probably update that as a result of the pilot studies16or the trial use studies, and we'll certainly be17updating it when we endorse the other standards as18they come in.19We will develop methods and develop20supporting documents for some of the technical issues21that were discussed earlier, and Larry will talk a22little later about some of the work that their Office23of Research is doing in some of these technical areas24and the NUREGs that we think will emerge after that.	9	standards. We already have tasks to do that, but we
12 talked about that in the last task. 13 One of these guides that we will be 14 updating obviously is Reg. Guide 1.200. We'll 15 probably update that as a result of the pilot studies 16 or the trial use studies, and we'll certainly be 17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of these technical areas 23 and the NUREGs that we think will emerge after that.	10	will have the explicit standards in there.
13One of these guides that we will be14updating obviously is Reg. Guide 1.200. We'll15probably update that as a result of the pilot studies16or the trial use studies, and we'll certainly be17updating it when we endorse the other standards as18they come in.19We will develop methods and develop20supporting documents for some of the technical issues21that were discussed earlier, and Larry will talk a22little later about some of the work that their Office23of Research is doing in some of these technical areas24and the NUREGs that we think will emerge after that.	11	Updates to regulatory guides. Then I
 14 updating obviously is Reg. Guide 1.200. We'll 15 probably update that as a result of the pilot studies 16 or the trial use studies, and we'll certainly be 17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGS that we think will emerge after that. 	12	talked about that in the last task.
15 probably update that as a result of the pilot studies 16 or the trial use studies, and we'll certainly be 17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGs that we think will emerge after that.	13	One of these guides that we will be
<pre>16 or the trial use studies, and we'll certainly be 17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGS that we think will emerge after that.</pre>	14	updating obviously is Reg. Guide 1.200. We'll
17 updating it when we endorse the other standards as 18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGs that we think will emerge after that.	15	probably update that as a result of the pilot studies
18 they come in. 19 We will develop methods and develop 20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGS that we think will emerge after that.	16	or the trial use studies, and we'll certainly be
We will develop methods and develop supporting documents for some of the technical issues that were discussed earlier, and Larry will talk a little later about some of the work that their Office of Research is doing in some of these technical areas and the NUREGs that we think will emerge after that.	17	updating it when we endorse the other standards as
20 supporting documents for some of the technical issues 21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGs that we think will emerge after that.	18	they come in.
21 that were discussed earlier, and Larry will talk a 22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGS that we think will emerge after that.	19	We will develop methods and develop
22 little later about some of the work that their Office 23 of Research is doing in some of these technical areas 24 and the NUREGS that we think will emerge after that.	20	supporting documents for some of the technical issues
of Research is doing in some of these technical areasand the NUREGs that we think will emerge after that.	21	that were discussed earlier, and Larry will talk a
24 and the NUREGs that we think will emerge after that.	22	little later about some of the work that their Office
	23	of Research is doing in some of these technical areas
25 And we'll also develop I think I said	24	and the NUREGs that we think will emerge after that.
	25	And we'll also develop I think I said

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

100
this earlier that we're going to have to develop
implementation guidelines for the staff to use, for
NRR staff to use, in the way that they deal with
licensee submittals and how to allocate priorities and
the like.
The next effort is to try and to find
schedules for transitions to Phase 2 as a function of
the application type. I think for different
applications we'll be transitioning into Phase 2 at
different phases because the applications may need a
different scope of PRA to support them, and the way we
will transition into Phase 2 is when we have endorsed

12 will transition into Phase 2 is when we have endorsed 13 standards for the significant contributors for each of 14 these application types.

Now, one of the problems that we have with defining the schedule for transition is it's fine to say that there will be a date, say -- I don't know --March 25th, 2006, when we have endorsed the fire PRA, and we have incorporated into Reg. Guide 1.200. Does that mean on March 26th that we adopt this new approach to review and approval?

Well, we think no. We think there has to be some sort of lag time because we know that once we have approved the standard there, the licensees cannot be expected to meet those standards and have the PRA

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

9

10

11

	101
1	peer reviewed the next day.
2	So we're building into the schedule some
3	time to allow a lag between our endorsement of the
4	standards and the guidance documents and full
5	implementation of that within the framework that I
6	showed you in those flow charts.
7	DR. ROSEN: Does that mean in that window
8	you would allow applications based on the standard as
9	long as someone could come in and show that they met
10	the standard?
11	MR. PARRY: I think it would mean
12	effectively
13	DR. ROSEN: I'm thinking about with a
14	proactive licensee who has upgraded his PRA during the
15	standards development process and is ready to go with
16	something he wants to get done just as soon as the
17	standard is voted and endorsed or voted through the
18	standards development organization and endorsed and a
19	reg. guide wants to come in, and you say, "No, because
20	all of that stuff has been done, but you've got to
21	wait two years because"
22	MR. PARRY: No, that's not what we're
23	saying. I think what we're saying is that up at that
24	point we will tolerate things that haven't gone
25	through the formal peer review process.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1DR. ROSEN: For a period of time.2MR. PARRY: For a period of time, r	
2 MR. PARRY: For a period of time, r	
	ight.
3 DR. ROSEN: For someone who has	been
4 proactive, but may not have been through a peer re	eview
5 yet because he can't schedule it.	
6 MR. PARRY: Right.	
7 MR. HARRISON: And what I would expect	ct is
8 maybe they would get an REI. If someone did that	and
9 the REI would say, you know, between the last ver	sion
10 of this endorsement and the one that went on	the
11 street there were a few changes, and you say you	a met
12 the one that was back three months ago. What have	e you
13 done to bridge the gap?	
14 You're going to have to do something	like
15 that.	
16 DR. ROSEN: Typically you are	at
17 diminishing returns. So it wouldn't be a big t	ask.
18 MR. PARRY: Right, right.	
DR. SIEBER: Yeah, that's right.	
20 MR. PARRY: Okay. Task 5 is really w	here
21 the bulk of our work will be, I think, and the	nat's
22 developing the necessary guidance document.	
23 In developing these guidance document	s, we
24 think there are a few implementation issues that	it we
25 have to resolve. They will have, I think, an im	pact

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	103
1	on the documents we write.
2	One of those is and we already
3	discussed it to some extent the level of review for
4	licensee submittals depending on, you know, these
5	high, low; do we need a medium priority level of
6	review?
7	So we will have to, I think, discuss that
8	and resolve it.
9	One of the real important things, I think,
10	is the definition of significance contributor as it
11	relates to the regulatory decision because that's
12	really what determines the scope of the PRA that's
13	needed for the particular application. We think this
14	has to be a quantitative type of definition, and you
15	may remember that when we were making comments on the
16	ASME standard, this was one of the issues that we
17	raised then in the context of defining what was a
18	significant accident sequence or a significance basic
19	event.
20	We wanted a quantitative definition that
21	would be easier to audit than the sort of qualitative
22	type of definition, and we think probably that's the
23	way we'll go,b ut clearly this is at a different level
24	than the accident sequences and the basic events.
25	Another issue I think we have to address

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 is what do we really mean by issuing the document	t and
2 how does it fit into this whole phased approac	ch of
3 things.	
4 DR. ROSEN: You know, we had a discus	ssion
5 of that one time at the ACRS. I mean, I think	the
6 discussion as I recall it, devolved down to the p	point
7 that it meant that the staff had an expectation	that
8 it would be revised at some point after	some
9 experience.	
10 MS. DROUIN: If you go to Reg. Guide 1	L.200
11 on the second page, there is a paragraph there	that
12 was inserted that explains what it means by trial	use.
13 DR. ROSEN: What does it say? Car	n you
14 read it to us?	
15 MS. DROUIN: Do you want me to read	l the
16 whole	
17 DR. ROSEN: Well, read the rele	evant
18 sections.	
19 CHAIRMAN APOSTOLAKIS: The rele	evant
20 sections.	
21 MS. DROUIN: The relevant part.	
22 DR. ROSEN: Nothing irrelevant.	
23 CHAIRMAN APOSTOLAKIS: The stuff that	will
24 affect our decision.	
25 DR. ROSEN: Not that anything in the	Reg.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

Guide is irrelevant.

1

2 MS. DROUIN: This regulatory guide does 3 not establish any final staff positions and may be 4 revised in response to experience with its use. As 5 such, this trial regulatory guide does not establish a staff position for purposes of the backfit rule and 6 7 any changes to those regulatory guides prior to staff adoption in any final form will not be considered to 8 be backfits as defined in 10 CFR 5109. 9 This will insure that the lessons learned from regulatory review 10 11 of the pilot applications are adequately addressed in 12 this document and that the quidance is sufficient to enhance regulatory stability in the review, approval, 13 14 and implementation in the use of PRA results in risk 15 informed activities.

When you read the first two 16 DR. ROSEN: thrilled 17 sentences Т was because it was my Then you started reading that stuff 18 recollection. 19 about backfitting and I got all kinds of confused.

20 MS. DROUIN: That's what happens when the 21 lawyers write.

DR. ROSEN: Regulatory guides are not requirements. So how do you get from talking about a regulatory guide into a backfit?

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

DR. SIEBER: Well, it's even worse than

(202) 234-4433

25

	106
1	that because you can adopt this regulatory guide or
2	you can go a deterministic way, and so it's not a
3	requirement because of that, too.
4	On the other hand, if the lawyers want to
5	write it, it didn't hurt a thing.
6	MR. PARRY: But I think the question that
7	we have to answer is how does that roll into our
8	scheduling of when we say we're in Phase 2. If we're
9	still in a trial use phase, I'm not clear how that
10	plays in, and that's something that I think we have
11	more of an impact on our scheduling, I think, that
12	anything else.
13	MS. DROUIN: I think the other question is
14	when it's out for trial use, and I think you've
15	answered it, you know, is it just applicable to the
16	pilots or is it applicable to everybody at large.
17	DR. SIEBER: To everybody. There is an
18	applicability implementation section in there, right?
19	And it doesn't say it was just for the pilot.
20	CHAIRMAN APOSTOLAKIS: But there was a
21	difference between a draft regulatory guide and a
22	guide for trial use, and I don't remember what the
23	difference was.
24	DR. SIEBER: The draft is still in
25	discussion.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	107
1	CHAIRMAN APOSTOLAKIS: The question at the
2	time was why are you issuing Regulatory Guide 1.200
3	for trial use and not as a draft regulatory guide, a
4	DG.
5	DR. SIEBER: Well, there was a DG.
6	MS. DROUIN: It did have a DG.
7	DR. SIEBER: It was 1122 or something.
8	MS. DROUIN: The difference is whether
9	this is a regulatory guide, just those words, versus
10	a regulatory guide for trial use.
11	CHAIRMAN APOSTOLAKIS: Okay. So what's
12	the difference.
13	MS. DROUIN: It's what I read you.
14	MR. HARRISON: Yes, but to get to
15	George's, I think, original question, there was a
16	draft reg. guide, and that was for the purpose of
17	getting
18	CHAIRMAN APOSTOLAKIS: I remember that.
19	MR. HARRISON: That was to get comment.
20	We went to the comment phase. We got to now being
21	ready to issue a reg. guide, and it was felt that we
22	needed to go through a pilot phase or trial phase.
23	CHAIRMAN APOSTOLAKIS: Yeah, the pilot
24	phase.
25	DR. SIEBER: Trial phase, not a pilot

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	108
1	phase.
2	MR. HARRISON: Right, trial phase.
3	MR. MAGRUDER: And the whole distinction,
4	I think, is really a legal one, and it gets to if a
5	licensee references a reg. guide and a submittal and
6	say they're complying with it, what legal standing
7	that has as far as our review, and then if it's only
8	for trial use and we decide to change it, which is
9	where the backfit stuff gets in there, can we say, no,
10	you don't comply with the reg. guide anymore when they
11	were actually complying with the trial use guide.
12	It's very legalistic, and it probably
13	doesn't matter too much, except that
14	DR. SIEBER: It actually does matter.
15	CHAIRMAN APOSTOLAKIS: It does matter.
16	DR. SIEBER: It does matter, and you're in
17	the right position, in my opinion.
18	CHAIRMAN APOSTOLAKIS: Because the pilots,
19	I remember, if you have a regulatory guide and you
20	have a pilot program, the pilot plants may do
21	something to their plant as they implement the
22	regulatory guide. then if you go back and say, "No, we
23	don't like what you did," then you have to justify it
24	on the basis of the backfit rule.
25	If it's trial use, you tell them, "No, we

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1don't like what you did." That was the difference.2DR. ROSEN: Yeah, I think I understand3that now. The distinction, it helps to have you talk4about that. The key step that I wasn't thinking about5was when the licensee takes the reg. guide and makes6a commitment to it.7CHAIRMAN APOSTOLAKIS: Right.8DR. ROSEN: Then it becomes no longer9voluntary. It's voluntary to make the commitment, but10once you make the commitment, you've got to meet it.11MR. MAGRUDER: Yes.12CHAIRMAN APOSTOLAKIS: Okay.13MR. PARRY: Task 6 is developing the Phase143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide251.200 that would say, "Here's the application. Here's		109
that now. The distinction, it helps to have you talk about that. The key step that I wasn't thinking about was when the licensee takes the reg. guide and makes a commitment to it. CHAIRMAN APOSTOLAKIS: Right. BR. ROSEN: Then it becomes no longer voluntary. It's voluntary to make the commitment, but once you make the commitment, you've got to meet it. MR. MAGRUDER: Yes. CHAIRMAN APOSTOLAKIS: Okay. MR. PARRY: Task 6 is developing the Phase 3 guidance, and I won't say any more about this other than the fact, as I said earlier, I really think this is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide	1	don't like what you did." That was the difference.
 about that. The key step that I wasn't thinking about was when the licensee takes the reg. guide and makes a commitment to it. CHAIRMAN APOSTOLAKIS: Right. DR. ROSEN: Then it becomes no longer voluntary. It's voluntary to make the commitment, but once you make the commitment, you've got to meet it. MR. MAGRUDER: Yes. CHAIRMAN APOSTOLAKIS: Okay. MR. PARRY: Task 6 is developing the Phase 3 guidance, and I won't say any more about this other than the fact, as I said earlier, I really think this is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	2	DR. ROSEN: Yeah, I think I understand
5 was when the licensee takes the reg. guide and makes 6 a commitment to it. 7 CHAIRMAN APOSTOLAKIS: Right. 8 DR. ROSEN: Then it becomes no longer 9 voluntary. It's voluntary to make the commitment, but 10 once you make the commitment, you've got to meet it. 11 MR. MAGRUDER: Yes. 12 CHAIRMAN APOSTOLAKIS: Okay. 13 MR. PARRY: Task 6 is developing the Phase 14 3 guidance, and I won't say any more about this other 15 than the fact, as I said earlier, I really think this 16 is just establishing a regulatory framework that rolls 17 up all of the quality requirements on PRAs into one 18 OR. SIEBER: So would this be a revision 19 DR. SIEBER: So would this be a revision 20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide	3	that now. The distinction, it helps to have you talk
 a commitment to it. CHAIRMAN APOSTOLAKIS: Right. DR. ROSEN: Then it becomes no longer voluntary. It's voluntary to make the commitment, but once you make the commitment, you've got to meet it. MR. MAGRUDER: Yes. CHAIRMAN APOSTOLAKIS: Okay. MR. PARRY: Task 6 is developing the Phase guidance, and I won't say any more about this other than the fact, as I said earlier, I really think this is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	4	about that. The key step that I wasn't thinking about
7CHAIRMAN APOSTOLAKIS: Right.8DR. ROSEN: Then it becomes no longer9voluntary. It's voluntary to make the commitment, but10once you make the commitment, you've got to meet it.11MR. MAGRUDER: Yes.12CHAIRMAN APOSTOLAKIS: Okay.13MR. PARRY: Task 6 is developing the Phase143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17up all of the quality requirements on PRAs into one18document. Otherwise Phase 3 is sort of like Phase 2.19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	5	was when the licensee takes the reg. guide and makes
8 DR. ROSEN: Then it becomes no longer 9 voluntary. It's voluntary to make the commitment, but 10 once you make the commitment, you've got to meet it. 11 MR. MAGRUDER: Yes. 12 CHAIRMAN APOSTOLAKIS: Okay. 13 MR. PARRY: Task 6 is developing the Phase 14 3 guidance, and I won't say any more about this other 15 than the fact, as I said earlier, I really think this 16 is just establishing a regulatory framework that rolls 17 up all of the quality requirements on PRAs into one 18 document. Otherwise Phase 3 is sort of like Phase 2. 19 DR. SIEBER: So would this be a revision 20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide	6	a commitment to it.
 voluntary. It's voluntary to make the commitment, but once you make the commitment, you've got to meet it. MR. MAGRUDER: Yes. CHAIRMAN APOSTOLAKIS: Okay. MR. PARRY: Task 6 is developing the Phase 3 guidance, and I won't say any more about this other than the fact, as I said earlier, I really think this is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	7	CHAIRMAN APOSTOLAKIS: Right.
10once you make the commitment, you've got to meet it.11MR. MAGRUDER: Yes.12CHAIRMAN APOSTOLAKIS: Okay.13MR. PARRY: Task 6 is developing the Phase143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17up all of the quality requirements on PRAs into one18document. Otherwise Phase 3 is sort of like Phase 2.19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	8	DR. ROSEN: Then it becomes no longer
11MR. MAGRUDER: Yes.12CHAIRMAN APOSTOLAKIS: Okay.13MR. PARRY: Task 6 is developing the Phase143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17up all of the quality requirements on PRAs into one18document. Otherwise Phase 3 is sort of like Phase 2.19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	9	voluntary. It's voluntary to make the commitment, but
12CHAIRMAN APOSTOLAKIS: Okay.13MR. PARRY: Task 6 is developing the Phase143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17up all of the quality requirements on PRAs into one18document. Otherwise Phase 3 is sort of like Phase 2.19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	10	once you make the commitment, you've got to meet it.
 MR. PARRY: Task 6 is developing the Phase 3 guidance, and I won't say any more about this other than the fact, as I said earlier, I really think this is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	11	MR. MAGRUDER: Yes.
143 guidance, and I won't say any more about this other15than the fact, as I said earlier, I really think this16is just establishing a regulatory framework that rolls17up all of the quality requirements on PRAs into one18document. Otherwise Phase 3 is sort of like Phase 2.19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	12	CHAIRMAN APOSTOLAKIS: Okay.
 15 than the fact, as I said earlier, I really think this 16 is just establishing a regulatory framework that rolls 17 up all of the quality requirements on PRAs into one 18 document. Otherwise Phase 3 is sort of like Phase 2. 19 DR. SIEBER: So would this be a revision 20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide 	13	MR. PARRY: Task 6 is developing the Phase
 is just establishing a regulatory framework that rolls up all of the quality requirements on PRAs into one document. Otherwise Phase 3 is sort of like Phase 2. DR. SIEBER: So would this be a revision to 1.200, this Task 6? MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	14	3 guidance, and I won't say any more about this other
17 up all of the quality requirements on PRAs into one 18 document. Otherwise Phase 3 is sort of like Phase 2. 19 DR. SIEBER: So would this be a revision 20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide	15	than the fact, as I said earlier, I really think this
18 document. Otherwise Phase 3 is sort of like Phase 2. 19 DR. SIEBER: So would this be a revision 20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide	16	is just establishing a regulatory framework that rolls
19DR. SIEBER: So would this be a revision20to 1.200, this Task 6?21MR. PARRY: Maybe not a revision. Maybe22an interpretation for all of the applications perhaps.23MR. HARRISON: Yeah, I could see maybe a24table or something like that being added to Reg. Guide	17	up all of the quality requirements on PRAs into one
<pre>20 to 1.200, this Task 6? 21 MR. PARRY: Maybe not a revision. Maybe 22 an interpretation for all of the applications perhaps. 23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide</pre>	18	document. Otherwise Phase 3 is sort of like Phase 2.
MR. PARRY: Maybe not a revision. Maybe an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide	19	DR. SIEBER: So would this be a revision
 an interpretation for all of the applications perhaps. MR. HARRISON: Yeah, I could see maybe a table or something like that being added to Reg. Guide 	20	to 1.200, this Task 6?
23 MR. HARRISON: Yeah, I could see maybe a 24 table or something like that being added to Reg. Guide	21	MR. PARRY: Maybe not a revision. Maybe
table or something like that being added to Reg. Guide	22	an interpretation for all of the applications perhaps.
	23	MR. HARRISON: Yeah, I could see maybe a
25 1.200 that would say, "Here's the application. Here's	24	table or something like that being added to Reg. Guide
	25	1.200 that would say, "Here's the application. Here's

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	110
1	the requirements for each of these applications."
2	DR. SIEBER: Here's the phase you should
3	be in.
4	MR. HARRISON: Right.
5	MR. PARRY: Yeah, I think so.
б	DR. SIEBER: All right.
7	MR. PARRY: Task 7, we put this in.
8	Buried in the white paper there is an expectation that
9	we would do continued ad hoc monitoring of PRA quality
10	using things like the specifically mentions using
11	things like the SPAR models and the SDP notebooks.
12	We do this now. When you heard this
13	morning that we did a lot of the ID of the SDP
14	notebooks against the licensee's PRAs, which meant
15	going out to the sites, doing comparisons, and by that
16	way not only were we revising the notebooks; we were
17	also understanding the differences.
18	And in understanding some of those
19	differences then, in fact, in a couple of cases there
20	were some problems identified with the licensee's
21	PRAs. So it's not a rigorous process, but it is a
22	process by which we at least get some feeling about
23	what the PRA looks like.
24	And the same way we did the iD for the
25	SPAR models. Pat O'Reilly is here in the background,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

and he could probably talk more about that, but in effect it is the same type of thing. Do a comparison of the SPAR model results with the licensee model results and, again, try and understand the differences which focuses in on those issues that can then drive the differences between the results.

7 So we will just keep on doing this type of 8 thing, I think, as opportunities arise. We do a lot 9 of this when we're doing things like SDP Phase 3 10 reviews because the licensee produces an analysis to 11 support his claim that it's a green finding, not a 12 white finding or whatever.

And then we would look further into that and somehow learn something about the PRAs, but it really is not a formal process, and it can never replace the type of thing we're envisaging with the phased approach.

And I think this whole activity should eventually become somewhat moot as we transition to Phase 3 because by that time we should know pretty much what we need to know or at least we would have access to knowledge about the licensee's PRA to sufficient detail that we can figure out what's in there.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

DR. FORD: How much are these seven tasks

(202) 234-4433

25

1dependent on input from the licensee?2MR. PARRY: I think3DR. FORD: I notice on Task 4 you have got4a specific5MR. PARRY: The schedule, for sure. The6schedule, for sure, but I think also I think Task 5,7developing the guidance because again, for example,8one of the elements of developing the guidance is9reviewing the standard.10DR. FORD: So if they don't produce on11time to the amount expected, does the whole project12crash?13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and25that's the low power and shutdown PRA and the fire		112
3DR. FORD: I notice on Task 4 you have got4a specific5MR. PARRY: The schedule, for sure. The6schedule, for sure, but I think also I think Task 5,7developing the guidance because again, for example,8one of the elements of developing the guidance is9reviewing the standard.10DR. FORD: So if they don't produce on11time to the amount expected, does the whole project12crash?13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	1	dependent on input from the licensee?
 a specific MR. PARRY: The schedule, for sure. The schedule, for sure, but I think also I think Task 5, developing the guidance because again, for example, one of the elements of developing the guidance is reviewing the standard. DR. FORD: So if they don't produce on time to the amount expected, does the whole project crash? MR. PARRY: No, it becomes a smaller scope, I think. There will be some things we can do early on for certain applications. I think for the more ambitious application that require full scope PRAs, that's where we would intend to be not transitioning to Phase 2. DR. FORD: Okay, okay. MR. PARRY: So for the industry activities that we need that need to be done. Well, first of all, what we've been talking about is developing the consensus sentence, and the two that are on the books, and they both have 2005 dates on them, I believe, and 	2	MR. PARRY: I think
5 MR. PARRY: The schedule, for sure. The 6 schedule, for sure, but I think also I think Task 5, 7 developing the guidance because again, for example, 8 one of the elements of developing the guidance is 9 reviewing the standard. 10 DR. FORD: So if they don't produce on 11 time to the amount expected, does the whole project 12 crash? 13 MR. PARRY: No, it becomes a smaller 14 scope, I think. There will be some things we can do 15 early on for certain applications. I think for the 16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	3	DR. FORD: I notice on Task 4 you have got
 schedule, for sure, but I think also I think Task 5, developing the guidance because again, for example, one of the elements of developing the guidance is reviewing the standard. DR. FORD: So if they don't produce on time to the amount expected, does the whole project crash? MR. PARRY: No, it becomes a smaller scope, I think. There will be some things we can do early on for certain applications. I think for the more ambitious application that require full scope PRAs, that's where we would intend to be not transitioning to Phase 2. DR. FORD: Okay, okay. MR. PARRY: So for the industry activities that we need that need to be done. Well, first of all, what we've been talking about is developing the consensus sentence, and the two that are on the books, and they both have 2005 dates on them, I believe, and 	4	a specific
developing the guidance because again, for example, one of the elements of developing the guidance is reviewing the standard. DR. FORD: So if they don't produce on time to the amount expected, does the whole project crash? MR. PARRY: No, it becomes a smaller scope, I think. There will be some things we can do early on for certain applications. I think for the more ambitious application that require full scope PRAs, that's where we would intend to be not transitioning to Phase 2. DR. FORD: Okay, okay. MR. PARRY: So for the industry activities that we need that need to be done. Well, first of all, what we've been talking about is developing the consensus sentence, and the two that are on the books, and they both have 2005 dates on them, I believe, and	5	MR. PARRY: The schedule, for sure. The
8 one of the elements of developing the guidance is 9 reviewing the standard. 10 DR. FORD: So if they don't produce on 11 time to the amount expected, does the whole project 12 crash? 13 MR. PARRY: No, it becomes a smaller 14 scope, I think. There will be some things we can do 15 early on for certain applications. I think for the 16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	6	schedule, for sure, but I think also I think Task 5,
 9 reviewing the standard. 10 DR. FORD: So if they don't produce on 11 time to the amount expected, does the whole project 12 crash? 13 MR. PARRY: No, it becomes a smaller 14 scope, I think. There will be some things we can do 15 early on for certain applications. I think for the 16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and 	7	developing the guidance because again, for example,
10DR. FORD: So if they don't produce on11time to the amount expected, does the whole project12crash?13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	8	one of the elements of developing the guidance is
11time to the amount expected, does the whole project12crash?13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	9	reviewing the standard.
12crash?13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	10	DR. FORD: So if they don't produce on
13MR. PARRY: No, it becomes a smaller14scope, I think. There will be some things we can do15early on for certain applications. I think for the16more ambitious application that require full scope17PRAs, that's where we would intend to be not18transitioning to Phase 2.19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	11	time to the amount expected, does the whole project
14 scope, I think. There will be some things we can do 15 early on for certain applications. I think for the 16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	12	crash?
15 early on for certain applications. I think for the 16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	13	MR. PARRY: No, it becomes a smaller
16 more ambitious application that require full scope 17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	14	scope, I think. There will be some things we can do
17 PRAs, that's where we would intend to be not 18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	15	early on for certain applications. I think for the
18 transitioning to Phase 2. 19 DR. FORD: Okay, okay. 20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	16	more ambitious application that require full scope
19DR. FORD: Okay, okay.20MR. PARRY: So for the industry activities21that we need that need to be done. Well, first of22all, what we've been talking about is developing the23consensus sentence, and the two that are on the books,24and they both have 2005 dates on them, I believe, and	17	PRAs, that's where we would intend to be not
20 MR. PARRY: So for the industry activities 21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	18	transitioning to Phase 2.
21 that we need that need to be done. Well, first of 22 all, what we've been talking about is developing the 23 consensus sentence, and the two that are on the books, 24 and they both have 2005 dates on them, I believe, and	19	DR. FORD: Okay, okay.
all, what we've been talking about is developing the consensus sentence, and the two that are on the books, and they both have 2005 dates on them, I believe, and	20	MR. PARRY: So for the industry activities
consensus sentence, and the two that are on the books,and they both have 2005 dates on them, I believe, and	21	that we need that need to be done. Well, first of
and they both have 2005 dates on them, I believe, and	22	all, what we've been talking about is developing the
	23	consensus sentence, and the two that are on the books,
25 that's the low power and shutdown PRA and the fire	24	and they both have 2005 dates on them, I believe, and
	25	that's the low power and shutdown PRA and the fire

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	113
1	PRA, although I'm hearing rumors that maybe the fire
2	PRA is getting pushed back a little bit, although I'm
3	not really sure.
4	The other thing that the industry may
5	do
6	CHAIRMAN APOSTOLAKIS: What happened to
7	the seismic? Is there a seismic?
8	MR. PARRY: It stopped.
9	MS. DROUIN: It's out.
10	MR. PARRY: It's out. We're reviewing it
11	right now. It's being published by ANS in December.
12	MS. DROUIN: December.
13	MR. PARRY: Last year. That's seismic,
14	high winds and other external events. It's all
15	together.
16	The other thing that the industry can do
17	is to develop guides for specific applications, and a
18	good example of this is NEI 00.04 for 10 CFR 5069. In
19	that case if the industry were to develop the guide,
20	then what we would have to do is develop a reg. guide
21	or some other means of endorsing that guidance.
22	There is also another IOU from the
23	industry which is the update of NEI 00.02, which is,
24	in particular, the self-assessment process part of
25	that document because we have commented on that in

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	114
1	Reg. Guide 1.200, and I think the NEI promised to
2	update that document, and that's really crucial; is
3	that right, Biff?
4	MR. BRADLEY: Yeah, we were just waiting
5	for the target to quit moving on the 1.200. The
6	answer is yes. We will
7	MR. PARRY: It stopped, until Addendum B
8	of the ASME standard.
9	DR. ROSEN: It makes it very easy shooting
10	at a still target though.
11	MR. PARRY: All right. So those are the
12	major things, I think, that we have identified. Okay.
13	I'm going to hand over to Mary on this slide, but
14	before I do so, you know the other thing that the SRM
15	asked us to do was address the resolution of technical
16	issues, and what I've been talking about primarily is
17	developing the plan for implementation, the phased
18	approach. I think what the plan will do is point at
19	certain other activities which probably would not be
20	done under this plan necessarily. They would be done
21	independently, and I'll let Mary talk about those.
22	MS. DROUIN: The ones we have listed here
23	were the ones that were specifically mentioned in the
24	SRM. There could be more, you know, as we go forward
25	and identify other technical issues, but these were

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	115
1	the three that were mentioned explicitly in the SRM,
2	you know, was model uncertainty.
3	And for all of these that were mentioned,
4	there's ongoing research activities to address them.
5	We've gotten a slow start, and I wasn't going to go
6	into detail because I know that some time we're going
7	to come back to the ACRS and talk into detail on each
8	one of these, but the point is just to make that we do
9	have activities underway looking at the model
10	uncertainty.
11	I will admit we've gotten a slow start on
12	that, which is not necessarily a bad thing because
13	it's going to give us a better opportunity to interact
14	with industry and other programs that are ongoing.
15	On the seismic and external events, I put
16	two bullets there because there's kind of two aspects
17	to this. There is the ANS standard that's out there.
18	It's out there under review. We hope to have a
19	preliminary staff position to go out for public review
20	and comment this summer and to have a final staff
21	position by the end of this calendar year.
22	But also part of this other work that
23	we're doing, and we had envisioned it to be in the
24	same document with the treatment of uncertainties
25	because it kind of all works together, is, you know,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

116
the bounding analysis.
You all had come back to us and said, you
know, when you look at Reg. Guide 1.174, you look at
the standards you look at Peg Guide 1 200 and they

1

2

3

4

5

6

7

.174, you look at the standards, you look at Reg. Guide 1.200, and they all allow you to do other things, such as a bounding analysis, such as sensitivity, and there wasn't guidance out there.

We admitted, yes, there wasn't, and we 8 would write some guidance. This becomes, I think, 9 particularly important under the seismic because when 10 11 you look at your bounding analyses, you can look at it 12 at three different ways: bounding on the scope level where you do something so that you can show that the 13 14 scope is not important, and then once you get into the 15 scope, whether the technical element is not important, and then within the technical element, maybe a 16 17 specific requirement is not important.

So it's looking at those three levels, but 18 19 right now our priority is to look at these kind of 20 analyses for screening at the scope level.

21 the human performance, you know, On 22 there's a lot of work going on in the Office of 23 The one I listed there I thought was the Research. 24 most relevant as it fits into this issue of PRA 25 quality.

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	117
1	There is the document that is, you know,
2	a handbook on good practices that is to support the
3	ASME standard.
4	So that's kind of a nutshell.
5	DR. ROSEN: A snapshot in time. It's
6	really a snapshot in time, and my comment is about as
7	a process the fact that you're always going to have
8	technical issues to resolve. It's just something you
9	need to anticipate. It won't be this same set.
10	MS. DROUIN: That's right.
11	DR. ROSEN: But it will always be true.
12	MS. DROUIN: That's absolutely correct.
13	i mean, we talk about this all the time. You know,
14	what other issues do we think are coming up that we
15	feel like we need guidance no?
16	CHAIRMAN APOSTOLAKIS: Isn't the human
17	performance issues a major model uncertainty case?
18	MS. DROUIN: Absolutely.
19	CHAIRMAN APOSTOLAKIS: Gareth, what did
20	you say about finishing these? You said something
21	before you turned it over to Mary.
22	MR. PARRY: About finishing these? Did I?
23	What did I say?
24	CHAIRMAN APOSTOLAKIS: You said they were
25	not part of the plan or something?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	118
1	MR. PARRY: Oh, no, no, no, no, no. I
2	mean I think they're going to be dealt with under
3	separate projects because most of these are going to
4	be done in the Office of Research.
5	MS. DROUIN: For example, George, the
6	plant is not going to come in and give schedules and
7	milestones for how these technical issues are going to
8	be treated as this is already being done under
9	separate ongoing activities which have their own
10	schedule, their own milestones.
11	CHAIRMAN APOSTOLAKIS: Yes, but if I look
12	at the block diagrams that Gareth showed us, if I'm in
13	Phase 2, for example and going strictly by the flow
14	diagram, all I need is standards.
15	MR. PARRY: Yeah.
16	CHAIRMAN APOSTOLAKIS: But I don't
17	necessarily need to have something on these issues.
18	MR. PARRY: Not necessarily, but let me
19	CHAIRMAN APOSTOLAKIS: But that would
20	really invalidate, it seems to me. Even in Phase 1 if
21	you're dealing with an issue that is a significant
22	model of uncertainty, you have to do something about
23	it.
24	MR. PARRY: Right.
25	CHAIRMAN APOSTOLAKIS: It's independent of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	119
1	any phased approach to PRA, it seems to me.
2	MR. PARRY: It's true, but I think we have
3	some guidance on how to deal with model uncertainty
4	and decision making, but it's very high level
5	guidance. I think what Mary is thinking about is
6	developing something that's a little more concrete.
7	CHAIRMAN APOSTOLAKIS: Right.
8	MR. PARRY: All I was saying is it's not
9	like we're unable to cope with these right now, but we
10	might be able to do better, and let me give you an
11	example again on the human performance issue on this
12	NUREG on good practices. All right?
13	There's two purposes for that document I
14	had. One is to be a source document that would enable
15	one of our reviewers to really understand a little bit
16	more about what goes into doing an HRA and be a way of
17	phrasing more pertinent REIs, for example.
18	But the other use that's going to be made
19	of this document is as a basis document for reviewing
20	the HRA methods that are out there, which is something
21	that you, I think, have particularly lobbied for.
22	That's not going to be
23	CHAIRMAN APOSTOLAKIS: Argued.
24	MR. PARRY: Argued. Okay.
25	It's not going to be done immediately, but

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	120
1	I think ASME is going to be here in a month or so to
2	talk about that issue.
3	CHAIRMAN APOSTOLAKIS: But my point is
4	that this activity on these three issues and maybe
5	others alter should be the number one priority, should
6	it not? Regardless of which phase I'm in, I'm really
7	at a loss how to handle some of these things.
8	I mean you probably can do something about
9	model uncertainty, but I haven't seen really a PRA
10	where people actually addressed it. You know, nobody
11	said that if I used somebody else's model I get
12	something different.
13	DR. ROSEN: This truly the moving target
14	that NEI was talking about. Model uncertainty, how to
15	handle it in a common practice PRA at the moment is
16	well beyond because you don't know what you're trying
17	to do.
18	MR. PARRY: Yeah, but I don't think you
19	necessarily handle it in the PRA itself. You
20	recognize where your model uncertainties are and then
21	you assess what the impact on the decision is.
22	CHAIRMAN APOSTOLAKIS: Okay. If somebody
23	does that, I'll be very happy, but
24	MR. PARRY: I believe that's what people
25	should be doing.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	121
1	CHAIRMAN APOSTOLAKIS: Yes.
2	MR. PARRY: Okay, and I think people will
3	do that.
4	DR. ROSEN: Let's talk about the principal
5	model uncertainty we've all talked about so far, which
6	is RCP seal LOCA. Would this document give us
7	alternative ways that one must test your RCP seal?
8	You know, if you have a PRA and you have a model in
9	there, will it tell us, yeah, that's Item No. 2, but
10	you also have to run your model over again with Models
11	No. 1, 3, 4 and 5 and see what the spread looks like?
12	MR. PARRY: Or maybe not even run it over,
13	but maybe understand what the significance of it is
14	and see if it is a good model.
15	CHAIRMAN APOSTOLAKIS: Yeah, let's no
16	prejudge the issue, but basically
17	DR. ROSEN: I'm trying to get at how meaty
18	is this going to be.
19	MR. HARRISON: And if I could jump in on
20	at least the reactor coolant pump seal modeling part
21	of that, that's an issue that goes on in reviews right
22	now, and typically a licensee may submit something,
23	and they have a model and they'll get an REI that
24	says, "What model are you using for this and why
25	should we believe the model that you're using is the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	122
1	right model?"
2	Currently what then happens a lot of times
3	is we'll then ask them to run the Rhodes model
4	(phonetic) to give us a feel for how did the answer
5	change if you used a different model, and if there's
6	not a substantial change, then we may say, okay,
7	that's fine for this application.
8	And that's how it's done pretty much now,
9	and we've also got a couple of topicals that we've
10	reviewed and approved. Well, one that we've approved,
11	and there's a topical that's in house right now for
12	CE, the owners group that
13	DR. ROSEN: Well, it would be terrifically
14	helpful for somebody who is entering this discussion
15	for them to have the list of things you're going to
16	ask them ahead of time so that he can tell his people
17	who are doing the modeling here is your test for this
18	month. Run all of these.
19	CHAIRMAN APOSTOLAKIS: In some instances
20	that's really impractical because if you want to do
21	the same thing in HRA, whoa, now you're asking them do
22	ATHENA; do MERMOS; do IDA.
23	They're going to say to hell with you.
24	I'm going to stick with traditional deterministic.
25	MR. PARRY: No, no, no, but I would say

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	123
1	CHAIRMAN APOSTOLAKIS: Yeah, I mean geez.
2	MR. PARRY: But I would say there's enough
3	guidance in the ASME standard to actually at least
4	identify the appropriate human failure events in the
5	model because it doesn't require currently that we do
6	ours
7	CHAIRMAN APOSTOLAKIS: The events I agree.
8	It's the quantification.
9	MR. PARRY: Well, the quantification, none
10	of those
11	CHAIRMAN APOSTOLAKIS: Anyway, these
12	NUREGS will address these issues.
13	MR. PARRY: Yes.
14	CHAIRMAN APOSTOLAKIS: First of all, I
15	believe it is a similar situation in my mind with
16	about 20 years ago with the errors of commission and
17	everybody was saying, "My God, the errors of
18	commission, oh, errors of commission."
19	Then somebody publishes this simple table
20	that says, you know, which initiating events can be
21	confused, the confusion matrix, which sheds so much
22	light into it.
23	So there are very few, like steam
24	generator tube rupture. You would think it's a small
25	LOCA, and all of a sudden there was so much

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	124
1	understanding.
2	So if, for example, your effort on model
3	uncertainty and EPRI's effort comes back and says in
4	Level 1 PRA the model uncertainties that really could
5	matter are, and there is only three of them, wow, all
б	of a sudden we all say, "Gee, that's great."
7	Eleven, two, of course, is a different
8	story.
9	So even those small steps, I think would
10	be very useful. Then you take each one and in the
11	seal LOCA case perhaps there are two models that you
12	judge to be extreme, and you say do both of them or
13	something. In the HRA I don't know how you're going
14	to do that though because it's a different beast, and
15	I appreciate the difficulty.
16	MR. PARRY: Yeah, the way we do it now, I
17	think, is to recognize that those that to try and
18	construct methods that at least rank the HEPs in an
19	appropriate manner and then recognize that the values
20	are going to be uncertain and to make sure that the
21	decision
22	CHAIRMAN APOSTOLAKIS: Well, my questions
23	when we were reviewing the power up rates, I mean, we
24	used the model and the human error probability was
25	three, ten to the minus three, but that was assuming

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	125
1	that there were 42 minutes available, and it went down
2	to 39 minutes. So it becomes one and a half, ten to
3	the minus three.
4	That drives me up the wall, you know.
5	MR. PARRY: Yeah, me, too.
6	CHAIRMAN APOSTOLAKIS: They use a model
7	that I cannot review because it's EPRI proprietary,
8	and they ignore also all sorts of other models.
9	So this is the kind of thing we need to
10	avoid, I think, and in that case a qualitative
11	argument would have been good enough actually, you
12	know, 42 to 39.
13	MR. PARRY: Yeah, zero, yeah.
14	CHAIRMAN APOSTOLAKIS: So but my point is
15	that the resolution of these issues really should take
16	the highest priority because they are applicable to
17	all phases of the proposed plan.
18	MR. PARRY: Yeah, but it depends on what
19	you mean by resolution though because I think you
20	can
21	CHAIRMAN APOSTOLAKIS: Well, a
22	recommendation is what to do.
23	MR. PARRY: Right. If you can construct
24	your decision algorithm to recognize these sources of
25	uncertainty

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	126
1	CHAIRMAN APOSTOLAKIS: Then do something
2	about it, yeah.
3	MR. PARRY: then I think you can do it.
4	But we can make better decisions by refining those
5	things.
6	CHAIRMAN APOSTOLAKIS: Yeah, so I would
7	say this is important to decision making, and maybe
8	some decisions do not rely much on these, but maybe
9	others do, and then, of course, there is a fourth
10	bullet that's missing since you're talking about
11	decisions.
12	DR. ROSEN: Safety culture.
13	CHAIRMAN APOSTOLAKIS: Exactly. I'm
14	sorry. I'm sorry. I can apply all of these to Davis-
15	Besse, everything, and come up with a ten to the minus
16	five core damage frequency, and then what? Then I
17	almost have a lock.
18	The truth of the matter is that we are
19	leaving out an extremely important aspect of plant
20	operations, and we're focusing on things that we
21	understand and we will deal with. We can deal with
22	immediately.
23	As far as I'm concerned, the Regulatory
24	Guide 1.174, the integrated decision making process
25	should how many inputs does it have now? I think

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	127
1	five.
2	MR. PARRY: Five, yeah.
3	CHAIRMAN APOSTOLAKIS: There should be a
4	sixth one related to some sort of cultural something.
5	DR. ROSEN: Crosscutting issues.
6	CHAIRMAN APOSTOLAKIS: Something, and yet
7	we consistently ignore it, and that will do us in.
8	Oh, my God, what did I say? No, that was a moment of
9	I take it back.
10	But really, I mean, look at it, and the
11	first time it came from you guys, you, the staff.
12	Years ago I remember Oyster Creek had just been put on
13	the watch list, and a week later they submitted a PRA.
14	The staff looks at the core damage frequency and say,
15	"How can that be?"
16	It's the same as any other BWR in the
17	country, and we just put them on that list. How good
18	are these PRA? Was the question ever answered? No.
19	So, I mean, to worry about seismic events
20	which have a ten to the minus six probability of
21	occurring just because there is a whole community out
22	there of seismic engineers and ignore this thing which
23	happened a year and a half ago, I mean, it seems to me
24	that doesn't make sense at all.
25	DR. ROSEN: Let me associate myself with

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	128
1	your remarks, George, with regard to the importance of
2	safety culture in the crosscutting issues, but not
3	with regard to the need to incorporate them into the
4	PRA. I'm not sure that's an essential piece of it.
5	CHAIRMAN APOSTOLAKIS: No, but the
6	integrated decision making process, I would like to
7	see an input that says have you considered that. We
8	have to consider sufficient safety margins, defense in
9	depth philosophy, delta for CDF, and the monitoring
10	problem, and all I'm saying is put a sentence in there
11	that says think about this other thing, too.
12	MR. PARRY: But, George, now you're
13	migrating towards decision making though, which is a
14	little
15	CHAIRMAN APOSTOLAKIS: Because you said
16	decision making. That was an excellent document, and
17	then somewhere else here you say that the didn't
18	you say that the issue must be relevant to the
19	decision?
20	MR. PARRY: Yeah.
21	DR. SIEBER: I think that Davis-Besse
22	taught us one other thing about PRAs. PRAs really
23	don't handle aging effects for materials degradation.
24	PARTICIPANTS: Right.
25	DR. SIEBER: Since I'm on the Metallurgy

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	129
1	Subcommittee I thought I should say that, but there is
2	an important series of phenomena that degrade and
3	change the risk of
4	DR. ROSEN: Well, we've now identified two
5	important things that are not in PRA, safety culture
6	and materials degradation. The question is: should
7	we insist that they be in PRAs?
8	My answer to that is no. My answer to
9	that is we're asking too much of this horse. We have
10	already loaded it down with everything we can think
11	of. This poor little donkey can hardly stand anymore.
12	DR. SIEBER: You know, on the other hand,
13	when you go to do a license renewal application
14	approval, you look at the PRA, and the PRA says
15	everything is fine, but the PRA doesn't deal with any
16	aging phenomena.
17	DR. KRESS: I didn't realize that we
18	looked at the PRA at license renewal.
19	DR. SIEBER: It's in there.
20	CHAIRMAN APOSTOLAKIS: At license renewal
21	we don't look at it.
22	MR. HARRISON: Yeah, it's actually only in
23	the environmental.
24	DR. SIEBER: If we do it, we don't make a
25	comment on it.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	130
1	DR. ROSEN: My comments are not to say
2	that either safety culture or materials degradation
3	are unimportant. They are critically important, but
4	putting them on PRA is too much for PRA.
5	DR. SIEBER: Well, it's hard to do.
6	CHAIRMAN APOSTOLAKIS: They should be part
7	of the integrated decision making process.
8	DR. SIEBER: That is true.
9	DR. KRESS: However, that means you need
10	some quantification of their effect on CDF and LERF.
11	CHAIRMAN APOSTOLAKIS: Well, the aging you
12	can do.
13	DR. KRESS: Well, I know, but if you're
14	going to factor it into your decision and your
15	decision process is looking at things like CDF and
16	delta CDFs, which it
17	DR. ROSEN: Well, it also looks at defense
18	in depth.
19	DR. ROSEN: The decision process uses CDF
20	and LERF as one input. It's risk informed. It's not
21	the only one.
22	CHAIRMAN APOSTOLAKIS: That's why I'm
23	saying you should be a sixth box, maybe a seventh as
24	well to satisfy Peter.
25	MR. SNODDERLY: George, what I'd like to

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	131
1	suggest is that at the end of this meeting I'm going
2	to hand out a status report for a meeting that we're
3	going to have next Thursday on risk informing 5046,
4	and in that in the status of the expert
5	solicitation that has taken place and in that
6	expert solicitation they do address safety culture and
7	materials degradation as part of the expert
8	solicitation. I think you'll find it interesting.
9	CHAIRMAN APOSTOLAKIS: I'd love seeing it.
10	MR. SNODDERLY: So my suggestion is take
11	a look at how the staff addressed those two issues for
12	that specific application and it will give you
13	something to
14	CHAIRMAN APOSTOLAKIS: But I guess the
15	bigger question is if we look at this SRM, and let's
16	say it's implemented, Phase 1, 2, 3 and so on. Are we
17	leaving out some important stuff from our decision
18	making process, not on PRA; from our decision making
19	process?
20	Yes, we are. Now, this SRM really
21	addressed the PRA, the PRA quality. So you might say
22	something about the aging, but it's not really I
23	mean, you can do that separately, too. It's a
24	different time scale.
25	MS. DROUIN: Well, I think one of the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	132
1	things that we can do is, you know, we're up to what,
2	seven tasks? And instead of having this discussion on
3	the technical issues separate, that one of the tasks
4	should be to look at as we go through the phases, as
5	we implement the various guidance documents, you know,
6	what are the technical issues and are they being
7	addressed.
8	I mean, that is part of our process.
9	CHAIRMAN APOSTOLAKIS: Yeah. I think the
10	technical issues should be in every phase, and by the
11	way, I don't know. I mean, when you say human
12	performance, it's affected a lot by the culture.
13	DR. ROSEN: Oh, of course.
14	MS. DROUIN: And hopefully an answer to
15	when we notice them is that we can then go out of the
16	plan, say these are being addressed under these other
17	programs.
18	DR. ROSEN: But the human performance
19	that's the PRAs now is the operator performance.
20	CHAIRMAN APOSTOLAKIS: Yes.
21	DR. ROSEN: And the safety culture issue
22	is much broader than just operator performance.
23	MS. DROUIN: Oh, yes.
24	DR. ROSEN: It's maintenance people
25	performance, technical people's performance,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	133
1	executives' performance.
2	CHAIRMAN APOSTOLAKIS: That's right.
3	DR. ROSEN: It's the whole performance and
4	the performance of these people in teams, a point that
5	we've made before in letters to the Commission, that
6	the performance of people in teams both in the control
7	room and outside the control room are elements of the
8	safety culture.
9	MR. HARRISON: And if I could just maybe
10	add a thought. A lot time ago when I first started
11	this, one of the and I've said it in our
12	organization a couple of times an underpinning of
13	the PRA is the plant is operating according to its
14	procedures and its programs, and if those aren't true,
15	then the underpinning of the PRA is not true.
16	And so to address the safety culture, to
17	address even aging, you do that through other programs
18	that establish a base and make sure that, if you will,
19	your PRA is okay above that.
20	CHAIRMAN APOSTOLAKIS: Actually, issues
21	well, it depends on how you interpret safety culture.
22	I mean, some people interpret it as attitudes of
23	people and values and so on. Other people, I think,
24	including the insight reports, they include
25	organizational structures and so on.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	134
1	But wasn't there a case from actual
2	experience where organizational screw-ups led to
3	initiators?
4	PARTICIPANTS: Sure.
5	CHAIRMAN APOSTOLAKIS: We lost 9,000
6	gallons of water in one plant because they postponed
7	work on Friday to Monday without informing people.
8	DR. ROSEN: Well, the tragic history of
9	the space shuttles.
10	CHAIRMAN APOSTOLAKIS: Well, nuclear.
11	So you might ask yourself, you know, is
12	our list of initiating events complete if we don't
13	look at these things, which is really a PRA issue.
14	MR. PARRY: It is a PRA issue, but I think
15	also we cannot predict or even identify things that we
16	don't know about.
17	CHAIRMAN APOSTOLAKIS: Well
18	MR. PARRY: You really can't.
19	CHAIRMAN APOSTOLAKIS: We don't know about
20	them because we're not looking at it. It's amazing.
21	I mean that's what they told Erasmus and Levine when
22	they started this thing. I mean, both of them told
23	me, said they were very distinguished people in this
24	industry who told us we were crazy. Both Saul Levine
25	and Norm Erasmus told me that, that this could never

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	135
1	be done. WASH 1400 could never be done.
2	So, you know, unless you look into
3	something and try it you cannot prejudge, but again,
4	let me understand something because it's important.
5	The resolution of these issues is part of
6	the plan or not?
7	MS. DROUIN: No, I'm saying identification
8	of the issues, a step of going through and noting in
9	the plan that we have an explicit step to look for
10	technical issues I think should be part of the plan
11	CHAIRMAN APOSTOLAKIS: And I agree.
12	MR. PARRY: And how they factor in.
13	MS. DROUIN: Yes.
14	CHAIRMAN APOSTOLAKIS: And right now it's
15	not, right?
16	MS. DROUIN: We don't have an explicit
17	task that says that.
18	CHAIRMAN APOSTOLAKIS: In what you
19	presented, it was not there.
20	MR. PARRY: It was not.
21	CHAIRMAN APOSTOLAKIS: And you agree that
22	it should be there.
23	MR. PARRY: As a link. I mean, in the
24	broader plan
25	CHAIRMAN APOSTOLAKIS: Yeah, but

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	136
1	MR. PARRY: we have to do all of these
2	things. We have to explain how these things get in.
3	CHAIRMAN APOSTOLAKIS: You don't seem to
4	acknowledge though that there is more urgency to this
5	than the plant.
б	MR. PARRY: I'm not sure.
7	CHAIRMAN APOSTOLAKIS: I think there is
8	more urgency to this because we're actually making
9	decisions now using risk informed, of course. I
10	agree, but what is the risk information?
11	MR. PARRY: I'm not sure that it's more
12	urgent. I think in a sense what all of these
13	activities will do what we have to do right now is
14	to accept the fact that there are in some places large
15	uncertainties, and we have to make those decisions
16	despite that.
17	CHAIRMAN APOSTOLAKIS: But didn't you give
18	people a little bit of guidance? Couldn't you give
19	them some guidance, what to do? I mean you don't have
20	to solve the issue, but say, "Look. In this
21	particular case, recognize there is model uncertainty
22	and here is what you can do right now, and work is
23	continuing."
24	MR. PARRY: Yeah, but that's within the
25	realm of the decision making process.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	137
1	CHAIRMAN APOSTOLAKIS: Absolutely.
2	MR. PARRY: The plan that we have does not
3	really address that.
4	CHAIRMAN APOSTOLAKIS: But in Phase 3 you
5	say that it will be applicable to all anticipated
6	applications. Therefore these issues must have been
7	resolved by then.
8	MR. PARRY: But what that does, the way it
9	feeds back though, I think, is you look at what the
10	decision making process is. What does it require?
11	Does it require CDF? Does it require LERF? Does it
12	require uncertainly analysis?
13	That feeds back into requirements on the
14	PRAs, which is already in the standard in the sense
15	that what the standard says is you have to identify
16	the key sources of uncertainty and be able to assess
17	their significance.
18	CHAIRMAN APOSTOLAKIS: You're talking at
19	a very high level about it. I'll tell you what. If
20	people applied 1.174, paying serious attention to all
21	of the discussion and uncertainty, we would have no
22	problem right now. I think the only guy who has read
23	it is you because you wrote it. And whether you
24	proofread it
25	(Laughter.)
•	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	138
1	CHAIRMAN APOSTOLAKIS: I mean, there is
2	beautiful stuff there that nobody does.
3	DR. BONACA: We have a meeting and don't
4	read it.
5	CHAIRMAN APOSTOLAKIS: He told me about
6	it.
7	Anyway, any other comments? Well, we will
8	go around the table to give me advice regarding the
9	letter.
10	MR. PARRY: We haven't quite
11	CHAIRMAN APOSTOLAKIS: You're not done?
12	MR. PARRY: I have two or three slides.
13	CHAIRMAN APOSTOLAKIS: Okay. Run through
14	your slides.
15	MR. PARRY: There may be only one more
16	slide.
17	DR. ROSEN: We're getting into the slide
18	quality issue.
19	MR. PARRY: The next steps then, and as
20	was pointed out to me yesterday, too, I ought to
21	reverse the first two bullets and get the stakeholder
22	comments first before finalizing the plan, and then
23	we'll send it to the Commission in July, and we have
24	a slide here with two potential policy issues, which
25	we have discussed.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	139
1	One was this famous Box 5 leading into Box
2	6, and the other one was whether we would expect or
3	whether the Commission expects the licensees to go
4	into Phase 3 if they want to play in the risk informed
5	regulatory arena.
6	And then the final slide is what we want
7	to discuss with you really. We're going to revise the
8	plan in response to stakeholder comments, and we
9	don't
10	MS. DROUIN: And ACRS.
11	MR. PARRY: Well, they're stakeholders.
12	PARTICIPANT: A major stakeholder.
13	MR. PARRY: Now, we need to return to you
14	guys to request a letter on this.
15	CHAIRMAN APOSTOLAKIS: In April.
16	MR. PARRY: But we're set for April, but
17	by April the 15th, we will not have revised this plan
18	to the level that we want to revise it.
19	CHAIRMAN APOSTOLAKIS: So?
20	MR. PARRY: So you could either give us a
21	letter on the concept on the 15th
22	CHAIRMAN APOSTOLAKIS: On what we have
23	heard today?
24	MR. PARRY: Of what you have heard today
25	or

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	140
1	CHAIRMAN APOSTOLAKIS: Or?
2	MR. PARRY: we could wait until we've
3	got a more complete plan and we can come back to you
4	in May perhaps, if that's possible.
5	CHAIRMAN APOSTOLAKIS: One mitigating
6	factor is that we are meeting with the Commission in
7	May, and one of the items we're discussing with them
8	is RPA SRM quality, and the committee is usually very
9	reluctant to trust one member to talk about something
10	unless there is an official ACRS letter, in which case
11	a member, of course, follows the letter.
12	So if we don't write a letter in April,
13	we're complicating everybody's life.
14	MR. PARRY: But the letter in April will
15	be on a must be on a yeah, it can only be on
16	CHAIRMAN APOSTOLAKIS: It must be on a
17	high level staff, and it can also say things that you
18	have already decided to change. That's the problem
19	when you write a premature letter. So we have to
20	discuss this with the leadership of the committee.
21	DR. ROSEN: Well, two out of three of us
22	are here.
23	CHAIRMAN APOSTOLAKIS: It's a very easy
24	thing. Just let me speak and
25	DR. ROSEN: That's right, George.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	141
1	(Laughter.)
2	DR. ROSEN: My feeling is we should write
3	a letter, Mario, write a letter that talks about our
4	view of it right about now and put George in irons and
5	tell them give him a copy of the letter.
6	CHAIRMAN APOSTOLAKIS: "Now, read."
7	DR. ROSEN: One to read and one to eat.
8	DR. SIEBER: Could you come up with a
9	draft by tomorrow morning?
10	CHAIRMAN APOSTOLAKIS: I understand the
11	Chairman though has approved.
12	Well, if we don't have to meet with the
13	Commission, then I think it's a good idea to postpone
14	the letter.
15	DR. ROSEN: Is there a really serious
16	potential that we won't have a meeting with the
17	Commission?
18	CHAIRMAN APOSTOLAKIS: As far as I know,
19	he's going to be there. I think we have to have a
20	letter.
21	DR. KRESS: I think they'll leave this one
22	on there.
23	DR. ROSEN: And if we have a meeting
24	DR. KRESS: Because they're very
25	interested in our view.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	142
1	CHAIRMAN APOSTOLAKIS: No, but look.
2	DR. ROSEN: Well, I don't feel comfortable
3	at all going to that meeting without having put
4	something in the letter. I think they can say to us
5	if we don't do that
6	DR. SIEBER: This time maybe they want the
7	comments more than the original letter.
8	DR. ROSEN: where are you?
9	CHAIRMAN APOSTOLAKIS: Why can't the
10	committee come up with three or four bullets in full
11	session without writing a letter and we present the
12	Commission the bullets?
13	DR. ROSEN: That's not the way we do
14	business though.
15	DR. KRESS: We can do that.
16	CHAIRMAN APOSTOLAKIS: Well, we can always
17	start now.
18	DR. KRESS: We can do that. It can be a
19	committee position if we agree on it.
20	DR. BONACA: Yeah, we have time on the
21	agenda to discuss what's going to be in these
22	presentations in detail. We definitely are going to
23	prepare the overheads, right?
24	DR. ROSEN: Mario, do you feel comfortable
25	about trying to come up with bullets or something like

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	143
1	that without a letter?
2	DR. BONACA: Well, right now it seems to
3	me that we should be able to generate a letter
4	anyway.
5	DR. KRESS: Well, the way we would come up
6	with the bullets is the same process we use to come up
7	with the letter.
8	DR. ROSEN: That's right.
9	DR. KRESS: And all we do is vote on it.
10	I don't see any problem.
11	CHAIRMAN APOSTOLAKIS: Yeah, but the
12	letter requires to go over it line by line and the
13	discussion and all of that. With the bullets you go
14	line by line and you have only 12 lines, and then they
15	can be turned into a latter later.
16	DR. KRESS: That was my point.
17	DR. ROSEN: A letter later, yeah.
18	DR. KRESS: And it's equivalent.
19	CHAIRMAN APOSTOLAKIS: Yes, John.
20	DR. SIEBER: it seems to me that we know
21	enough to write a general purpose letter right now or
22	at least for the next meeting as opposed to coming up
23	with a committee position, writing a letter later, and
24	ending up the letter saying something different than
25	what the committee position was.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	144
1	CHAIRMAN APOSTOLAKIS: It won't say
2	anything different because if we have bullets, we will
3	have big letters, preliminary whatever, thoughts or
4	conclusions.
5	DR. ROSEN: I think we've had
6	CHAIRMAN APOSTOLAKIS: Well, the letter
7	will say the same thing because we will not have seen
8	the final
9	DR. ROSEN: We can write a brief now. We
10	need a letter draft for the full committee meeting in
11	a couple of weeks.
12	DR. BONACA: Let me give you my
13	impression. Okay? We went from an SRM which at the
14	beginning puzzled us. I mean everybody interpreted it
15	somewhat. I believe we have here a plan that to me is
16	a good interpretation of the SRM.
17	DR. SIEBER: Yes.
18	DR. BONACA: And also gives me some more
19	comfort than I had because I see the result of
20	incentives there for the industry to buy in, okay, for
21	the development of standards to come. So at the
22	beginning at times we thought that this would be
23	almost the end of the progress in improvement of
24	methods. I see it now differently. I see it as an
25	incentive for people to get, first of all, the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	145
1	standards in place and, second, better models to have
2	to proceed.
3	I think we have some observation about a
4	couple of areas where it doesn't provide the
5	incentives. In fact, it's counter productive, and
6	that's an issue where you have raised it as a policy
7	issue. I think we have to comment on that.
8	CHAIRMAN APOSTOLAKIS: I'd like to hear
9	from NEI.
10	DR. BONACA: Yeah.
11	CHAIRMAN APOSTOLAKIS: How come we didn't
12	hear from NEI?
13	DR. BONACA: But I'm saying I'm just
14	giving you some example of some use that already
15	CHAIRMAN APOSTOLAKIS: There's no NEI.
16	DR. SIEBER: They went home.
17	DR. BONACA: because a minimum could be
18	useful to you because that would be supportive of what
19	you're doing right now.
20	MR. PARRY: Yeah, I think generally from
21	our discussions, I think we've had general agreement
22	with the approach, but with certainly some arguments
23	about some of the specifics, like Box 5, for example.
24	DR. ROSEN: Perhaps we could get to the
25	answer if we went around the table and you heard what

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	146
1	the comments were.
2	CHAIRMAN APOSTOLAKIS: I'd like to hear
3	from NEI.
4	MR. MAGRUDER: Well, yeah. At yesterday's
5	meeting NEI agreed to give us a letter on their
6	position by the middle of April. So by the time the
7	full committee meets no, no.
8	MR. PARRY: We asked them by April the
9	6th. Well, we asked for it by April the 6th.
10	DR. ROSEN: That's time for you to draft
11	a letter.
12	MR. MAGRUDER: Yeah.
13	MR. SNODDERLY: Well, we invited NEI to
14	participate in this meeting, and they said that they
15	were apprehensive because they hadn't had a lot of
16	time with the action plan yet, but we'll definitely
17	work with them to get them to brief us in April with
18	these same
19	CHAIRMAN APOSTOLAKIS: Yeah, at the full
20	committee meeting NEI will also brief us and tell us
21	where you disagree.
22	MS. DROUIN: Okay, So if I understand,
23	your preference is for us not to postpone our briefing
24	with the full committee to May, but to go ahead and
25	proceed on the April date.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	147
1	CHAIRMAN APOSTOLAKIS: If I have to write
2	a letter, Mary, yes, because the full committee is not
3	here.
4	MS. DROUIN: Right, but recognizing that
5	on April 15th you will not see our final action plan,
6	and you won't see the SECY paper.
7	CHAIRMAN APOSTOLAKIS: Geez.
8	MS. DROUIN: I mean that's what that
9	means.
10	CHAIRMAN APOSTOLAKIS: So if we come back
11	in May you will have this stuff?
12	DR. SIEBER: Will we see that then?
13	MS. DROUIN: Yes.
14	MR. MAGRUDER: We have to then.
15	CHAIRMAN APOSTOLAKIS: So let me come back
16	to this suggestion. Why don't we develop three or
17	four bullets based on what we have seen and reserve
18	the right to write a letter after we see the SECY?
19	It would be easier for us to
20	DR. SIEBER: Well, I think we are almost
21	forced to do that.
22	CHAIRMAN APOSTOLAKIS: Yeah, we are forced
23	to do that.
24	DR. SIEBER: Because those are key
25	documents.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 MS. DROUIN: I know. That's why I wanted 2 to make it clear. 3 CHAIRMAN APOSTOLAKIS: It shouldn't be 4 hard for us to come up with two or three bullets. 5 We'll go around the table right now. 6 MS. DROUIN: We have to be. Otherwise we 7 will not meet our deadline. 8 MR. MAGRUDER: We have to do that. 9 CHAIRMAN APOSTOLAKIS: Without the SECY? 10 DR. BONACA: No, I'm saying develop the 11 bullets. 12 CHAIRMAN APOSTOLAKIS: The bullets will be 13 easy to develop. 14 DR. BONACA: I understand. We want to, 15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 CHAIRMAN APOSTOLAKIS: No, Mary, it will 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secre		148
3 CHAIRMAN APOSTOLAKIS: It shouldn't be 4 hard for us to come up with two or three bullets. 5 We'll go around the table right now. 6 MS. DROUIN: We have to be. Otherwise we 7 will not meet our deadline. 8 MR. MAGRUDER: We have to do that. 9 CHAIRMAN APOSTOLAKIS: Without the SECY? 10 DR. BONACA: No, I'm saying develop the 11 bullets. 12 CHAIRMAN APOSTOLAKIS: The bullets will be 13 easy to develop. 14 DR. BONACA: I understand. We want to, 15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 CHAIRMAN APOSTOLAKIS: No, Mary, it will 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.	1	MS. DROUIN: I know. That's why I wanted
 hard for us to come up with two or three bullets. We'll go around the table right now. MS. DROUIN: We have to be. Otherwise we will not meet our deadline. MR. MAGRUDER: We have to do that. CHAIRMAN APOSTOLAKIS: Without the SECY? DR. BONACA: No, I'm saying develop the bullets. CHAIRMAN APOSTOLAKIS: The bullets will be easy to develop. DR. BONACA: I understand. We want to, you know CHAIRMAN APOSTOLAKIS: You guys will give me ideas today, but we need the staff there. Do you guys have anything else to say? MR. MAGRUDER: No. MS. DROUIN: No, we just would like to know your decision whether we should get back in April or May. You'll let us know? CHAIRMAN APOSTOLAKIS: No, Mary, it will be my secret. 	2	to make it clear.
 We'll go around the table right now. MS. DROUIN: We have to be. Otherwise we will not meet our deadline. MR. MAGRUDER: We have to do that. CHAIRMAN APOSTOLAKIS: Without the SECY? DR. BONACA: No, I'm saying develop the bullets. CHAIRMAN APOSTOLAKIS: The bullets will be easy to develop. DR. BONACA: I understand. We want to, you know CHAIRMAN APOSTOLAKIS: You guys will give me ideas today, but we need the staff there. Do you guys have anything else to say? MR. MAGRUDER: No. MS. DROUIN: No, we just would like to know your decision whether we should get back in April or May. You'll let us know? CHAIRMAN APOSTOLAKIS: No, Mary, it will be my secret. 	3	CHAIRMAN APOSTOLAKIS: It shouldn't be
 MS. DROUIN: We have to be. Otherwise we will not meet our deadline. MR. MAGRUDER: We have to do that. CHAIRMAN APOSTOLAKIS: Without the SECY? DR. BONACA: No, I'm saying develop the bullets. CHAIRMAN APOSTOLAKIS: The bullets will be easy to develop. DR. BONACA: I understand. We want to, you know CHAIRMAN APOSTOLAKIS: You guys will give me ideas today, but we need the staff there. Do you guys have anything else to say? MR. MAGRUDER: No. MS. DROUIN: No, we just would like to Know your decision whether we should get back in April or May. You'll let us know? CHAIRMAN APOSTOLAKIS: No, Mary, it will be my secret. 	4	hard for us to come up with two or three bullets.
<pre>7 will not meet our deadline. 8 MR. MAGRUDER: We have to do that. 9 CHAIRMAN APOSTOLAKIS: Without the SECY? 10 DR. BONACA: No, I'm saying develop the 11 bullets. 12 CHAIRMAN APOSTOLAKIS: The bullets will be 13 easy to develop. 14 DR. BONACA: I understand. We want to, 15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 Or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.</pre>	5	We'll go around the table right now.
 MR. MAGRUDER: We have to do that. CHAIRMAN APOSTOLAKIS: Without the SECY? DR. BONACA: No, I'm saying develop the bullets. CHAIRMAN APOSTOLAKIS: The bullets will be easy to develop. DR. BONACA: I understand. We want to, you know CHAIRMAN APOSTOLAKIS: You guys will give me ideas today, but we need the staff there. Do you guys have anything else to say? MR. MAGRUDER: No. MS. DROUIN: No, we just would like to know your decision whether we should get back in April or May. You'll let us know? CHAIRMAN APOSTOLAKIS: No, Mary, it will be my secret. 	6	MS. DROUIN: We have to be. Otherwise we
9CHAIRMAN APOSTOLAKIS: Without the SECY?10DR. BONACA: No, I'm saying develop the11bullets.12CHAIRMAN APOSTOLAKIS: The bullets will be13easy to develop.14DR. BONACA: I understand. We want to,15you know16CHAIRMAN APOSTOLAKIS: You guys will give17me ideas today, but we need the staff there. Do you18guys have anything else to say?19MR. MAGRUDER: No.20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22Or May. You'll let us know?23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	7	will not meet our deadline.
10DR. BONACA: No, I'm saying develop the11bullets.12CHAIRMAN APOSTOLAKIS: The bullets will be13easy to develop.14DR. BONACA: I understand. We want to,15you know16CHAIRMAN APOSTOLAKIS: You guys will give17me ideas today, but we need the staff there. Do you18guys have anything else to say?19MR. MAGRUDER: No.20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22or May. You'll let us know?23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	8	MR. MAGRUDER: We have to do that.
11 bullets. 12 CHAIRMAN APOSTOLAKIS: The bullets will be 13 easy to develop. 14 DR. BONACA: I understand. We want to, 15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.	9	CHAIRMAN APOSTOLAKIS: Without the SECY?
12CHAIRMAN APOSTOLAKIS: The bullets will be13easy to develop.14DR. BONACA: I understand. We want to,15you know16CHAIRMAN APOSTOLAKIS: You guys will give17me ideas today, but we need the staff there. Do you18guys have anything else to say?19MR. MAGRUDER: No.20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22Or May. You'll let us know?23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	10	DR. BONACA: No, I'm saying develop the
<pre>13 easy to develop. 14 DR. BONACA: I understand. We want to, 15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.</pre>	11	bullets.
14DR. BONACA: I understand. We want to,15you know16CHAIRMAN APOSTOLAKIS: You guys will give17me ideas today, but we need the staff there. Do you18guys have anything else to say?19MR. MAGRUDER: No.20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22chAIRMAN APOSTOLAKIS: No, Mary, it will23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	12	CHAIRMAN APOSTOLAKIS: The bullets will be
<pre>15 you know 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.</pre>	13	easy to develop.
 16 CHAIRMAN APOSTOLAKIS: You guys will give 17 me ideas today, but we need the staff there. Do you 18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret. 	14	DR. BONACA: I understand. We want to,
17 me ideas today, but we need the staff there. Do you guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.	15	you know
<pre>18 guys have anything else to say? 19 MR. MAGRUDER: No. 20 MS. DROUIN: No, we just would like to 21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.</pre>	16	CHAIRMAN APOSTOLAKIS: You guys will give
19MR. MAGRUDER: No.20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22or May. You'll let us know?23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	17	me ideas today, but we need the staff there. Do you
20MS. DROUIN: No, we just would like to21know your decision whether we should get back in April22or May. You'll let us know?23CHAIRMAN APOSTOLAKIS: No, Mary, it will24be my secret.	18	guys have anything else to say?
21 know your decision whether we should get back in April 22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.	19	MR. MAGRUDER: No.
<pre>22 or May. You'll let us know? 23 CHAIRMAN APOSTOLAKIS: No, Mary, it will 24 be my secret.</pre>	20	MS. DROUIN: No, we just would like to
 CHAIRMAN APOSTOLAKIS: No, Mary, it will be my secret. 	21	know your decision whether we should get back in April
24 be my secret.	22	or May. You'll let us know?
	23	CHAIRMAN APOSTOLAKIS: No, Mary, it will
25 (Laughter.)	24	be my secret.
	25	(Laughter.)

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	149
1	CHAIRMAN APOSTOLAKIS: Thank you very much
2	for coming. This was a very informative presentation.
3	I really mean that. As Mario said, we have different
4	interpretations of the SRM, and I think you gave us a
5	very valuable interpretation which probably is a
6	correct one. So we appreciate that.
7	PARTICIPANTS: Thank you.
8	CHAIRMAN APOSTOLAKIS: Thank you.
9	Okay, gentlemen. We start with Mr. Sieber
10	this time.
11	DR. SIEBER: This time? Okay. This is
12	historical.
13	CHAIRMAN APOSTOLAKIS: If you were to
14	write bullets, tell me what you would write.
15	DR. KRESS: First give us your opinion on
16	whether we should write bullets or not.
17	CHAIRMAN APOSTOLAKIS: Versus a letter.
18	DR. SIEBER: I think if you're going to
19	have the subject in May we have got to sit down and
20	write the bullets between now and April.
21	DR. KRESS: As versus a letter.
22	DR. SIEBER: So that we can get the
23	committee to agree to them. And the first overall
24	bullet is, if I were writing them, is I believe the
25	staff has developed a concept of a plan that addresses

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	150
1	the necessary elements to fulfill the requirements of
2	the SRM, and I think they've done a pretty good job at
3	doing that.
4	DR. BONACA: These are bullets. Okay?
5	Let's make it clear. The committee is not here right
6	now.
7	DR. SIEBER: Yeah, they would be.
8	CHAIRMAN APOSTOLAKIS: We are going around
9	the table after we do it, after every subcommittee,
10	getting individual viewpoints. These people are
11	experienced enough to know that. These are not
12	committee positions.
13	DR. SIEBER: Okay, and beyond that I don't
14	think that we have addressed all of the technical
15	issues that are outstanding at this time, but they
16	will be forthcoming as they are developed by the
17	staff, and then we can deal with them.
18	And perhaps this isn't the time to be
19	dealing with the technical intricacies of some of
20	these things. WE're really talking more about a
21	framework and a concept and a time sequence or
22	schedule as to how to implement.
23	And I think it has been pretty well done.
24	CHAIRMAN APOSTOLAKIS: Thank you, Jack.
25	Okay. Peter.
1	·

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

11	151
1	DR. FORD: Well, I agree with Jack's top
2 two bullets	. I think it's an admirable objective, and
3 I think it'	s an appropriate plan.
4	I don't think it's appropriate to go down
5 to deeper de	epths, but let me just for the record say
6 what my teo	chnical issues. I heard us talk about
7 safety cult	cure, which I agree with, but I don't
8 understand	why it has not been put in, why you backed
9 off by burde	ening the donkey, as you said, Steve, and
10 materials d	egradation, as you know, I still
11	DR. ROSEN: Too weighty those issues.
12	CHAIRMAN APOSTOLAKIS: Whoa, whoa, whoa.
13 It's his fl	oor.
14	DR. ROSEN: I thought he asked me.
15	CHAIRMAN APOSTOLAKIS: Your time will
16 come.	
17	DR. ROSEN: I thought when my name was
18 mentioned I	was given a chance to respond.
19	DR. SIEBER: He's just attacking you now.
20 You can't f	ight back.
21	DR. FORD: I've got a nagging concern
22 about the r	route that you're taking to reduce this
23 whole plan	to practice because it is going to depend
24 on the colla	boration between the NRC, licensee and the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	152
1	interaction being there.
2	Specifically, if it can take the standards
3	operations five to ten years, which we heard, to come
4	up with a standard, that is just not on and,
5	therefore, there has got to be a way to come around
6	that.
7	I don't know how you get around it legally
8	or whatever, whether it's by regulatory guidelines
9	which are not enforceable. I just don't know.
10	The second issue is that we heard from
11	over there that many of the licensees haven't bought
12	into this approach and, therefore, if that is true
13	then they won't put the resources to it, and therefore
14	if that is true, then you won't succeed.
15	Those are two kind of project management
16	type concerns which I don't know if it is our
17	agreement to judge, but those are nagging concerns
18	that I have. We won't be able to do this unless those
19	concerns are met.
20	But those are my comments.
21	CHAIRMAN APOSTOLAKIS: Thank you, Peter.
22	Mario.
23	DR. BONACA: Yeah, as I said before, when
24	the SRM first came out, I was one of those that was
25	concerned about the fact that, you know, Phase 4

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	153
1	seemed so far in the future we would never get to it,
2	and I didn't see too much difference between Phase 1
3	and Phase 2.
4	The reality now with the plan in front of
5	me, I'm just more supportive of the SRM, the way it is
6	going. I believe that the industry probably is going
7	to be incentivated in participating, and there are
8	benefits, real benefits, coming.
9	As I mentioned before, I see that there
10	are the appropriate incentives, except in the specific
11	case of the Box No. 6 that really have to be looked at
12	because, I mean, it's almost a deterrent to be capable
13	and ahead of the pack. It means that you can't do
14	anything with the PRA just because you don't have some
15	peer review or standard there to support it. I think
16	something has to be done about that.
17	Clearly, we still have the conceptual. I
18	mean, I think the proof will come with implementation
19	of the tasks, and I am pretty anxious to see what
20	comes out for 5046, clearly, trying to understand, you
21	know, what are the requirements of PRA will be to fill
22	the needs to you to change 5046 on a risk informed
23	basis. And that we'll have to see in the future.
24	I'm not sure that if we wrote a letter or
25	if we had us some bullets we have to say anything

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	154
1	about human factors at this stage or the aging issues.
2	I do believe there are still significant issues that
3	we have to address at some point.
4	CHAIRMAN APOSTOLAKIS: Safety culture, you
5	mean?
6	DR. BONACA: Safety culture and the plant
7	aging.
8	You know, I have a sense, however, that
9	safety culture has been a major issue and component to
10	risk. In the past the plants really have learned to
11	run the plants much better. Davis-Besse seems to say
12	something else, but in general, I see the industry
13	working so much more effectively than they did 20
14	years ago. I mean the way the plants are run, et
15	cetera, it tells me that probably safety culture is
16	less of an issue because the whole industry has come
17	up.
18	But again is the one that is coming and we
19	haven't see yet, and some of these days we're going to
20	see sufficient degradations in numbers that probably
21	will have some expectations of
22	CHAIRMAN APOSTOLAKIS: Do you have any
23	evidence of that?
24	DR. BONACA: No, we don't have it yet.
25	I'm saying in the future.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	155
1	DR. FORD: Yes, the history of plant
2	outage, unplanned plant outages because of materials
3	degradation problems going back 20 years, and it
4	varies from era to era depending on what the specific
5	degradation.
6	CHAIRMAN APOSTOLAKIS: Maybe we can make
7	that a separate ACRS initiative and spend some time
8	thinking about the collecting the data and so on. I
9	don't want to bring it, you know, on an ad hoc
10	DR. BONACA: The last comment I'd like to
11	make is that clearly there was on the part of the
12	Commission an interest in knowing where the ACRS was
13	coming from on this SRM, I mean, what the thoughts of
14	the ACRS would be.
15	I mean, we were asked to provide some
16	CHAIRMAN APOSTOLAKIS: You have missed
17	that stupid E-mail.
18	DR. BONACA: No. You decide to send an E-
19	mail. I decide not to send one, you know.
20	CHAIRMAN APOSTOLAKIS: Yeah.
21	DR. BONACA: But what I'm trying to say
22	is
23	CHAIRMAN APOSTOLAKIS: Are we still there?
24	DR. BONACA: in and of itself those
25	DR. ROSEN: We're off the record now,

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

 right? CHAIRMAN APOSTOLAKIS: Are we off record now? No. DR. SIEBER: No? CHAIRMAN APOSTOLAKIS: No. DR. BONACA: I'm saying in and of itsel 	lf,
 3 record now? No. 4 DR. SIEBER: No? 5 CHAIRMAN APOSTOLAKIS: No. 6 DR. BONACA: I'm saying in and of itsel 	lf,
 4 DR. SIEBER: No? 5 CHAIRMAN APOSTOLAKIS: No. 6 DR. BONACA: I'm saying in and of itsel 	
5 CHAIRMAN APOSTOLAKIS: No. 6 DR. BONACA: I'm saying in and of itse	
6 DR. BONACA: I'm saying in and of itse	
	ill
7 I think that kind of communication and feedback w	_
8 be a reason to the Commission, and we'll see this p	lan
9 as being an effective way to proceed.	
10 CHAIRMAN APOSTOLAKIS: Well, I told him	to
11 shut up earlier. So I should shut up myself.	
12 Go ahead. Mr. Rosen.	
13 DR. ROSEN: Okay. I think this is go	ing
14 the right direction. I support it. I have a coup	ple
15 of specific comments.	
16 One is on Phase 3 I'm worried that	the
17 schedule for completion is held hostage to	the
18 schedule for the standards development completion, a	and
19 that worries me a little bit and I think it needs	to
20 be fairly explicit somehow about how you go arou	und
21 that problem if it turns out to be one.	
22 As to the issue of my little PRA don	κеу
23 trying to go up the mountain to collect, coming ba	ack
24 from the mountain with all of the wood on it and	the
25 little peasant leading it and it has got this enorm	ous

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	157
1	part of the wood, one of the pieces of wood that says
2	materials and the other one says safety culture, you
3	know, and
4	DR. SIEBER: You need a bigger donkey.
5	DR. ROSEN: it's too big a load for
6	this little donkey.
7	PARTICIPANT: Get a mule.
8	DR. ROSEN: He doesn't have the money for
9	a mule, this man. So
10	DR. SIEBER: Actually you could call those
11	two items snippets.
12	DR. ROSEN: Well, I think, coming away
13	from my donkey for a minute, I think the issue is
14	going to have to be to deal with the question of the
15	completion of the standards holding this Phase 3
16	hostages. You're going to need to have some
17	incentives so that you don't get into the position
18	where you say, "All right. No standards? We're going
19	to have to do something else."
20	I don't think that would be good. It
21	needs to be explicit that that's what you would do if
22	you got into the point. You're not going to leave
23	this whole thing crash simply because the industry
24	decides not to put the resources into standards.
25	But it would be better if there were some

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	158
1	incentives so that they never even thought that that
2	was the right way to go.
3	Finally, the last comment I want to make
4	is about Phase 4. I made it earlier. To me it's to
5	have a requirement for staff review and approval.
6	It's unrealistic and well beyond anything the staff
7	could ever do.
8	To me you're going to be in Phase 4 only
9	into which is state of the art phase. To
10	distinguish that from Phase 3, you're going to be
11	seeing innovation, lots of innovation, things that are
12	beyond what other people are doing. It's not common
13	practice. You'll see organizational culture and PRAs
14	in some PRAs just as an example of innovation.
15	And then you're going to have to go out
16	there and somehow review and approve all of those,
17	just not likely to be able to do that.
18	So two things. Phase 3 is held hostage to
19	the standards development, and you need to be careful
20	about that, and in Phase 4, it's unrealistic as to
21	expecting the staff to have the resources to actually
22	do that work.
23	Thank you.
24	DR. KRESS: Well, I agree with the concept
25	of having bullets instead of a letter. We will have

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	159
1	to get the full committee to agree to them, and that
2	probably means they have to come back and give us the
3	same presentation in an hour, or are you going to
4	summarize? How are we going to get the buy-in from
5	the full committee?
6	PARTICIPANT: It's scheduled.
7	DR. KRESS: It is scheduled?
8	MR. SNODDERLY: Right now the staff is
9	scheduled to brief us in April.
10	CHAIRMAN APOSTOLAKIS: But they will come
11	back again in May? I mean we are imposing on them too
12	much.
13	DR. KRESS: Yeah, is it possible that we
14	could have a subcommittee chairman's summary and get
15	buy-in from the full committee that way?
16	CHAIRMAN APOSTOLAKIS: And it's a fact;
17	it's not my interpretation. It's a fact that in April
18	you will not have the SECY document.
19	DR. KRESS: Yeah, exactly.
20	CHAIRMAN APOSTOLAKIS: that is a powerful
21	argument against writing a letter.
22	DR. KRESS: So I'm in favor of perhaps
23	George summarizing it and trying to get by the full
24	committee on a set of bullets because we don't have
25	all of them here, but we have quite a few of them.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	160
1	DR. BONACA: We can always go to the
2	bullets' representation and then zip his lips.
3	(Laughter.)
4	DR. KRESS: With respect to the
5	implementation plan, I like it. I like the
6	interpretation they gave to the SRM like you guys do,
7	and I like the way the incentives have been built into
8	it, and I think they are real incentives.
9	I guess I'm not as worried about standards
10	holding Phase 3 hostage. I think our experience has
11	been that the industry is not about to lag. I think
12	they're going to jump on this and try to get standards
13	going. I think they see a lot of benefit in this and
14	will be cooperative.
15	I also guess I don't think ACRS is ready
16	to have any kind of recommendation on either safety
17	culture or aging in PRA, and I think our bullets
18	shouldn't even broach those subjects right now. I
19	don't think we're ready, and I don't think we're of
20	one mind in the committee because we don't have a
21	committee position on either of those things.
22	So this is too premature to even think
23	about those.
24	I also think that the technical issues
25	should have high priority. Now, I don't know if they

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	161
1	should be in the implementation plan or how they
2	should be, but I think they should have high priority,
3	and in my mind, I think the guidance on how to deal
4	with uncertainty is probably the highest priority one
5	in the bunch.
6	And so I'd like to have that somehow
7	reflected in our bullets.
8	And I guess I disagree with Steve on the
9	Phase 4. I think it's NRC's job to review and approve
10	these things. If they're going to be used for
11	substantial purposes, regulatory purposes, I think
12	they have to review them and approve them at one
13	point.
14	I don't know. Maybe it takes a lot of
15	resources and maybe it doesn't. I don't know. But I
16	think they will have to sign off on them, yeah.
17	CHAIRMAN APOSTOLAKIS: Clarification,
18	please. What was your position that Tom disagrees
19	with? Because I'm not sure I
20	DR. ROSEN: Well, I thought that if you
21	have 70 PRAs out there, I mean, it's just a mess, and
22	to do review and approval at the level of detail that
23	I saw the staff do it at South Texas, then I just
24	don't think it's rational.
25	I mean, they're talking about hundreds and

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	162
1	hundreds of man-years of effort.
2	CHAIRMAN APOSTOLAKIS: But isn't the point
3	of having standards that they would not have to do
4	that?
5	DR. ROSEN: No, I think not. I think
6	they'll have to get in and look at
7	CHAIRMAN APOSTOLAKIS: Gareth?
8	MR. PARRY: You would sort of think so,
9	but it definitely says
10	CHAIRMAN APOSTOLAKIS: Oh, NRC approved,
11	yeah.
12	MR. PARRY: NRC approved.
13	PARTICIPANT: Yeah, the SRM is clear on
14	that.
15	CHAIRMAN APOSTOLAKIS: Well, that is not
16	Phase 4.
17	MR. PARRY: Yeah, that's Phase 4. That's
18	Phase 4.
19	DR. ROSEN: i think we need to send a
20	signal. Maybe Tom doesn't agree with it. I think
21	maybe the bullets ought to send a signal. The
22	committee is not of one mind, but at least some
23	members, maybe only one member, is worried that the
24	staff is biting off too much in talking about
25	CHAIRMAN APOSTOLAKIS: Okay. Now it's

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1clear.2DR. ROSEN: review and approval.3CHAIRMAN APOSTOLAKIS: Let's give the4floor back to Tom.5DR. KRESS: Well, that was it.6CHAIRMAN APOSTOLAKIS: You're done? Okay.7So I'm supposed to say now. Basically I8agree with what appears to be the sense of the9subcommittee that we should try to come up with10bullets and write a letter after we have a chance to,11after the staff has a chance to crystallize its12approach and the plan and develops a SECY so that we13have a chance to review the SECY.14And I understand this will be by May.15May?16MS. DROUIN: We have to.17CHAIRMAN APOSTOLAKIS: Yeah. Okay. So18then we write a letter in May, the latest in June, but19may.20So we can agree on a number of bullets.21I didn't hear any violent disagreement.22DR. ROSEN: No, I'm just worried about23the24CHAIRMAN APOSTOLAKIS: No, I understand.		163
 CHAIRMAN APOSTOLAKIS: Let's give the floor back to Tom. DR. KRESS: Well, that was it. CHAIRMAN APOSTOLAKIS: You're done? Okay. So I'm supposed to say now. Basically I agree with what appears to be the sense of the subcommittee that we should try to come up with bullets and write a letter after we have a chance to, after the staff has a chance to crystallize its approach and the plan and develops a SECY so that we have a chance to review the SECY. And I understand this will be by May. May? May? CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	1	clear.
 floor back to Tom. DR. KRESS: Well, that was it. CHAIRMAN APOSTOLAKIS: You're done? Okay. So I'm supposed to say now. Basically I agree with what appears to be the sense of the subcommittee that we should try to come up with bullets and write a letter after we have a chance to, after the staff has a chance to crystallize its approach and the plan and develops a SECY so that we have a chance to review the SECY. And I understand this will be by May. May? Ms. DROUIN: We have to. CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	2	DR. ROSEN: review and approval.
5DR. KRESS: Well, that was it.6CHAIRMAN APOSTOLAKIS: You're done? Okay.7So I'm supposed to say now. Basically I8agree with what appears to be the sense of the9subcommittee that we should try to come up with10bullets and write a letter after we have a chance to,11after the staff has a chance to crystallize its12approach and the plan and develops a SECY so that we13have a chance to review the SECY.14And I understand this will be by May.15May?16CHAIRMAN APOSTOLAKIS: Yeah. Okay. So18then we write a letter in May, the latest in June, but19may.20So we can agree on a number of bullets.21I didn't hear any violent disagreement.22DR. ROSEN: No, I'm just worried about23the	3	CHAIRMAN APOSTOLAKIS: Let's give the
 CHAIRMAN APOSTOLAKIS: You're done? Okay. So I'm supposed to say now. Basically I agree with what appears to be the sense of the subcommittee that we should try to come up with bullets and write a letter after we have a chance to, after the staff has a chance to crystallize its approach and the plan and develops a SECY so that we have a chance to review the SECY. May? May? CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	4	floor back to Tom.
7 So I'm supposed to say now. Basically I 8 agree with what appears to be the sense of the 9 subcommittee that we should try to come up with 10 bullets and write a letter after we have a chance to, 11 after the staff has a chance to crystallize its 12 approach and the plan and develops a SECY so that we 13 have a chance to review the SECY. 14 And I understand this will be by May. 15 May? 16 MS. DROUIN: We have to. 17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	5	DR. KRESS: Well, that was it.
8 agree with what appears to be the sense of the 9 subcommittee that we should try to come up with 10 bullets and write a letter after we have a chance to, 11 after the staff has a chance to crystallize its 12 approach and the plan and develops a SECY so that we 13 have a chance to review the SECY. 14 And I understand this will be by May. 15 May? 16 MS. DROUIN: We have to. 17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	6	CHAIRMAN APOSTOLAKIS: You're done? Okay.
9 subcommittee that we should try to come up with 10 bullets and write a letter after we have a chance to, 11 after the staff has a chance to crystallize its 12 approach and the plan and develops a SECY so that we 13 have a chance to review the SECY. 14 And I understand this will be by May. 15 May? 16 MS. DROUIN: We have to. 17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	7	So I'm supposed to say now. Basically I
 bullets and write a letter after we have a chance to, after the staff has a chance to crystallize its approach and the plan and develops a SECY so that we have a chance to review the SECY. And I understand this will be by May. May? May? May? CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	8	agree with what appears to be the sense of the
11 after the staff has a chance to crystallize its approach and the plan and develops a SECY so that we have a chance to review the SECY. 14 And I understand this will be by May. 15 May? 16 MS. DROUIN: We have to. 17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	9	subcommittee that we should try to come up with
12 approach and the plan and develops a SECY so that we have a chance to review the SECY. 14 And I understand this will be by May. 15 May? 16 MS. DROUIN: We have to. 17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	10	bullets and write a letter after we have a chance to,
 have a chance to review the SECY. And I understand this will be by May. May? MS. DROUIN: We have to. CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	11	after the staff has a chance to crystallize its
14And I understand this will be by May.15May?16MS. DROUIN: We have to.17CHAIRMAN APOSTOLAKIS: Yeah. Okay. So18then we write a letter in May, the latest in June, but19may.20So we can agree on a number of bullets.21I didn't hear any violent disagreement.22DR. ROSEN: No, I'm just worried about23the	12	approach and the plan and develops a SECY so that we
 May? Ms. DROUIN: We have to. CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	13	have a chance to review the SECY.
 MS. DROUIN: We have to. CHAIRMAN APOSTOLAKIS: Yeah. Okay. So then we write a letter in May, the latest in June, but may. So we can agree on a number of bullets. I didn't hear any violent disagreement. DR. ROSEN: No, I'm just worried about the 	14	And I understand this will be by May.
17 CHAIRMAN APOSTOLAKIS: Yeah. Okay. So 18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	15	May?
18 then we write a letter in May, the latest in June, but 19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	16	MS. DROUIN: We have to.
<pre>19 may. 20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the</pre>	17	CHAIRMAN APOSTOLAKIS: Yeah. Okay. So
20 So we can agree on a number of bullets. 21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	18	then we write a letter in May, the latest in June, but
21 I didn't hear any violent disagreement. 22 DR. ROSEN: No, I'm just worried about 23 the	19	may.
22 DR. ROSEN: No, I'm just worried about 23 the	20	So we can agree on a number of bullets.
23 the	21	I didn't hear any violent disagreement.
	22	DR. ROSEN: No, I'm just worried about
24 CHAIRMAN APOSTOLAKIS: No, I understand.	23	the
	24	CHAIRMAN APOSTOLAKIS: No, I understand.
25 I understand. Look. The bullets can always say that	25	I understand. Look. The bullets can always say that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	164
1	some concern was expressed. I mean, it doesn't have
2	to be definitive, "this is it."
3	DR. ROSEN: And bullets have to clearly
4	say, you know
5	CHAIRMAN APOSTOLAKIS: Yeah.
6	DR. ROSEN: this is an interim thing.
7	CHAIRMAN APOSTOLAKIS: So I agree with
8	everything. Tom was the only one who actually raised
9	the issue that I want to raise about the technical
10	issues. It seems to me they are fundamental to all
11	phases, and somehow they should be reflected on the
12	diagrams that Gareth is developing and also, you know,
13	in everything, the technical resolution.
14	The resolution, again, has to be taken
15	with a grain of salt. We don't mean here is a
16	rigorous methodology for handling it, but addressing
17	it and doing something about it. So that's all I'm
18	saying.
19	So okay. The agreement is then that these
20	gentlemen and lady will not come back to the April
21	meeting.
22	MR. SNODDERLY: George, can I make two
23	comments?
24	CHAIRMAN APOSTOLAKIS: Yeah.
25	MR. SNODDERLY: First, remember that also

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	165
1	the reason the Commission likes to have a letter
2	before they discuss something is so that they can have
3	time to consider the position. So we have to consider
4	how we communicate these positions prior to
5	CHAIRMAN APOSTOLAKIS: They usually have
6	our slides well before the meeting.
7	MR. SNODDERLY: Okay, and then the other
8	point I wanted to make concerns the importance of
9	developing a position relative to Box 5 and 6. I
10	personally believe that it's very important that the
11	current incentives as presented by the staff for
12	developing the standards I'm not concerned as much
13	about holding industry hostage because if you do not
14	have the
15	DR. ROSEN: No, I mean the staff not
16	holding industry hostage. I was saying that the
17	industry holds the staff hostage. So you
18	misunderstood.
19	MR. SNODDERLY: Oh, okay. Thank you.
20	Thank you.
21	Well, the point I wanted to make goes to
22	what you were saying, is that if you don't have
23	usually the toughest part of the standard is there's
24	some controversial aspect of either the fire PRA or
25	the external events PRA, and in the absence of the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	166
1	standard then the burden of these controversial
2	issues goes to the reviewer and the ad hoc review, and
3	you lose consistency.
4	CHAIRMAN APOSTOLAKIS: You're absolutely
5	right.
6	MR. SNODDERLY: And so I do think and
7	I'm sorry I misunderstood.
8	CHAIRMAN APOSTOLAKIS: No, you're all
9	right.
10	MR. SNODDERLY: But I think that's an
11	important policy issue.
12	CHAIRMAN APOSTOLAKIS: I would not want to
13	get into Box 5 and 6 in our meeting with the
14	Commissioners because we don't know. Even the staff
15	hasn't reached the final conclusion. So for us to
16	speculate so I think we should keep it at a high
17	level. There seems to be consensus that, yes, this is
18	a good interpretation, good thing to go ahead, and so
19	on.
20	Technical issues we'll figure out some
21	recognized words to say, maybe express some concern
22	about being held hostage, not using those words.
23	DR. ROSEN: No, that's maybe not the right
24	words. Just controlling the schedule.
25	CHAIRMAN APOSTOLAKIS: Yeah. Now, they

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	167
1	will not make a presentation, but do we want Gareth to
2	be here?
3	MR. SNODDERLY: I think they should keep
4	the date open on their calendar and Mario will have to
5	make a decision.
6	DR. KRESS: Have we already put out a
7	notice, <u>Federal Register</u> notice?
8	CHAIRMAN APOSTOLAKIS: I don't think so.
9	Not for the full committee.
10	MR. HARRISON: It's on the Web.
11	CHAIRMAN APOSTOLAKIS: Okay. Then you
12	have to be here. Don't give the whole presentation,
13	please. I mean, it's
14	PARTICIPANT: How much time do we have on
15	that?
16	CHAIRMAN APOSTOLAKIS: An hour and a half?
17	How much is it?
18	MR. MAGRUDER: Eight, thirty to ten.
19	PARTICIPANT: An hour and a half.
20	DR. BONACA: but this is of interest to
21	the rest of
22	CHAIRMAN APOSTOLAKIS: Yeah, but then we
23	will go through the presentation again, and there will
24	be no time to formulate any opinion, and then I'll
25	have to go no. I want us to start formulating the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

```
(202) 234-4433
```

	168
1	bullets.
2	MR. PARRY: Can I suggest maybe that what
3	we maybe want to do is just provide that flow logic
4	diagram and walk through that?
5	DR. KRESS: That would be
6	CHAIRMAN APOSTOLAKIS: And the technical
7	issues.
8	MR. PARRY: And the technical issues.
9	DR. ROSEN: Dana and others will take an
10	hour and a half dragging you through that.
11	PARTICIPANT: You need to define the
12	phases.
13	DR. SIEBER: Well, to me the phases'
14	definitions are important because the way I envision
15	this all happening is it's going to be like the New
16	York Marathon. Everybody is going to start running,
17	and South Texas is going to win, and they'll get to
18	the last phase and here will come some slow bunnies
19	that make it to Phase 2 and that's as far as they want
20	to run
21	MS. DROUIN: But I think when you go
22	through the flow chart, it defines the bases.
23	DR. SIEBER: It does. The definitions are
24	there.
25	CHAIRMAN APOSTOLAKIS: Okay. Let's do

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	169
1	something together here so it will be like we're all
2	together now.
3	Do we all agree that Slide 15 is very
4	informative?
5	DR. ROSEN: Fifteen? Let me get to it.
6	DR. KRESS: Hold on, hold on.
7	DR. SIEBER: They're all informative.
8	MR. HARRISON: That's the staff review PRA
9	slide.
10	CHAIRMAN APOSTOLAKIS: On page 8. People
11	were saying they want to define the basis.
12	DR. ROSEN: But Phase 4 is controversial
13	in my view.
14	CHAIRMAN APOSTOLAKIS: Yeah. So when he
15	presents it, you raise your concerns, but is Slide 15
16	something we want Gareth to start with?
17	DR. ROSEN: Stop with?
18	CHAIRMAN APOSTOLAKIS: Start. Then
19	definitely he has to present the two slides with the
20	boxes. Maybe you modify them by then. It's three
21	weeks from now, four weeks from now, right?
22	Now, what else do you think? The tasks,
23	do you want to present the tasks?
24	PARTICIPANTS: No.
25	DR. ROSEN: Just that much, and Dana

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	170
1	Powers is two and a half hours.
2	DR. KRESS: That's all right.
3	CHAIRMAN APOSTOLAKIS: Excuse me, but Dana
4	is also a member. What can you do?
5	DR. KRESS: But also Slide 30 you want to.
6	CHAIRMAN APOSTOLAKIS: Slide 30, Slide 30.
7	I like the Slide 30, but let's not forget the
8	presentation is by Gareth and his colleagues. Gareth
9	and your colleagues, what else do you think you should
10	present? It's your presentation, but you've got the
11	idea now.
12	MR. PARRY: I think it would be useful to
13	have the Phase 1, 2 and 3 slides because
14	CHAIRMAN APOSTOLAKIS: Which numbers are
15	these?
16	MR. PARRY: Those are ten, 11, 12.
17	CHAIRMAN APOSTOLAKIS: Fine, okay. All
18	right. You start with ten.
19	MR. PARRY: Yes.
20	CHAIRMAN APOSTOLAKIS: Okay. Anything
21	else that you would like?
22	Mario said something about standards.
23	MS. DROUIN: Can I ask a different
24	question?
25	DR. BONACA: And 29.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	171
1	MS. DROUIN: You have on the schedule an
2	hour and a half. Are you telling us we're going to
3	have the full hour and a half?
4	CHAIRMAN APOSTOLAKIS: No.
5	MS. DROUIN: Are you telling us you want
6	us for a half an hour?
7	DR. SIEBER: Forty-five minutes.
8	CHAIRMAN APOSTOLAKIS: We want you to make
9	a presentation, and then we will start formulating
10	bullets and so on.
11	MS. DROUIN: Okay. So 45 minutes of which
12	half of it we'll leave for discussion. I mean that's
13	normally how we prepare.
14	PARTICIPANT: That's right. So you've got
15	20 minutes' worth.
16	MS. DROUIN: So we've got 20 minutes worth
17	of slides you want us to prepare for.
18	CHAIRMAN APOSTOLAKIS: Which means ten
19	slides.
20	MS. DROUIN: And we'll figure it out.
21	CHAIRMAN APOSTOLAKIS: So you don't want
22	us to give you some idea which slides we like?
23	MS. DROUIN: No, no. I'm not saying that.
24	PARTICIPANT: I think we have just got
25	about ten slides.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1 CHAIRMAN APOSTOLAKIS: Okay, great. But 2 you've got the idea now. Did you take a note of 3 DR. BONACA: I think the message they got 4 was the interaction between the standards and the 5 guidance and the possible progress. That has to be 6 communicated somehow. When you talk about Phase 1, 2, 7 3, that will come out. 8 CHAIRMAN APOSTOLAKIS: Let me ask another 9 thing of the subcommittee members. Why don't we let 10 them go through the whole presentation? I suspect 11 that some of the members may object to a shortened 12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want <th></th> <th>172</th>		172
3 DR. BONACA: I think the message they got 4 was the interaction between the standards and the 5 guidance and the possible progress. That has to be 6 communicated somehow. When you talk about Phase 1, 2, 7 3, that will come out. 8 CHAIRMAN APOSTOLAKIS: Let me ask another 9 thing of the subcommittee members. Why don't we let 10 them go through the whole presentation? I suspect 11 that some of the members may object to a shortened 12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I sen	1	CHAIRMAN APOSTOLAKIS: Okay, great. But
 was the interaction between the standards and the guidance and the possible progress. That has to be communicated somehow. When you talk about Phase 1, 2, 3, that will come out. CHAIRMAN APOSTOLAKIS: Let me ask another thing of the subcommittee members. Why don't we let them go through the whole presentation? I suspect that some of the members may object to a shortened presentation. What do you think? DR. SIEBER: I don't think you've got enough time. DR. SIEBER: I don't think you have enough time. DR. SIEBER: I don't think you have enough time. Matter a good idea to about ten slides. Okay? Ten slides. And it's not log normal. It doesn't have an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to 	2	you've got the idea now. Did you take a note of
5guidance and the possible progress. That has to be communicated somehow. When you talk about Phase 1, 2, 3, that will come out.8CHAIRMAN APOSTOLAKIS: Let me ask another thing of the subcommittee members. Why don't we let them go through the whole presentation? I suspect10them go through the whole presentation? I suspect that some of the members may object to a shortened presentation. What do you think?13DR. SIEBER: I don't think you've got14enough time.15DR. KRESS: You don't have enough time.16DR. SIEBER: I don't think you have enough17time.18CHAIRMAN APOSTOLAKIS: Okay. So then it's a good idea to about ten slides. Okay? Ten slides.20And it's not log normal. It doesn't have21an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to	3	DR. BONACA: I think the message they got
 communicated somehow. When you talk about Phase 1, 2, 3, that will come out. CHAIRMAN APOSTOLAKIS: Let me ask another thing of the subcommittee members. Why don't we let them go through the whole presentation? I suspect that some of the members may object to a shortened presentation. What do you think? DR. SIEBER: I don't think you've got enough time. DR. KRESS: You don't have enough time. DR. SIEBER: I don't think you have enough time. CHAIRMAN APOSTOLAKIS: Okay. So then it's a good idea to about ten slides. Okay? Ten slides. And it's not log normal. It doesn't have an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to 	4	was the interaction between the standards and the
7 3, that will come out. 8 CHAIRMAN APOSTOLAKIS: Let me ask another 9 thing of the subcommittee members. Why don't we let 10 them go through the whole presentation? I suspect 11 that some of the members may object to a shortened 12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	5	guidance and the possible progress. That has to be
 CHAIRMAN APOSTOLAKIS: Let me ask another thing of the subcommittee members. Why don't we let them go through the whole presentation? I suspect that some of the members may object to a shortened presentation. What do you think? DR. SIEBER: I don't think you've got enough time. DR. KRESS: You don't have enough time. DR. SIEBER: I don't think you have enough time. CHAIRMAN APOSTOLAKIS: Okay. So then it's a good idea to about ten slides. Okay? Ten slides. And it's not log normal. It doesn't have an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to 	6	communicated somehow. When you talk about Phase 1, 2,
9 thing of the subcommittee members. Why don't we let them go through the whole presentation? I suspect that some of the members may object to a shortened presentation. What do you think? DR. SIEBER: I don't think you've got enough time. DR. KRESS: You don't have enough time. DR. SIEBER: I don't think you have enough time. DR. SIEBER: I don't think you have enough time. R. CHAIRMAN APOSTOLAKIS: Okay. So then it's a good idea to about ten slides. Okay? Ten slides. And it's not log normal. It doesn't have an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to	7	3, that will come out.
10 them go through the whole presentation? I suspect 11 that some of the members may object to a shortened 12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	8	CHAIRMAN APOSTOLAKIS: Let me ask another
11 that some of the members may object to a shortened 12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	9	thing of the subcommittee members. Why don't we let
<pre>12 presentation. What do you think? 13 DR. SIEBER: I don't think you've got 14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to</pre>	10	them go through the whole presentation? I suspect
13DR. SIEBER:I don't think you've got14enough time.15DR. KRESS:16DR. SIEBER:16DR. SIEBER:17time.18CHAIRMAN APOSTOLAKIS:19a good idea to about ten slides.20And it's not log normal.21an error factor with ten or 11, huh?22have prepared maybe a set of bullets, but I don't want23to send them to the members who have not been exposed24to anything here.	11	that some of the members may object to a shortened
14 enough time. 15 DR. KRESS: You don't have enough time. 16 DR. SIEBER: I don't think you have enough 17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	12	presentation. What do you think?
15DR. KRESS: You don't have enough time.16DR. SIEBER: I don't think you have enough17time.18CHAIRMAN APOSTOLAKIS: Okay. So then it's19a good idea to about ten slides. Okay? Ten slides.20And it's not log normal. It doesn't have21an error factor with ten or 11, huh? And Mike will22have prepared maybe a set of bullets, but I don't want23to send them to the members who have not been exposed24to anything here. Maybe should I send them only to	13	DR. SIEBER: I don't think you've got
16DR. SIEBER: I don't think you have enough17time.18CHAIRMAN APOSTOLAKIS: Okay. So then it's19a good idea to about ten slides. Okay? Ten slides.20And it's not log normal. It doesn't have21an error factor with ten or 11, huh? And Mike will22have prepared maybe a set of bullets, but I don't want23to send them to the members who have not been exposed24to anything here. Maybe should I send them only to	14	enough time.
17 time. 18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	15	DR. KRESS: You don't have enough time.
18 CHAIRMAN APOSTOLAKIS: Okay. So then it's 19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	16	DR. SIEBER: I don't think you have enough
19 a good idea to about ten slides. Okay? Ten slides. 20 And it's not log normal. It doesn't have 21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	17	time.
And it's not log normal. It doesn't have an error factor with ten or 11, huh? And Mike will have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to	18	CHAIRMAN APOSTOLAKIS: Okay. So then it's
21 an error factor with ten or 11, huh? And Mike will 22 have prepared maybe a set of bullets, but I don't want 23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	19	a good idea to about ten slides. Okay? Ten slides.
have prepared maybe a set of bullets, but I don't want to send them to the members who have not been exposed to anything here. Maybe should I send them only to	20	And it's not log normal. It doesn't have
23 to send them to the members who have not been exposed 24 to anything here. Maybe should I send them only to	21	an error factor with ten or 11, huh? And Mike will
24 to anything here. Maybe should I send them only to	22	have prepared maybe a set of bullets, but I don't want
	23	to send them to the members who have not been exposed
25 you gentlemen in advance?	24	to anything here. Maybe should I send them only to
	25	you gentlemen in advance?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	173
1	We can't do things in secret.
2	DR. ROSEN: No, no, no. Don't do that.
3	Send them to everybody. The ones of us those of us
4	who have been here will understand them better. Those
5	who won't will be amazed.
6	CHAIRMAN APOSTOLAKIS: Then I'm going to
7	show them here when we come here.
8	Okay, and I would appreciate it if you
9	guys stayed for the whole hour and a half when we
10	discuss the bullet in case we have questions.
11	MS. DROUIN: We will.
12	DR. ROSEN: Well, we have your bank
13	account in our hands.
14	CHAIRMAN APOSTOLAKIS: One other thing,
15	one other thing. I was talking to maybe we can go
16	off the record now.
17	This meeting is officially adjourned.
18	(Whereupon, at 4:46 p.m., the Subcommittee
19	meeting in the above-entitled matter was concluded.)
20	
21	
22	
23	
24	
25	